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  Abstract 
The  unique  optical  properties  of  colloidal  gold  nanoparticles:  high  extinction  coefficient  and 
adjustable plasmon band, as well as their excellent biocompatibility (low toxicity and a natural 
affinity towards thiols and amines) make them very attractive materials for biomedical research.  In 
this  project,  two  types  of  gold  nanoparticles  (NPs):  spherical  and  anisotropic  were  utilised.  
Spherical NPs predominantly absorb in the visible range of the electromagnetic spectrum, while the 
plasmon band of anisotropic NPs, e.g. rod-like is shifted into the longer wavelengths.  Such variety 
in the optical signatures of NPs enables their usage in a number of imaging and therapy techniques.  
Biological  activity  of  NPs  is  determined  by  the  chemical  composition  of  the  organic  corona, 
surrounding the gold core.  Appropriate surface capping provides NPs with substantial stability 
against aggregation (and loss of their properties) in physiological media.  Hence, crude colloids 
were stabilised with a variety of organic molecules, strongly interacting with the gold surface.  A 
selection  of  functional  peptides  was  incorporated  into  the  organic  corona  of  NPs,  in  order  to 
achieve desired biological activity of colloids.  Functionalised NPs interacted with a certain type of 
human cells in a selective manner.  Such selectivity was obtained by precise recognition between 
peptides attached to NPs and cell receptors. 
In this project, human umbilical vein endothelial cells (HUVECs) were studied.  These cells build 
the interior layer of blood vessels in the entire circulatory system and participate in many important 
physiological  processes,  as  well  as  pathological  developments,  e.g.  blood  vessels  formation 
(angiogenesis).  In angiogenesis, several cell receptors are involved.  Two of them are: vascular 
endothelial growth factor receptor type 1 (VEGFR-1) and neuropilin receptor type 1 (NRP-1).  
Both, VEGFR-1 and NRP-1 were targeted with peptide functionalised NPs.  Selectivity of the 
binding was investigated.  Following the binding event, physiological changes in cell metabolism 
were  triggered.    The  nature  and  efficiency  of  these  changes  were  studied,  by  measuring  the 
expression levels of several angiogenesis related genes, as well as the ability of cells to form 
capillaries using in vitro angiogenesis assays.   
HUVECs  targeted  with  anisotropic  NPs  were  illuminated  with  near-infrared  (NIR)  laser  light.  
Light at this frequency penetrates human tissue and is absorbed by associated with cells anisotropic 
NPs.  NPs convert the absorbed light into heat, which causes an increase in the local temperature.  
Increased temperatures result  in  cell  damage  and/or  stimulate  cellular response.    Physiological 
changes in HUVECs upon a moderate heat stimuli were assessed by measuring the expression 
levels of two genes (ELAM-1 and ELAM-1), which are responsive to the temperature changes.  
Elevated heat resulted in thermal damage of HUVECs, the degree of which was studied by cell 
viability assays.  
In  this  project,  a  dual  approach  towards  controlled  regulation  of  HUVECs  physiology  was 
demonstrated.  Not only regulation of cell metabolism, but the whole angiogenesis process was 
achieved with peptide functionalised NPs.  Targeted with anisotropic NPs cells were illuminated 
with the NIR laser, which induced the heat shock response in the cell or at the extreme led to death.  
This work possesses a clear potential and relevance for therapy of various disorders related to 
insufficient or excessive angiogenesis of endothelial cells.  I 
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1.  Introduction. 
Within the circulatory system in the human body, the interior layer of blood vessels is 
composed of endothelial cells (endothelium) 
[1].  These cells perform several important 
functions in the organism, e.g. responding to a pathogen and developing new blood vessels 
(angiogenesis) 
[1-3].    Angiogenesis  is  a  physiological  process  occurring  naturally  (e.g. 
wound  healing),  but  is  also  involved  in  pathological  developments 
[2-5],  e.g.  excessive 
blood vessels growth is associated with cancer, while insufficient angiogenesis occurs in 
coronary artery disease and strokes 
[4,5].  Pathological angiogenesis in general derives from 
disruptions in a fragile balance (homeostasis) between stimulating and inhibiting factors 
[5].  
To restore the homeostasis and gain control upon pathological angiogenesis, anti- or pro-
angiogenic  molecules  can  be  introduced 
[3-16].    Consequently,  some  of  the  angiogenic 
therapies  developed  in  recent  years,  are  based  on  synthetic  or  natural  angiogenesis 
regulating drugs 
[3,6,7,10-14] (chapter 2).  
Pioneering work conducted by Ferrara and co-workers demonstrated that by inhibiting 
angiogenesis,  the  growth  and  progression  of  tumours  can  be  suppressed  in  vivo 
[10]. 
Following this idea, nanoparticles (NPs) were employed in selective regulation of blood 
vessel growth towards the development of alternative cancer therapies.  Specifically, this 
research project was focused on the design and synthesis of ‘smart’ nanocomposites, which 
can selectively target desired cell types (human umbilical vein endothelial cells, HUVECs) 
and regulate their primary cellular function (angiogenesis).   
Recently, Mukhopadhyay and co-workers reported that inorganic NPs, e.g. europium 
III hydroxide nanorods promote proliferation and vascular sprouting of HUVECs in a dose 
dependent manner 
[17].  These pro-angiogenic properties were attributed to an increase in 
production of reactive oxygen species, induced by nanorods.  Moreover, Murkhopadhyay’s 
and  Mukherjee’s  groups  demonstrated  that  other  types  of  inorganic  NPs  have  anti-
angiogenic properties 
[18-21].  Specifically, it was shown that gold NPs pre-incubated with 
vascular  endothelial  growth  factor  (VEGF,  natural  angiogenesis  stimulator,  chapter  2) 
could not induce angiogenesis in endothelial cells, because the VEGF activity was blocked 
by gold NPs 
[18,20].  All these attractive properties of nanomaterials were however based on 
non-selective  (hence  non-controllable)  interactions  of  nanocomposites  with  complex 
biological systems.  
To  achieve  selectivity  and  more  efficient  control  upon  the  cellular  fate  of  NPs, 
biomolecules such as peptides or oligonucleotides can be employed in NPs surface capping  
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[22-50].    Capped  NPs  show  desired  bioactivity  and  serve  as,  e.g.  endothelium  targeting 
vectors, for imaging and manipulation of angiogenesis.   
Possible applications of engineered gold NPs, e.g. as in vivo drug delivery systems, 
therapeutics  and  high  contrast  imaging  agents 
[22,35,41,43,47,49,51-87]  are  based  on  the 
interesting  optoelectronic  properties  of  gold  (along  with  its  high  biocompatibility).   
Specifically, at the nanoscale (10
-9 metre) gold exhibits unique optical (highly efficient 
resonant absorption and scattering of light) and thermal (light absorption and conversion 
into heat) properties, which are strongly correlated with the size and shape of NPs (and not 
seen in bulk) 
[51,76,88-98].  Spherical NPs highly absorb the light in the visible spectral range 
[99-104],  while  the  maximum  absorption  of  anisotropic  NPs  (e.g.  rod-like,  hollow  and 
core/shell)  is  shifted  into  longer  wavelengths 
[78,89-94,96-98,102,105-107]  (near-infrared  ‘NIR’ 
region, chapter 2).  Gold NPs are generally considered to be biocompatible because of the 
relatively  low  toxicity  (referred  to  other  types  of  inorganic  NPs,  e.g.  cadmium  based 
quantum dots) 
[61,108-113] and high affinity towards amines and thiols 
[23, 29,114].  Thiol based 
molecules  are  commonly  used  to  cap  NPs  surface 
[24,26,29,33,34,37,39,114-123].    Appropriate 
surface  stabilisation  ensures  water  solubility  and  enhances  stability  of  NPs  against 
aggregation in biological environments, thus preserving their properties 
[92,115,118,119,124].   It 
is absolutely necessary to retain the properties of NPs to prevent any intoxication deriving 
from, e.g. exposure of the inorganic core and/or non-specific adsorption of biomolecules 
on the gold surface.  Except of the stabilising role, the composition of an organic corona 
(chemical  structure,  net  charge  and  hydrodynamic  diameter  and  the  presence  of 
biomolecules) determines the cellular fate of colloids 
[23,24,42,58,108,125-129] (see chapter 5 and 
6 for results). 
Nanocomposites, capable of selective targeting of HUVECs, were developed during 
this  research  project  (see  Scheme  1).    Gold  NPs  (spherical  and  anisotropic)  were 
synthesised  following  well-established  wet  chemistry  methods 
[36,89,91,100,101,104-106,130-150] 
(see chapter 2 for theoretical background), which were optimised to match the project 
requirements (see chapter 3 for detailed synthetic protocols).  The NPs surface was capped 
with  a  selection  of  ligands  (see  chapter  2  for  theoretical  background;  chapter  3  for 
chemical  structures  and  experimental  protocols),  including  oligoethylene  glycol  (OEG) 
based molecules 
[23,151] and its diacetylene (DA-PEG) 
[119] modified version, as well as 
CALNN  based  peptides 
[24,34,35,46].    The  physicochemical  properties  of  the  resulting 
colloids were studied (see chapter 4 for results).  
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Basic  mechanisms  of  interactions  between  OEG  capped  NPs  and  HUVECs  were 
studied (see chapter 5 for results).  Internalisation of colloids by cells was attributed to the 
strong  charge  of  the  OEG  capping  layer.    The  overall  uptake  rate  of  NPs  was 
predominantly size and shape dependent.  
To obtain better selectivity and control upon the cellular fate of colloids, OEG NPs 
were modified with synthetic peptides.  Peptides were designed (see chapter 2 for details) 
to show versatile bioactivity, whilst exhibiting similar physicochemical properties.  Each 
sequence was composed of the same overall number of amino acid residues, but different 
primary structure (amino acids arrangements, see chapter 2 for sequences).  The primary 
structure determined the biological activity of the peptides.  All peptides, were conjugated 
to OEG NPs via standard coupling protocols 
[40,44,152] (see chapter 2 for theoretical basis 
and chapter 3 for experimental).  Conjugated colloids (pep-OEG NPs) were used to target 
HUVECs.  Targeting was achieved by a selective recognition between peptide sequences 
and appropriate receptors on HUVECs cellular membrane (see chapter 2 for theoretical 
background and chapter 6 for results).  The receptor binding of pep-OEG NPs triggered a 
cellular  response,  resulting  in  selective  regulation  (activation  or  inhibition)  of 
physiological processes in HUVECs.  
HUVECs  were  also  targeted  with  NIR  absorbing,  anisotropic  pep-OEG  NPs  and 
exposed to NIR laser light (Scheme 2).  The light at NIR frequency penetrated cells (see 
chapter 2 for theoretical background) and was absorbed by NPs 
[84,98,153-155].  The absorbed 
light was converted to heat, resulting in a local temperature increase 
[76,84,98,156].  Elevated 
temperatures induced cellular response, or at the extreme lead to cell death 
[157-165] (see 
chapter 2 for theoretical background).  Detailed studies upon laser induced photo-thermal 
effects in HUVECs will be presented in chapter 7. 
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2.  Theoretical background. 
Gold NPs were applied in selective regulation of an important physiological process – 
blood  vessels  growth,  called  angiogenesis 
[1].    Since  angiogenesis  is  conducted  by 
endothelial cells 
[1,2] (e.g. human umbilical vein endothelial cells: HUVECs), the research 
efforts were focused on studying the interactions between HUVECs and NPs.  Selective 
interactions  resulted  in  controlled  stimulation  or  suppression  of  angiogenesis  related 
cellular  functions  in  HUVECs  and  effectively  the  whole  angiogenesis  process.    The 
theoretical basis of this multidisciplinary project, covering the synthesis of bioactive NPs 
(sections  2.1.  and  2.2.),  as  well  as  the  biology  of  HUVECs  (section  2.6.),  will  be 
discussed in this chapter. 
Firstly, the basic principles of NPs preparation, including synthetic routes (section 
2.1.) and capping techniques (section 2.2.), will be discussed.  This will be then followed 
by  a  general  overview  on  the  physicochemical  properties  of  resulting  nanomaterials 
(section 2.3.).  Advanced therapy technique based on the optoelectronic properties of NPs 
(heat generation upon laser exposure), which has evolved in recent  years 
[3-16], will be 
introduced (section 2.4.).  Biochemical basis of the resulting physiological changes in heat 
treated cells will also be discussed (section 2.6.2.).  
The reader’s attention will be drawn to the primary area of the research project  – 
HUVECs and angiogenesis.  Regulatory mechanisms of this process in HUVECs and the 
fundamental  role  of  natural  and  pathological  angiogenesis  in  the  human  body  will  be 
explained (section 2.6.).  Therapy techniques based on angiogenesis regulating molecules 
[17-26] will then be introduced.  Such therapeutics have inspired the design of pro- and anti-
angiogenic peptides and their conjugation to NPs, as well as studying their interactions 
with HUVECs.   
2.1.  Synthesis of NPs. 
Wet chemistry methods were employed in the synthesis of several types of colloidal gold 
NPs,  including  spherical  (section  2.1.1.),  rod-like  (section  2.1.2.),  core/shell  (section 
2.1.3.) and hollow (section 2.1.4.).  Basic principles of synthetic routes, including reaction 
mechanisms will be given in the following sub-sections. 
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(-OCCH2)2C(OH)C O-
O O
(-OCCH2)2C
O
O
2.1.1.  Synthesis of spherical gold NPs. 
Gold colloids are one of the oldest known nanomaterials, dating back to ancient times, 
when they were used in glass staining techniques 
[27,28].  In modern science, the synthesis 
of spherical gold NPs was first reported by Faraday in 1851 
[29].  Further development was 
conducted by Turkevich 
[30,31] and Frens 
[32] in 1951 and 1970s, respectively. 
The citrate reduction method was utilised in the preparation of spherical gold NPs 
[30-
34].  This method involves aqueous solutions of only two starting materials: chloroauric 
acid  (gold  precursor)  and sodium  citrate (see  chapter 3 for  chemical  structures  and  a 
protocol).  Mixing their boiling solutions at certain molar ratios leads to the formation of 
NPs.  
The mechanism of NPs formation was intensely investigated over the past years by 
several research groups 
[30-34].  Only recently Kumar and co-workers proposed that three 
simultaneous reactions (Scheme 3) are involved in this synthesis 
[33,34].  At first, citrate 
anions  are  oxidised  (by  oxygen  from  air,  accompanied  by  heat)  to  dicarboxy  acetone 
(Scheme 3A).  At the same time, the gold precursor (Au
3+ cations) is reduced to aurous salt 
(Au
+ cations, Scheme 3B).  Au
+ cations form complexes with dicarboxy acetone, which 
according to Turkevich and co-workers, serves as ‘an organiser’ of this complexation 
[30,31].  
Exactly  three  Au
+  can  be  tethered  to  at  least  two  dicarboxy  acetone  moieties,  as 
demonstrated by Kumar’s group 
[33,34].  Finally, aurous species are disproportionated to 
gold atoms (Au
0) (Scheme 3C).  
 
 
                                                                                          
 
 
 
 
 
 
 
 
 
+   CO2   +   H2   +   2e
- 
AuCl3   +   2e
-  AuCl   +   2Cl
- 
3AuCl  2Au
0  +   AuCl3 
Scheme 3.  Citrate oxidation (A), reduction of auric salt (B) and disproportionation of 
aurous species (C); taken from 
[34]. 
A 
B 
C  
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Au
0 produced during the disproportionation reaction, adsorbs Au
+ from the solution 
and  forms  large  aggregates  (by  the  complexation  with  dicarboxy  acetone).    When 
aggregates reach the critical size value (e.g. 2 nm was proposed by Kumar’s group 
[34]), a 
nucleus of gold atoms is formed.  More Au
0 are released during the disproportionation and 
absorbed by the nucleus, resulting in nanoparticle growth.  Growing NPs are stabilised by 
the remaining sodium citrate (Na3Ct) in the solution.  Therefore, the Na3Ct moiety serves 
as both, a reducing agent (gold precursor) and surface stabiliser (gold NPs). 
However, according to Peng and co-workers there is a third role of Na3Ct in NPs 
synthesis: a solution pH modulator 
[33].  It was demonstrated that depending on the solution 
pH, the reaction can undergo one of two possible pathways.  Specifically, at low pH (3.7 ÷ 
6.5) the rapid nucleation step (below 10 s) is followed by fast random attachment, resulting 
in  elongated  structures.    Within  these  structures,  an  intra-particle  ripening  process 
effectively leads to the formation of spherical NPs.  On the contrary, at pH above 6.5 (up to 
7.7), nucleation is rather slow (60 s) and is followed by slow growth of NPs to spherical 
structures.  
These two pH dependent pathways were attributed to dominant species of gold and 
citrate, which co-exist in the reaction mixture at the certain pH (Scheme 4).  Specifically, 
at low pH, very reactive [AuCl3(OH)]
- can be found, which initiate fast nucleation.  At 
higher  pH  values,  these  species  are  converted  to  the  less  reactive  [AuCl2(OH)]2
-  and  
[AuCl(OH)]3
-, resulting in slow nucleation and growth.         
 
 
 
 
 
2.1.2.  Synthesis of gold nanorods. 
Murphy’s group developed a seed mediated surfactant guided method for preparation of 
anisotropic  gold  NPs,  e.g.  nanorods 
[35-41].    The  anisotropic  growth  into  elongated 
structures  is  controlled  by  surfactant  molecules  (e.g.  hexadecyltrimethylammonium 
bromide – CTAB, see chapter 3 for chemical structure) and/or additive ions, like Ag
+ 
[35-
pH 3.7 ÷ 6.5                    [AuCl3(OH)]
-     +     H2Ct
- / HCt
2-   
pH 6.5 ÷ 7.7            [AuCl2(OH)]2
-  / [AuCl(OH)]3
-     +     HCt
2-/ Ct
3- 
Scheme 4.  Schematic illustration of gold and citrate species found at low (top row) or 
high (bottom row) pH; taken from 
[33].  
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40,42-48].   Rod-like NPs are  grown from  the  gold precursor (chloroauric acid),  which is 
reduced  by  ascorbic  acid  (in  the  presence  of  CTAB)  on  small  NPs  called  seeds  (see 
chapter 3 for experimental protocol). 
As  demonstrated  by  Murphy  and  co-workers,  the  type  of  seeds  (size  and  surface 
capping)  strongly  affects  the  length-to-width  aspect  ratio  of  the  produced  NPs,  which 
increases with lowering the seed size 
[36].  According to El-Sayed and co-workers, good 
reaction yields can be achieved with CTAB-capped seeds, prepared by the reduction of the 
gold precursor with a strong reducing agent (e.g. sodium borohydride, see Scheme 5) in 
the presence of CTAB 
[42]. 
2AuCl4
-   +   2Na
+   +   18H2O   +   6NaBH4                           2Au
0   +   8NaCl   +   21H2   +   6B(OH)3 
 
 
As  already  mentioned,  nanorod  growth  is  guided  by  CTAB,  which  because  of  its 
amphiphilic  character,  forms  micelles  in  aqueous  solutions  (see  Scheme  6) 
[49].    The 
micelle shape depends on the concentration of surfactant and is spherical at low (below  
0.1 M) or high (above 0.4 M) concentrations and rod-like in between 
[49].  
 
 
 
 
 
 
 
 
 
However, the shape of CTAB micelles is not the only aspect of the nanorod synthesis 
controlled by the surfactant moiety.  According to the mechanism proposed by Mulvaney’s 
group 
[48], CTAB molecules bind the gold precursor: AuCl4
- (Au
3+), which is then reduced 
to AuCl2
- (Au
+).  As a consequence, stable AuCl2
--CTAB micelles are formed.  These 
micelles collide with gold seeds, entrapped within.  The frequency of collisions determines 
>  0.1 M 
Scheme 5.  Reduction of gold precursor with sodium borohydride. 
Scheme 6.  Schematic illustration of the shape of CTAB micelle, formed in water with 
varying surfactant concentration
  [49].  Green circles represent ammonium 
head, while red zigzags carbon tails. 
>  0.4 M  
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the rate of nanorod formation.  The collision rate is the fastest at the nanorod tips.  As a 
consequence, growth along the longitudinal axis of nanorods is promoted.  
Growth into elongated structures is promoted by another factor, also involving CTAB 
(in a combination with a reducing agent – ascorbic acid).  Several research groups reported 
that in the presence of CTAB, ascorbate mono-anion (not ascorbic acid) is the favoured 
form 
[35,38,50].  Therefore, the ascorbate species act as a dominating reductant of the gold 
precursor.  Murphy’s group proposed that ascorbate along with its intermediate complexes 
(with  CTAB  and  Au
+)  preferably  adsorb  on  the  nanorod  tips,  thereby  promoting  the 
formation of longer nanorods 
[38].  
As  already  mentioned,  additive  ions  (e.g.  Ag
+)  also  play  an  important  role  in 
controlling the nanorod growth direction.  This can be explained by the under potential 
deposition (UPD) of silver (reduction of Ag
+ to Ag
0 on a metal substrate), reported by 
Guyot-Sionnest 
[51].  The UPD is favourable on the nanorod sides, followed by a strong 
CTAB  binding, effectively leading to  the  inhibition  of the  side  growth and elongation 
along the longitudinal axis (Scheme 7).  The length-to-width aspect ratio of the resulting 
nanorods, depends on the initial concentration of Ag
+ and increases with the amount of 
silver cations present (see chapter 4 for experimental detail).  
 
 
 
 
 
2.1.3.  Synthesis of silica/gold core/shell NPs. 
Anisotropic NPs consisting of two components: gold and silica were developed by Halas 
and co-workers 
[52-55].  The synthesis of silica/gold hetero-structures (silica core and gold 
shell) is based on a template strategy (see Scheme 8).  This involves separate preparation 
of large silica NPs (templates) and small gold NPs (seeds).  Silica templates are decorated 
with seeds, from which the gold shell is grown around the silica core.   
nanorod-tip  nanorod-sides 
Ag
0 
growth  growth 
Scheme 7.  Schematic illustration of nanorod-growth along longitudinal axis, promoted 
by under potential deposition of silver (Ag
0) 
[51].  
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Silica NPs can by prepared by a popular method 
[52,56-61], called Stöber or the sol-gel 
method,  first  reported  in  1968 
[62].    In  this  method,  silica  NPs  are  grown  from 
tetraalkoxysilane precursor (specifically, tetraethyl orthosilicate – TEOS; see chapter 3 for 
chemical  structure  and  protocol)  in  alcoholic  solution,  containing  water  and  ammonia.  
Water is required for hydrolysis (see Scheme 9A) of the alkyl silicates, while ammonia 
plays a role of a morphological catalyst.  Subsequent, water (see Scheme 9B) and alcohol 
(see Scheme 9C) condensation reactions of silicic acid result in the formation of NPs.  Vrij 
and  co-workers  reported  that  the  nucleation  process  is  realised  by  the  aggregation  of 
siloxane sub-structures, while the overall rate of NPs growth is limited by the hydrolysis of 
the alkoxide substrate 
[58].  Next, the surface of silica NPs is grafted with amine containing 
molecule ((3-aminopropyl)trimethoxysilane, see chapter 3 for protocol), to allow further 
attachment of gold seeds (via amine groups) 
[52].  
 
≡Si–OR   +    H2O                                        ≡Si–OH    +    ROH 
≡Si–OH   +    HO–Si≡                                     ≡Si–O–Si≡    +    H2O 
≡Si–OR   +    HO–Si≡                                      ≡Si–O–Si≡    +    ROH 
 
 
The preparation of gold seeds (e.g. via Duff method) involves aqueous reduction of 
the  gold  precursor  (chloroauric  acid)  with,  e.g.  alkaline 
tetrakis(hydroxymethyl)phosphonium chloride 
[63,64] (THPC, see chapter 3 for chemical 
C 
B 
A 
Scheme 9.  Sol-gel synthesis of silica NPs.  A – hydrolysis, B – water condensation, C 
– alcohol condensation; taken from 
[62]. 
A 
silica NPs  APTMS-silica   seeds-APTMS-silica   silica/gold       
core/shells  
APTMS   seeds  
B  C 
Scheme 8.  Schematic  illustration  of:  silica  NPs  grafted  with  APTMS  (A),  seeds-
attachment (B) and gold shell growth (C).  
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structure and protocol).  Duff and Baiker proposed that formaldehyde, released throughout 
the alkaline elimination of THPC (see Scheme 10A), acts as an active reducing agent of 
the Au
3+ precursor 
[63,64].  The remaining tris(hydroxymethyl)phosphine can either undergo 
water  hydrolysis  (see  Scheme  10B)  and/or  act  as  a  NPs  surface  stabiliser  (via 
phosphorous; see section 2.2. for BSPP).     
 
P(CH2OH)4
+    +    OH
-                                P(CH2OH)3    +    CH2O    +    H2O 
 
                          P(CH2OH)3    +    2H2O                                O2P(CH2OH)3    +    2H2 
 
 
 
As already mentioned, gold seeds were attached to APTMS-grafted silica NPs (see 
chapter 3 for experimental protocol) via amine groups.  In the final step of the core/shell 
synthesis, the gold shell is grown from the gold precursor (chloroauric acid mixed with 
potassium carbonate; gold is transformed to KAuO2 under the action of excess carbonate 
[65]; see chapter 3 for protocol), assisted with formaldehyde 
[53]. 
2.1.4.  Synthesis of hollow gold NPs. 
Gold  shells  with  hollow  interiors  can  be  prepared  by  dissolving  (calcination  or  wet 
chemical  etching)  the  core  of  core/shell  hetero-structures 
[66],  e.g.  silica  cores  can  be 
degraded by an etching with hydrofluoric acid (HF) 
[67].  This method however, involves 
very  toxic  HF  reagent 
[68].  As  an  alternative,  Xia’s  group  developed  a  fairly  simple, 
template based method for the preparation of gold NPs with hollow interiors 
[66,69-74].  This 
method  is  based  on  the  galvanic  replacement  reaction  (reflux  at  high  temperatures) 
between solid silver NPs and an aqueous solution of the gold precursor (chloroauric acid).  
Silver  templates  (NPs)  determine  the  final  size  and  shape  of  hollow  gold  NPs. 
According  to  the  stoichiometry  of  the  reaction  (see  Scheme  11),  silver  templates  are 
converted into soluble species, while the gold precursor is reduced to Au
0.  One gold atom 
replaces three silver atoms at a time, leading to the formation of hollow nanostructures.  
 
Scheme 10.  Alkaline elimination (A) and hydrolysis (B) reactions of THPC; taken from 
[63, 64]. 
A 
B  
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3Ag (s)    +    AuCl
-
4 (aq)                           Au (s)    +    3Ag
+ (aq)    +    4Cl
- (aq) 
 
   
 
 
 
 
 
   
 
 
It is widely accepted that the replacement reaction begins from the highest surface 
energy sites on silver NPs (e.g. defects or stacking faults) 
[66,69,71,72,75,76].  At these sites, 
Au
0 species are generated, while released Ag
+ cations will diffuse away from the template.  
Within the template, remaining Ag atoms will migrate towards its surface.  As a result, 
more  Au
3+  precursor  will  be  converted  to  Au
0  species  and  deposited  on  the  template 
surface, until the critical concentration of Au
0 is reached and nuclei are formed.  Nuclei 
will grow into clusters, leading to the formation of a partial shell-like gold structure around 
the silver template.  Alloying and de-alloying processes will continue until the complete 
shell is formed (or gold precursor is consumed).  According to Xia and co-workers, at the 
final stage of the synthesis, the shell-wall will undergo an Ostwald ripening process (at 
high temperatures – reflux) resulting in a crystalline structure 
[66,69,71,72,76].  As already 
mentioned,  the  final  morphology  of  hollow  gold  NPs  is  pre-determined  by  the  silver 
template, e.g. shell-wall thickness of hollow gold will reach approximately 10 % of the 
template radius 
[66,69,71,72,76].   
 A  variety  of  shapes  and  sizes  of  silver  NPs  can  be  synthesised  by  simple  wet 
chemistry methods 
[66,69,71-73,76-79], e.g. Xia’s group developed a polyol method, utilising 
ethylene glycol (a solvent and Ag
+ reductant) 
[69,72,73,76,80,81].  At high temperatures (e.g. 
160  ºC),  ethylene  glycol  is  oxidised  to  glycoaldehyde,  which  then  serves  as  an  active 
reducing agent of Ag
+ to Ag
0.  The reduction rate and the final shape of silver NPs can be 
controlled  by  adjusting  the  reaction  temperature,  which  can  lead  to  the  formation  of: 
silver NPs 
Au
3+  
gold-silver 
alloy 
Au
3+  
gold-silver 
alloy 
Au
3+  
hollow gold NPs 
Ag
+   Ag
+  
Scheme 11.  Galvanic replacement reaction between Au
3+ and Ag
0 (A), taken from
 [66] 
and a schematic illustration of the formation of hollow gold NPs (B). 
A 
B  
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nanospheres,  nanocubes,  nanobars,  nanobeams,  nanorice,  nanoplates,  cuboctahedra  or 
bipyramids. 
As an alternative to the polyol route involving high temperatures, Oh and co-workers 
developed a seed mediated method for the preparation of silver nanorods and nanospheres, 
grown from small silver NPs (seeds) in the presence of a surfactant (CTAB) 
[78].  
Seeds are prepared by the reduction of the silver precursor (AgNO3, see Scheme 12A) 
with a strong reducing agent (NaBH4) and stabilised with sodium citrate 
[78]. 
 
        2NaBH4    +    2AgNO3    +    6H2O                      2Ag    +    2NaNO3    +    2H3BH4    +    7H2  
 
 C6H8O6   +   2AgNO3   +   2NaOH   +   seeds                      2Ag-seeds   +   C6H6O6   +   2H2O   +   2NaNO3 
 
 
 
 
 
From seeds, in an alkaline (NaOH) mixture of CTAB with the silver precursor and a 
weak  reducing  agent  (ascorbic  acid),  silver  NPs  are  grown  (see  Scheme  12B) 
[78].  
Spherical NPs were also prepared by this method, according to the protocol described in 
chapter 3. 
2.2.  NPs surface capping, further modifications and assembly. 
The surface of newly synthesised NPs (obtained with methods presented in the previous 
section) was stabilised by weakly bound protective agents (e.g. citrate anions, Scheme 
13A) or ionic surfactants (e.g. CTAB) via electrostatic or Van der Waals interactions 
[82-84].  
A physical barrier created by these molecules (steric hindrance) prevented direct contact 
between gold surfaces of neighbouring NPs 
[84].  
Such  NPs  are  soluble  in  water,  but  sensitive  to  pH  and  ionic  strength  changes  in 
solution 
[84-86].  Specifically, NPs are subjected to aggregation in media containing high 
concentrations  (e.g.  0.1  M)  of  sodium  chloride  (NaCl)  or  other  salts 
[87].    To  prevent 
instability in aqueous solutions, the surface of NPs can be capped with carefully chosen 
organic ligands (e.g. dithiols, thiols, amines and phosphines) 
[82-84,86-110].  These molecules, 
unlike  CTAB  or  citrate,  are  chemisorbed  on  the  gold  surface,  thus  providing  better 
Scheme 12.  Reduction of the silver precursor with a strong (A) and a weak (B) reducing 
agent, taken from 
[78].  
A 
B  
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stability, e.g. Schultz’s group demonstrated that bis(p-sulfonatophenyl)phenyl phosphine 
dehydrate dipotassium salt (BSPP, see Scheme 13B and chapter 3 for protocol) capped 5 
nm  gold  NPs  are  stable  in  0.3  M  NaCl  and  1  mM  magnesium  chloride 
[87].    The 
precipitation of larger (10 nm) NPs with 0.15 M NaCl was a reversible process, since NPs 
could be easily redispersed in fresh water.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
However, in the presence of thiols (e.g. glutathione), NPs stabilised with weak ligands 
(e.g. BSPP or amines) or protective agents can undergo displacement reactions and lose 
their original functionality 
[82-84,89].  Complete ligand substitution is possible because of 
much stronger interactions between thiol anchoring groups and the gold surface than, e.g. 
amines and gold 
[83,84].  Displacement reactions were successfully adopted and are now 
commonly used to functionalise gold NPs larger than 5 nm with thiol based ligands, since 
larger NPs cannot be easily obtained by direct synthesis in the presence of thiols 
[83,84,111]. 
A number of thiol based capping ligands have been reported in recent years, including: 
oligonucleotides 
[87,103-106,112],  peptides 
[90,92,95,113,114],  lipids 
[115],  polyethylene  glycols 
[91,98,107,116-118], alkylthiols and mercaptoacids 
[88,97,100,111,119,120], as well as newly developed 
polydiacetylene based ligand (DA-PEG) 
[89].  Some have been employed in the NPs surface 
capping  over  the  course  of  this  research  project,  and  will  be  discussed  further  in  the 
following sub-sections. 
 
Scheme 13.  Citrate (A) and BSPP (B) stabilised gold NPs 
[82].  
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2.2.1.  Oligoethylene glycol based capping ligand. 
An amphiphilic ligand based on oligoethylene glycol (OEG) was first employed to cap the 
surface of gold NPs by Brust and co-workers 
[99].  In the original version of the ligand 
proposed  by  Brust,  the  OEG  unit  contained  four  steps  of  ethylene  glycol  and  was 
terminated  with  a  hydroxy  group 
[99].    The  modified  version  employed  here,  was 
terminated with a carboxy group and consisted of six ethylene glycol steps (see Scheme 
14).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In general, the hydrophilic unit [-(CH2CH2O)6-OCH2-COOH] ensured NPs solubility 
in  aqueous  media 
[82,99]  and  allowed  further  modifications  with,  e.g.  amine  containing 
molecules (via the formation of an amide bond) using standard catalysts, e.g. 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide 
[117,121-123] (see section 2.2.1.1.).  Except the OEG unit, 
the ligand also contained an alkyl chain, terminated with a thiol anchoring group, which 
chemisorbed directly on the surface of gold NPs 
[83,84,99].  The alkylthiol unit of OEG 
provided a uniform hydrophobic layer with carbon chains of neighbouring ligands closely 
packed via Van der Waals interactions 
[82,99].  
As demonstrated in chapter 4, it was possible to stabilise with OEG, a number of 
different  types  of  gold  NPs,  including  spherical,  rod-like,  hollow  and  core/shell  (see 
chapter  3  for  capping  protocols).    OEG  capped  NPs  showed  good  stability  against 
Scheme 14.  Schematic representation of OEG capping layer on gold NPs.   
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aggregations in a wide pH range and in a presence of salts (see chapter 4 for stability 
tests). 
2.2.1.1.  Further modifications of NPs surface. 
As previously stated, OEG capped NPs can be further modified with amine containing 
molecules  via  simple  coupling  chemistry  methods,  e.g.  using  1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) as a catalyst 
[121].  
EDC is a commonly used zero-length crosslinker, which couples carboxyl groups with 
primary amines 
[121].  Initially,  EDC  reacts  with  a  carboxylic  group  to  form  an  amine 
reactive intermediate (O-acylisourea, see Scheme 15).  O-acylisourea can either react with 
the amine or undergo hydrolysis and regeneration to the carboxyl.  To avoid hydrolysis, N-
hydroxysulfosuccinimide (s-NHS) is often used to increase the efficiency of the reaction.  
S-NHS is known to stabilise O-acylisourea, by converting it into amine reactive s-NHS 
ester.  
EDC/s-NHS method was reported before in conjugation of various biomolecules to 
NPs, e.g. Nie and co-workers coupled proteins to mercaptoacetic acid capped quantum 
dots using EDC 
[123], while Mason’s group conjugated antibodies to polyethylene glycol 
(PEG) coated gold NPs with EDC/s-NHS 
[117].  It will be demonstrated in chapter 4 that 
using EDC/s-NHS (see chapter 3 for protocol) also small peptides can be conjugated to 
OEG stabilised gold NPs (spherical, rod-like, hollow and core/shell).    
 
Chapter 2 – Theoretical background 
 
 
24 
N
H
O
OH
O
NH
N
NH
Cl
-
+
O
O
N C N Cl- NH+
N
HO
O
S
O
O
O
O
-
N O
O
S
O
O
O
O
-
O
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
Scheme 15.  Schematic  illustration  of  EDC/s-NHS  coupling  reaction  between  OEG 
capped gold NPs and amine group containing molecule. 
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2.2.2.  Diacetylene based capping ligand. 
A new type of capping ligand, namely 46-mercapto-22,43-dioxo-3,6,9,12,15,18-hexaoxa-
21,44-diazahexatetraconta-31,33-diyn-1-oic  acid  (DA-PEG)  was  developed  during  this 
research project 
[89].  The key feature of this design was a diacetylene group, which can be 
polymerised by ultra violet (UV) light induced 1,4-topochemical polymerisation, resulting 
in poly(enyne) structures 
[89,119,124-129] (Scheme 16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DA-PEG ligand consists of hydrophobic and hydrophilic units.  The hydrophobic part 
contains an alkyl chain with a diacetylene group and is terminated with a thiol anchoring 
group.    The  hydrophilic  component  is  based  on  a  carboxyl  terminated  hexa-ethylene 
Scheme 17.  Schematic representation of photo-crosslinked DA-PEG capping layer on 
gold NPs.  
UV-irradiation 
Scheme 16.  Schematic representation of diacetylene groups photo-crosslinking 
[89,  118, 
123-128].  
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glycol, providing water solubility and the possibility of further modifications (e.g. EDC/s-
NHS coupling, see the previous section).  
As demonstrated in chapter 4, photo-crosslinked DA-PEG capped NPs (see Scheme 
17) display enhanced stability against aggregation in buffered environments at a broad 
range of  pH.  These  NPs  are also  resistant to  temperature variations,  ligand  exchange 
reactions and high ionic strength solutions.  Their stability derives from a crosslinked shell, 
which is created by photo-polymerisation of DA-PEG monomers already attached to the 
surface of NPs. 
2.2.3.  CALNN peptide based capping ligand. 
Levy and co-workers designed a penta-peptide (CALNN), which can serve as a capping 
ligand for gold NPs 
[92,95,113].  N-terminus cysteine (C) provides the peptide with a thiol 
anchoring group.  Hydrophobic side chains of alanine (A) and leucine (L) residues promote 
self-assembly of peptides on the gold surface.  The side chain of the first asparagine (N) is 
hydrophilic  but  uncharged, while  the C-terminus  asparagine  (N) is negatively charged.  
CALNN-capped NPs are stable in buffered environments, up to 1 M NaCl, as well as 
basic, neutral and slightly acidic pH.  
Brust and co-workers demonstrated that bi-functional CALNN based gold NPs can be 
prepared,  simply  by  using  mixed  peptide  monolayers  composed  of  CALNN, 
CALNNGKbiotinG  or  CALNN-DNA  conjugates 
[92].    Following  this  idea, 
oligodeoxynucleotide (ODN) binding NPs were developed during this research project, in 
a close collaboration with Stulz’s group (School of Chemistry, University of Southampton, 
Southampton, UK) 
[114].  A key part of this design was a penta-peptide sequence (FQGII), 
which  as  shown  by  Sasaki  and  co-workers,  can  selectively  bind  to  an  AT-rich  (A  – 
adenosine, T – thymidine) region of a short deoxyribonucleic acid (DNA) duplex with a 
high binding constant 
[130,131].  Consequently, a bi-functional capping ligand composed of 
CALNN  and  FQGII  sequences  linked  by  aminohexanoic  acid  (Ahex)  was  derived.  
CALNN-Ahex-FQGII (c-FQGII) ligand was mixed with CALNN peptide and employed in 
the preparation of ODN binding gold NPs (see Scheme 18 and chapter 3 for experimental 
details).         
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2.2.3.1.  Assembly of NPs on oligodeoxynucleotide templates. 
Gold NPs capped with a mixed layer of CALNN/c-FQGII were employed in the formation 
of  NPs  assemblies  on  ODN templates 
[114].   Two ODN  based systems  were  designed.  
Specifically, long DNA duplexes, which were formed from two different, staggered ODNs 
(Scheme 19A) and a short self-complementary building block (Scheme 19B).  The self-
complementary construct contained two AT-steps (see chapter 3 for detailed sequence), 
while the staggered duplex had AT-regions at regular intervals along the duplex length.   
Scheme 18.  Schematic representation of CALNN/c-FQGII capping layer.   
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According to Scheme 19, it was anticipated that the long ODN based construct would 
form extended chains of NPs, while the short building blocks would rather bind around the 
NP with little or no control of NPs organisation.  The resulting assemblies of NPs will be 
presented and discussed in chapter 4. 
2.3.  Physicochemical properties of capped gold NPs. 
At  the  nanoscale,  materials  exhibit  properties  not  seen  in  bulk 
[7,15,16,27-30,39,53-
55,65,70,73,82,102,132-146], e.g. gold NPs smaller than the light wavelength, are subjected to an 
optical phenomenon, called surface plasmon resonance (SPR) 
[135,142,143,147].  SPR derives 
from free conductive electrons, which collectively oscillate in a resonant frequency with 
the  electromagnetic  wave,  resulting  in  enhanced  absorption  and  scattering  (extinction) 
properties of NPs (see Scheme 20) 
[135,142,143,147].  
 
 
 
 
 
 
 
 
 
Scheme 19.  Schematic  representation  of  the  ODN-NPs  arrays  formed  along  pseudo-
infinite duplexes (A) or short self-complimentary building blocks (B) 
[114].  
A  
B  
electromagnetic 
field 
electron-cloud 
of metal NPs 
Scheme 20.  Schematic  representation  of  interactions  between  metal  NPs  and  the 
electromagnetic radiation of wavelength, taken from 
[135].  
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B 
B 
As predicted by Mie’s theory, SPR of NPs is controlled by the shape and size of NPs, 
as well as electric properties of the embedding material (Fig. 1A) 
[27,135,142,143,147].  If the 
dielectric constant of the surrounding medium is represented as εm, while ε’(λ) + iε” (λ) is 
the dielectric function of the nanoparticle, the maximum extinction of spherical NPs occurs 
as a single plasmon band at λ wavelength, where ε’ = -2εm.  According to equation A, the 
SPR position of spherical colloids, suspended in different solvents would vary slightly.  
Also self-assembly or aggregation of NPs would lead to a shift (into longer wavelengths, 
see section 4.2.1. for NPs assemblies spectra) of the SPR peak, based on the plasmonic 
coupling between NPs. 
In general, spherical NPs absorb in the visible region of the electromagnetic spectrum.  
The  SPR  position  of  non-spherical  NPs  (e.g.  rods)  depends  on  the  orientation  of  the 
electromagnetic  field 
[27,142,148,149].    Consequently,  in  elongated  nanostructures,  two 
oscillation  peaks  are  possible;  along  the  longitudinal  and  the  transverse  axis.    The 
longitudinal peak is usually shifted into the infra-red spectral region and its exact position 
depends on the nanoparticle width-to-length aspect ratio.  To calculate the SPR of rod-like 
nanostructures, the orientation of NPs to the oscillating electric field must be accounted, as 
proposed by Gans (Fig. 1B) 
[149].  In this equation, depolarisation factors for the nanorod 
axes  are  represented  by  Pj.    Following  this  idea,  El-Sayed  and  co-workers  calculated            
(Fig. 1C) how the nanorod aspect ratio (a/b) and the wavelength at which the maximum 
longitudinal SPR occurs (λmax) are correlated 
[148].  
      
        
   
 
  
                  
      
       
   
    
 
 
  
    
    
    
  
            
              
 
 
                   
 
  
 
The SPR of other types of NPs, like hollow gold or core/shell nanostructures can be 
calculated by other numerical approaches, e.g. the discrete dipole approximation (DDA) of 
Mie’s theory 
[70,134,150-155].  In the DDA, the nanoparticle is considered as a group of N 
A 
Figure 1.  Mie’s  theory  for  spherical  NPs  (A) 
[142],  extinction  cross -section  of 
elongated NPs by Gans (B) 
[149] and empirically calculated by El-Sayed the 
longitudinal SPR (C) 
[148].  
C  
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identical elements.  Each element is approximated by the polarisable dipole point, located 
at the certain position in the local electromagnetic field.  The dipole moment is affected by 
other dipoles in the nanoparticle.  Following this idea, it was calculated that the SPR of 
hollow gold  NPs,  strongly depends  on the shell thickness  and the nanoparticle  radius, 
while the plasmon band of silica/gold core/shells is determined by core-to-shell size ratio 
[70,134,150,152,154]. 
As  already  mentioned  the  extinction  of  NPs  is  comprised  of  both,  absorption  and 
scattering.    As  demonstrated  by  El-Sayed  and  co-workers,  small  gold  NPs  (20  nm  in 
diameter) mostly absorb the light, whilst scattering effects are negligible 
[154].  Whereas, 
increasing  the  size  of  NPs  results  in  a  more  significant  contribution  of  the  scattering 
component  to  the  overall  excitation  spectra.    Absorption  and  scattering  cross-section 
characteristics determine possible (based on the optical properties) applications of NPs, 
e.g.  as  high  contrast  agents  in  new  imaging  techniques 
[11,41,70,134,144,147,154,156-162].  
Predominantly scattering NPs can be used in optical coherence tomography and reflectance 
confocal microscopy.  Predominantly absorbing NPs can be employed in micro-absorption 
spectroscopy techniques, which are based on detecting shifts in the SPR caused by changes 
in the refractive index of the surrounding medium.  
Gold  NPs  can  generate  heat  after  the  SPR  absorption  of  light,  e.g.  the  laser  light 
[5,7,15,16].    Specifically,  the  laser  electric  field  induces  carriers’  vibrations  inside  the 
nanoparticle.    These  movements  release  energy,  which  is  then  converted  into  heat.  
Generated heat diffuses away from the nanoparticle and increases the local temperature of 
the surrounding medium.  In general, the temperature increase is proportional to the second 
power of the nanoparticle radius and depends on the energy coming from the laser light 
and the heat transfer from the NPs surface.  As an example, Richardson and co-workers 
calculated that a single gold nanoparticle, around 60 nm in diameter, can generate 5 μW of 
heat if SPR-illuminated with 2 mW laser light 
[16].  Moreover, the heating intensity can be 
enhanced  by  collective  effects  of  several  NPs,  based  on  Coulomb  interactions  and 
accumulative effects; more NPs lead to a stronger temperature increase 
[16]. 
The ability to convert absorbed light into localised heat by gold NPs was applied in 
photo-thermal therapy of cancer 
[3,4,6-14,156,161,163-166] and bacterial infections 
[156,167] using 
near-infrared  (NIR)  absorbing  NPs.    Such  requirements  are  necessary,  because  of  the 
absorption properties of the tissue components, e.g. haemoglobin (red blood cells) or water 
(major component of all tissue types) 
[168-170].  As demonstrated in Fig. 2, haemoglobin 
strongly absorbs in the visible spectral range, while water becomes absorbing over the NIR  
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region.    In  the  region  between  650  and  900  nm  both,  water  and  haemoglobin  are 
transparent,  resulting in the highest  transitivity  of the tissue  (biological NIR window).  
Consequently, tissue can be penetrated by the laser light at the frequency falling within the 
biological NIR window.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The main idea of the laser induced NPs mediated cancer treatment, is that the NIR 
laser light will pass through the healthy tissue (without causing any damage) and will be 
absorbed by NPs placed inside the tumour 
[3-15,47,134,144,147,156,161,163-166,168-175].  The light will 
be then converted into localised heat, resulting in the increase of the local temperature 
around the tumour site.  A few degrees increase of the local temperature (depending on the 
laser  power  and  heating  properties  of  NPs)  will  cause  damage  to  cancerous  cells  and 
B 
Figure 2.  Extinction coefficients of haemoglobin (A, full line), haemoglobin-oxygen 
complex (A, dashed line) and water (B); taken from 
[168-170]. 
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destroy the tumour 
[3,4,6-16,161,163,176-183].  The mechanism of heat damage in cells will be 
discussed in the section 2.6.2. (see also chapter 7).  
Sufficient tumour damage can be obtained only when NPs optical signatures, thus the 
ability to generate heat, are retained within the cellular matrix.  This can be achieved by 
capping of the NPs surface with appropriate ligands, which was already discussed in the 
previous section.  The functionality of NPs also determines their chemical properties (e.g. 
hydrophilicity or charge, see chapter 4).  When biomolecules (e.g. peptides or antibodies) 
are  incorporated  in  the  capping  layer,  NPs  can  be  employed  in  selective  targeting  of 
desired  tissue  or  cell  types,  e.g.  tumours 
[116,117,122,147,157-159,164-166,175,184-197].    Possible 
mechanisms  of  interactions  between  cells  and  NPs  will  be  discussed  in  the  following 
section. 
2.4.  Interactions of NPs with mammalian cells. 
As mentioned previously, the mechanism of interactions between NPs and cells depends 
on  the  NPs  functionality 
[19,98,116,117,122,147,157-159,164-166,175,184-186,188-191,193-222].    ‘Bare’  NPs 
(meaning: without any specific functionality) would interact with cells in a non-selective 
manner,  controlled  by  the  size,  shape  and  charge  of  NPs 
[186,190,206,213,214,221]  (see  also 
chapter 5).  As demonstrated by several research groups, ‘bare’ NPs can be internalised by 
mammalian  cells  by  engulfing  with  cellular  membrane  (endocytosis,  Scheme  21) 
[186,206,214,221].  Uptaken NPs are confined within cellular vesicles (e.g. endosomes), which 
can  be  either  secreted  out  of  the  cell  (exocytosis)  or  fused  with  other organelles,  like 
lysosomes.  
Chan and co-workers reported that spherical and rod-like NPs are both endocytosed by 
cancerous  cells  (HeLa,  see  section  2.5.),  however  spherical  NPs  are  taken-up  more 
efficiently than rod-like NPs 
[206,214].  It was demonstrated that, the uptake rate of 50 nm 
NPs was higher than 14 or 74 nm, while 14 nm NPs were exocytosed the fastest.  In 
general, neutral or positively charged NPs interact stronger with the cellular membrane 
than negatively charged NPs, which are repelled from it 
[206,213]. 
To achieve better control upon interactions between cells and colloids, biomolecules 
can be incorporated in their organic corona 
[84,92,98,116,117,121,122,147,157-159,164-166,173,184-190,193-
198,201,202,204,205,207,210,217,223,224] (see also chapter 6).  NPs conjugated to biomolecules can 
interact  with  cells  in  a  selective  manner,  driven  by  precise  recognition  between 
biomolecules and their receptors allocated on the cellular membrane (Scheme 21).  The  
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binding event triggers a cellular response, which can lead to NPs internalisation or a signal 
transduction within the cell (while the receptor-biomolecule-NPs complex stays outside the 
cell).  The efficiency of selective targeting of mammalian cells, depends on the type of 
biomolecules attached to NPs and on the cell type 
[117,195,197,198,210,217,223].  This is because, 
on the cellular membrane of each cell type a different family of receptors is dominating, 
thus the use of cell type specific biomolecules and nanocomposites is required; e.g. Andres 
and  co-workers  demonstrated  that  folic  acid  functionalised  gold  NPs  were  selectively 
taken-up by foliate receptor positive cancer cells, while their uptake was minimal in cells 
that do not over-express these receptors 
[195]. 
 
 
 
 
 
 
 
Since  the  cellular  fate  of  NPs  strongly  depends  on  the  cell  type,  two  kinds  of 
mammalian cells (cancerous and healthy human cells) employed in this research, will be 
introduced and discussed in the following sections.                                                                                                                                         
2.5.  HeLa cells. 
HeLa is an immortal cell line, derived from human cancerous cells and one of the most 
commonly used in scientific research 
[225-229].  It was isolated from cervical cancer cells of 
Henrietta Lacks (Note: HeLa were named after the patient – two first characters of her 
Scheme 21.  Schematic  illustration  of  selective  (left)  and  non-selective  (right) 
interactions between NPs and cells. 
cellular 
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name and surname), who died of cancer in 1951 
[225,226].  HeLa was propagated by George 
Otto Gey without donor’s permission and later commercialised 
[225,229].  
As long as sufficient amount of nutrients, oxygen and growth space are provided in the 
cell  culture,  HeLa  can  divide  an  unlimited  number  of  times 
[225-228,230]  (Note:  healthy 
human cells normally split only several times, then undergo apoptosis – programmed cell 
death, while cancerous cells do not commit suicide 
[228,231]).  HeLa evolved in many strains 
after being cultured in separate laboratories 
[227,232].  Some of them might over-express 
types  of  receptors, which are deficient in  other HeLa strains.   HeLa  employed in  this 
project, do not over-express growth factor receptors (see the next section), thus served as a 
negative control (see chapter 6).  
2.6.  Endothelial cells. 
Endothelial cells are healthy human cells, which build the internal layer of blood vessels 
(endothelium) 
[2,233,234].  In the endothelium, cells are linked by cell-to-cell junctions or 
adhesive  structures  to  form  a  continues  monolayer 
[233,235,236].    Endothelial  monolayers 
serve  as  selective  barriers  between  blood  and  tissues,  participating  in  important 
physiological  processes 
[2,233,237].    Endothelial  cells  are  involved  in  response  of  the 
organism to a pathogen (inflammation), in a modulation of blood flow and blood vessel 
tone, as well as the formation of blood vessels (angiogenesis) 
[1,2,26,233,238].  
The  angiogenesis  process  is  controlled  by  a  complex  signalling  between  cells, 
involving  binding  of  secreted  biomolecules  to  appropriate  cell  surface  receptors 
[1,2,17,18,20,21,24-26,233,237-251].  Three major types of signalling molecules have been reported: 
a) angiopoietins – important for further vessel remodelling, b) ephrins – participating in 
primary vessel remodelling and c) growth factors – acting as angiogenesis initiators.  A 
growth factors family, called vascular endothelial growth factors (VEGF) is considered as 
a major regulator of angiogenesis 
[1,21,240,243,245,247-249,251].  There are six members of the 
VEGF family (types A, B, C, D, E and a placental growth factor – PIGF) 
[240,243,245,252-254].  
Each type consists of several isoforms.  Every isoform is composed of a different number 
of amino acids, resulting in molecular weight variations, e.g. there are two isoforms of 
VEGF-B with molecular masses of 167 and 186 kDa.  
Each isoform binds to a specific receptor (or receptors) over-expressed by endothelial 
cells, including four types of vascular endothelial growth factor receptors (VEGFR type 1, 
2 and 3, as well as a soluble form of VEGFR-1) and two neuropilin receptors (NRP types 1  
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and 2) 
[240,243-245,247,252-254].  NRP-1 and VEGFR-1 can both be targeted with VEGF-B167 
isoform, while VEGF-A165 shows binding affinity towards VEGFR-2, NRP-1, NRP-2 and 
a soluble form of VEGFR-1.  It is important to highlight that types of receptors over-
expressed by different types of endothelial cells significantly vary, thus particular types of 
endothelial cells  generate specific responses to  the same stimuli 
[1,233,234,244,253,254].  For 
instance, lymphatic endothelial cells mainly express VEGFR-3, while VEGFR-1 and 2 are 
expressed by vascular endothelial cells.  
A  sub-type  of  vascular  cells,  specifically  human  umbilical  vein  endothelial  cells 
(HUVECs) was employed in this project.  These cells were isolated from umbilical cords 
by Dr Timothy M. Millar (School of Medicine, University of Southampton, Southampton, 
UK) according to a protocol described in chapter 3.  Since cells isolated from individual 
donors, even from the same cord, can vary their response to the stimuli, each experiment 
(see chapter 6 and 7) was performed in at least three repeats, using separate cords of 
HUVECs.  Research efforts were focused on targeting two receptors over-expressed by 
these cells; specifically VEGFR-1 and NRP-1 (see chapters 6 and 7).  
VEGFR-1  is  a  trans-membrane  tyrosine  kinase  receptor 
[240,244,247,249,250,252-254].  
Meaning, receptor binding and formation of receptor-ligand complexes is followed by the 
phosphorylation  and  activation  of the intracellular signalling pathways,  while receptor-
ligand complexes  stay outside the  cell.    NRP-1  serves as  a  co-receptor, regulating the 
formation of VEGFR-1-ligand complexes 
[18,241,243,248,249,254].  NRP-1, upon ligand binding, 
undergoes  trafficking  on  the  cell  surface  followed  by  endocytosis  of  receptor-ligand 
complexes.    Both,  NRP-1  and  VEGFR-1  actively  participate  in  the  regulation  of 
angiogenesis  process 
[1,18,21,26,233,238,240,243,244,247,248,252-254].    The  mechanisms  of  blood 
vessels formation will be discussed in more details in the following sub-section. 
2.6.1.  Angiogenesis. 
Physiological angiogenesis, in an adult healthy organism, occurs only during a cycling 
ovary, pregnancy and wound healing 
[1,2,26,233,234,238].  New capillaries are formed either by 
sprouting or by vessels splitting 
[1,2,233,255].  Sprouting angiogenesis starts from proteolitic 
digestion of the extracellular matrix.  This is followed by migration and proliferation of 
endothelial  cells,  lumen  formation  and  maturation  of  endothelium.    In  non-sprouting 
angiogenesis,  vessels  split  by  trans-capillary  pillars  or  posts  of  extracellular  matrix.  
Mature vessels undergo remodelling, until fully functional endothelium is formed 
[1,233,255].   
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The formation of endothelium is regulated by a fragile balance (angiogenic switch) 
between  angiogenesis  stimulators  (e.g.  growth  factors)  and  inhibitors 
[1,2,233,253,255].  
Disruptions in this homeostasis lead to a pathological angiogenesis and many disorders 
[1,20,25,26,233,238,242,253,255].  Insufficient angiogenesis occurs in coronary artery disease and 
strokes, while excessive neo-vascularisation takes place in rheumatoid arthritis and cancer.  
As illustrated in Scheme 22, tumour angiogenesis is initiated by cancerous cells, which 
secrete various stimuli (e.g. VEGF-A) 
[1,25,233,238,253,255].  Upon stimulation, endothelial cells 
migrate into the tumour site and new blood vessels are being formed.  Newly developed 
Scheme 22. Schematic illustration of tumour angiogenesis. 
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blood  vessels  supply  cancerous  cells  with  essential  nutrients  and  oxygen,  resulting  in 
tumour growth, progression and metastasis.  
Since tumours require continues nutrient supply to expand, their prolonged cut off can 
lead  to  cancer  regression 
[21,25,26,238].    This  can  be  achieved  by  inhibiting  tumour 
angiogenesis with e.g. angiogenesis inhibitors 
[20,21,24-26,238,242].  Consequently, a number of 
cancer therapies developed in recent years, are based on anti-angiogenic molecules 
[1,20-
25,192,193,239,242,255,256].    These molecules are  prone to  target  endothelial cells, rather than 
cancerous cells.  This is a clear advantage, because endothelial cells, unlike cancerous 
cells, are genomically stable and remain sensitive to angiogenesis inhibiting drugs 
[1,2,20-
26,192,193,228,230-234,239,242,255-257].  In general, anti-angiogenic therapies, baring minimum level 
of  side  effects,  are  considerably  safer  than  e.g.  tumour  chemotherapy 
[1,2,20-
23,25,26,192,234,238,239,255,256].    Also  therapies  against  other  disorders,  e.g.  coronary  artery 
disease,  are  being  developed 
[1,2,17,19,20,22,233,234,238,249,250,255].    These  are  based  on  pro-
angiogenic drugs, stimulating insufficient angiogenesis. 
Several  natural  (e.g.  growth  factors  antibodies  or  interleukin)  and  synthetic  (e.g. 
peptides) pro- and anti-angiogenic compounds are currently under clinical trials 
[20,238], but 
there  is  still  a  demand  for  new  angiogenesis  regulators.    Especially  peptide  based 
molecules seem to be promising candidates.  Following this idea pro- and anti-angiogenic 
octa-peptides were developed during this project (see the following sub-section for details).   
2.6.1.1.  Octa-peptide based angiogenic regulators. 
In  general,  peptide  based  drugs  can  be  prepared  by  undemanding,  well-known  and 
relatively cheap chemical protocols (e.g. solid state synthesis) 
[20,158,258].  It is possible to 
adjust the physicochemical properties of peptides (e.g. hydrophilicity) by simply replacing 
(mutating)  the  amino  acid  residues 
[259-261].    Shuffling  the  amino  acid  order  leads  to 
changes  in  the  primary  structure  and  conformation  (secondary  structure)  and  more 
importantly in the overall bioactivity of peptides 
[261-263].  Peptides, unlike large proteins or 
antibodies, possess only one epitope (biological recognition element) and are considered as 
structurally  more  stable 
[20,158].    Reduced  molecular  complexity  makes  them  ideal 
candidates  to  study  molecular pathways  of dissect  biological  response  and to  visualise 
specific receptor targets (e.g. peptides labelled with fluorescent tags or NPs), as proposed 
by Benedetti and co-workers 
[20].  Any side effects
 and immunogenicity deriving from 
multiple epitopes is likely to be reduced, when employing peptides as drugs.  
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Several peptides showing pro- or anti-angiogenic activities have been reported so far 
[18,20,193,241,246,264].    Perret  and  co-workers  reported  anti-angiogenic  ATWLPPR  peptide, 
which inhibits VEGF-A165 binding to NRP-1 via LPPR motif 
[18].  Pedone and co-workers 
on the other hand, proposed a VEGF-A mimicking peptide (Ac-KLTWQELYQLKYKGI-
amide), which can bind and activate VEGFR’s, thus exhibits pro-angiogenic activity 
[264].  
Also based on the VEGF-A structure was a cyclic peptide (CPQPRPLC), reported by Arap 
and  co-workers 
[246].    The  RPL  tri-peptide  within  this  sequence,  displayed  the  affinity 
towards VEGFR-1 and NRP-1.   
 
 
 
 
 
  
 
 
 
 
 
 
 
Following the idea of angiogenesis regulating peptides, it was intended to design a 
new family of peptides composed of the same number of amino acid residues and showing 
similar physicochemical properties (e.g. hydrophilicity), but different angiogenic activity.  
Consequently, three different sequences were deliberated, out of which one was designed 
to serve as an angiogenesis inhibitor, second as an activator and third to show no activity.  
The design of pro-angiogenic sequence was based on RPL motif (Scheme 23A), proposed 
by  Arap  and  co-workers 
[246],  while  anti-angiogenic  –  on  LPPR  motif  (Scheme  23B), 
A 
B 
Scheme 23.  Schematic illustration of RPL (A) and LPPR (B) motifs; prepared by Mr 
Jonathan  R.  Burns  (Stulz’s  group,  School  of  Chemistry,  University  of 
Southampton, Southampton, UK).  
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introduced by Perret’s group 
[18].  Except of an appropriate activity, peptides had to contain 
a functional group, allowing conjugation with fluorescent tags or NPs (e.g. OEG NPs).  
One  popular  conjugation  method  is  EDC/s-NHS  coupling 
[121]  (already  discussed  in 
section  2.2.1.1.).    This  technique  requires  a  primary  amine  group,  involved  in  the 
formation of an amide bond between conjugated molecules.  Consequently, N-terminus 
lysine  (K)  containing  two  primary  amines  (N-terminus  and  side  chain)  was  fixed  in 
position one of all three deliberated sequences.   
In  one  of  proposed  sequences,  first  amino  acid  residue  (K)  was  extended  by 
ATWLPPR fragment, which according to Perret and co-workers, shows anti-angiogenic 
activity 
[18].  By this way KATWLPPR octa-peptide was selected (Scheme 24, P3) to act as 
an inhibitor.  Two remaining sequences should therefore also be eight amino acids long. 
 In the design of the pro-angiogenic octa-peptide, CPQPRPLC sequence served as a 
starting point 
[246].  Since this cyclic peptide already contains eight amino acids, at least one 
of them had to be replaced to introduce N-terminus K, which is necessary for the future 
conjugation.  When conjugating to OEG NPs (see section 2.2.), two cysteine (C) residues 
(in positions one and eight) of the cyclic sequence should be considered as problematic, 
since side chain of cysteine contains a thiol group 
[83,84,89] (Note: thiols can bind to NPs 
surface, see section 2.2.).  Consequently, both cysteines were removed from the sequence.  
First was replaced with K residue, while the other one with serine (S), which shows similar 
side chain structure as C, with a hydroxyl instead of a thiol group 
[260,261].  This resulted in 
KPQPRPLS sequence (Scheme 24, P1).  Within this sequence, simply by scrambling the 
amino  acid  arrangement,  randomly  mutated  version:  KPRQPSLP  was  created.    The 
mutated  sequence  (Scheme  24,  P2)  was  expected  to  lose  its  binding  affinity  towards 
growth factor receptors and show no angiogenic activity.  
All three sequences are positively charged, with a calculated 
[260] net charge value 2 (at 
pH  7).    The  isoelectric  points  are  11.5.    There  are  only  slight  variations  in  peptides 
hydrophilicity.  P3 consist of 25 % hydrophilic residues and its calculated 
[260] average 
hydrophilicity is 0, while P1 and its mutated version (P2) contain 50 % of hydrophilic 
amino acids, showing 0.6 average hydrophilicity.  Detailed studies upon binding affinity 
towards growth factor receptors (VEGFR-1 and NRP-1) and the resulting bioactivity of 
these newly developed octa-peptides and peptide-OEG NPs (pep-OEG NPs) conjugates 
will be demonstrated in chapter 6. 
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Scheme 24.  Chemical  structures  of  octa-peptides.  N-terminus  lysine  (K)  residue  is 
marked in blue; binding motifs in green.   
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2.6.1.2.  NPs in angiogenesis 
NPs have been used before as angiogenesis regulators, e.g. Mukhopadhyay and co-workers 
demonstrated pro-angiogenic activity of europium (III) hydroxide nanorods, promoting the 
proliferation  and  vascular  sprouting  of  HUVECs  in  a  dose  dependent  manner 
[19].  
Angiogenesis  induction  was  attributed to  an  increase  in  the  production  of  the  reactive 
oxygen  species  (ROS),  deriving  from  uptaken  nanorods.    Mukhopadhyay’s  group  also 
reported anti-angiogenic activity of gold NPs, which were pre-incubated with VEGF-A165, 
then employed in treatment of endothelial cells 
[23,200,256].  Angiogenesis was not induced 
with VEGF-A165-NPs complexes, because VEGF-A165 binds to the gold surface through 
cysteine residue.  Since, cysteine is located in the active site of the protein, VEGF-A165 
activity  is  blocked  upon  NPs  binding.    These  attractive  properties  of  nanomaterials 
however,  are  purely  based  on  non-selective  interactions  between  ‘bare’  NPs  and 
biostructures 
[19,23,200,256], which do not provide sufficient control over their cellular fate.  
To  overcome  this  issue,  various  molecules,  including  selective  receptor  targeting 
agents  and/or  pro-  or  anti-angiogenic  drugs,  can  be  attached  to  NPs 
[20,121,122,147,158,159,162,165,184,186,190,192-195,197,215,223] (see sections 2.2. and 2.4.).  Cheresh and 
co-workers reported cationic vesicles conjugated to a molecule, which selectively targets 
αvβ3  integrin  (Note:  αvβ3  integrin  is  a  receptor  involved  in  cell  adhesion  to  the 
extracellular matrix and over-expressed by endothelial cells during neo-vascularisation) 
[265].  Except of the integrin, NPs were carrying a mutated gene, which blocks endothelial 
signalling and angiogenesis.  In vivo treatment with these NPs resulted in endothelium 
apoptosis, leading to tumour regression.  
A selective approach based on octa-peptides (see the previous section) conjugated to 
gold NPs (pep-OEG NPs) was adapted in this research project.  Pep-OEG NPs have a 
uniform organic layer composed of OEG capping ligands and octa-peptides.  The octa-
peptide serves as both, selective targeting agent and angiogenesis regulator (see chapter 
6).  One clear advantage of using pep-OEG NPs is their diverse bioactivities, as determined 
by the peptide sequence (P1 is an activator, while P2 an inhibitor).  Another benefit from 
adapting pep-OEG NPs comes from the metallic core of NPs, e.g. NIR absorbing gold NPs 
can be applied in laser induced thermal treatment of cells (see section 2.3.).  Consequently, 
endothelium targeted with pep-OEG NPs and exposed to NIR laser light would either be 
destroyed or certain cellular response would be induced (see chapter 7 for results and the 
following section for the theoretical background).  
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2.6.2.  Physiology of HUVECs under heat shock. 
It  is  widely  accepted  that  all  types  of  cells  are  affected  by  the  exposure  to  elevated 
temperatures  (hyperthermia) 
[3,4,6,8-14,161,163,176-183,239,266-269].    Heat  acts  as  stress  stimuli, 
leading to a cellular heat shock response 
[176-182,239,266-269].  This involves the expression of 
certain  types  of  proteins,  called  heat  shock  proteins  (HSPs)  and  is  followed  by  cell 
recovery 
[178,181,266-269].    More  severe  heating  eventually  activates  apoptotic  program 
(programmed  death;  suicide),  while  extreme  heat  leads  to  cellular  necrosis  (premature 
death; external factors) 
[3,4,8,12,14,176,180,181]. 
 
Hence, it can be distinguished between death causing primary effects of heat and an 
active cellular response to the heat stressor (e.g. expression of HSPs) 
[176-183,239,266-269].  In 
general,  direct  heat  leads  to  physicochemical  and  molecular  changes,  which  include: 
inhibition of replication, transcription and translation of several genes, arrest in a certain 
cell  cycle  phase,  degradation  (e.g.  denaturation)  of  proteins  and  cytoskeleton  and 
disruption  in  cellular  membrane  permeability.    These  changes  effectively  lead  to 
hyperthermia induced cell death and can be considered as its biochemical mechanisms.  On 
the contrary, in a response to nonlethal heat stress, cells undergo complex biochemical 
adaptation processes.  These include distortions in expression levels of several genes and 
activities of expressed proteins. 
In HUVECs, hyperthermic treatment inhibits, e.g. biosynthesis of adhesion proteins, 
like  endothelial  adhesion  molecule  (ELAM-1)  and  inter-cellular  adhesion  molecule 
(ICAM-1),  as  reported  by  Justus  and  co-workers 
[267].    ELAM-1  is  not  constitutively 
expressed by HUVECs, but can be induced upon stimulation with various factors (e.g. 
tumour  necrosis  factor),  while  ICAM-1  is  over-expressed  by  non-stimulated  cells 
[267,270,271].  ELAM-1 serves as a mediator of neutrophil granulocytes (type of white blood 
cells) migration and adhesion to the endothelial layer, as well as adhesion of circulating 
cancerous cells (tumour metastasis) 
[270,272-274].  ICAM-1 participates in adhesion of T-cells 
(lymphocytes,  a  type  of  white  blood  cells),  as  well  as  neutrophil  and  eosinophil 
granulocytes (type of white blood cells) 
[271,275-278].  Heat mediated inhibition of adhesion 
molecules  expression  in  HUVECs  can  therefore  lead  to  the  suppression  of  tumour 
metastasis, while tumour growth can be inhibited by the destruction of endothelium 
[21,24-
26,192,239,265,279]  (see  section  2.6.1.).    According  to  Bouchier-Hayes  and  co-workers, 
endothelial cell apoptosis can be induced when moderate heat treatment is combined with 
ROS treatment, resulting in enhanced
 heat shock by simultaneous oxidative stress
 response  
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[279].  However, as demonstrated in chapter 7, NPs mediated (laser induced) hyperthermia 
alone (without additional ROS stressors) can also lead to cell death. 
It  is  also  worth  highlighting  that  healthy  mammalian  cells  (e.g.  HUVECs)  are 
generally less sensitive to moderate heat (within the range of 41 ÷ 43 ºC) than malignant 
cells  (e.g.  HeLa) 
[14,176-182,267-269,279].    Selective  destruction  of  malignant  cells  without 
noticeable damage to healthy cells (like endothelial cells) was reported by several research 
groups 
[3,4,8,12-14,176,180].    Enhanced  sensitivity  of  cancerous  cells  was  attributed  to  the 
differences  in  cell  metabolism  (e.g.  respiration  and  lysosomal  activity)  and  cell 
environment  (increased  acidity  in  the  tumour  site).    Nonetheless,  as  demonstrated  in 
chapter 7, thermal inactivation of healthy endothelial cells (HUVECs) was achieved with 
NPs mediated laser hyperthermia.      
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3.  Methods and techniques. 
Experimental methods and techniques applied in the presented research, are considered a 
significant part of the development, therefore shown as an independent chapter in  this 
thesis.  Synthetic methods and protocols will be introduced in sections 3.1. and 3.2., while 
characterisation techniques in sections 3.3. and 3.5.   
3.1.    Synthesis of NPs. 
NPs, both spherical and anisotropic (rod-like, hollow and core/shell) were synthesised by 
relatively simple and cost effective wet chemistry methods, following conventional routes.  
Specifically,  spherical  gold  NPs  were  synthesised  via  a  citrate  reduction  method 
[1-6] 
(section 3.1.1.).  Gold nanorods were prepared by seed mediated protocols 
[7-18] (section 
3.1.2.).  Silica/gold core/shell nanostructures were produced using a seed mediated method, 
utilising  silica  NPs  as  templates 
[19-29]  (section  3.1.3.),  while  hollow  gold  NPs  were 
synthesised by a galvanic replacement reaction 
[30-38] (section 3.1.4.).  Standard protocols 
were  slightly  modified  and  optimised  according  to  own  requirements,  which  will  be 
detailed in the following sub-sections. 
3.1.1.  Synthesis of spherical gold NPs.  
Sodium citrate (Scheme 25A) stabilised spherical gold NPs were prepared by a citrate 
reduction method, developed by Turkevich 
[1-6] (see chapter 2 for reaction mechanism).  
Citrate-NPs  were  capped  with  bis(p-sulfonatophenyl)phenyl  phosphine  dehydrate 
dipotassium  salt  –  a  phosphine  derivative  (BSPP,  Scheme  25B,  see  chapter  2  for 
theoretical background) via the ligand exchange reaction 
[39-43].  
 
   
 
   
 
 
A solution of trisodium citrate (2.5 ml, 19.5 mM in Milli-Q water) was brought to boil 
and poured quickly into a vigorously stirred, boiling solution of sodium tetrachloroaurate 
(III) dihydrate (0.5 mM, 25 ml).  The molar ratio between Ct
3- and Au
3+ was 1 : 3.9 (Note: 
the ratio of Ct
3- to Au
3+ can be decreased to 1 : 1.95 and further to 1 : 0.39 to prepare larger 
Scheme 25.  Chemical structures of: trisodium citrate (A) and BSPP (B). 
A  B  
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NPs, see chapter 4 for results).  Colour change from pale yellow through colourless to 
deep red indicated the formation of NPs 
[1-6,44].  The reaction mixture was boiled and stirred 
for an additional 15 min., cooled to room temperature and purified by filtration (0.45 µm 
filter, Millipore).  NPs were then capped with BSPP.   
BSPP (10 mg; Molecular Weight, MW = 498.6) was added to citrate stabilised gold 
NPs (27.5 ml) and stirred overnight at room temperature.  BSPP-coated nanocrystals were 
precipitated  with  sodium  chloride  (50  mg,  MW  =  58.5)  and  purified  by 
centrifugation/decantation  (5000  rpm,  5  min).    Precipitated  NPs  were  redispersed  by 
sonication in 2 ml of Milli-Q water, characterised (see chapter 4 for physicochemical 
characterisation) and kept at 4 °C prior to further surface modifications (see section 3.2. 
for experimental details). 
3.1.2.  Synthesis of gold nanorods. 
Gold nanorods were prepared by the one-step seed mediated growth method (method I), 
reported  by  El-Sayed 
[14],  while  more  elongated  nanorods  –  gold  nanowires  were 
synthesised via a three-step protocol (method II), developed by Murphy 
[7,11,15-18].  Original 
versions of both methods were slightly modified.  
In  method  I,  the  growth  solution  was  prepared  by  mixing  in  the  following  order 
aqueous solutions of: CTAB (0.2 M, 7.12 ml, Scheme 26), sodium tetrachloroaurate (III) 
dihydrate  (5  mM,  2  ml),  silver  nitrate  (5  mM,  0.15  ‚  0.4  ml)  and  freshly  prepared             
L-ascorbic  acid  (0.0788  M,  0.16  ml).    Gold  seeds  were  prepared  separately  by  the 
reduction of sodium tetrachloroaurate (III) dihydrate (5 mM, 1 ml) and CTAB (0.2 M, 1 
ml) mixture, with an ice cold solution of sodium borohydride (0.01 M, 0.5 ml), added 
dropwise.  Colour change from orange through colourless to deep brown indicated the 
formation of small gold NPs 
[44,45] (see chapter 4 for physicochemical characterisation).  
Fresh solution of seeds (16 µl) was added to the growth solution, shaken gently and the 
reaction  mixture  was  left  overnight  at  35  °C.    The  formation  of  gold  nanorods  was 
indicated by the solution colour change from colourless to blue 
[14,46] (when 0.17 ml of 
silver nitrate was added, see chapter 4 for more details).  Nanorods were purified from an 
excess  of  reagents  by  two  steps  of  centrifugation/decantation  (10’000  rpm,  10  min.), 
redispersed in 5 ml of Milli-Q water, characterised (see chapter 4) and kept at 4 °C prior 
to surface capping (see section 3.2.).    
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Nanowires were synthesised  by method II.  The growth solution  containing CTAB 
(0.1 M) and sodium tetrachloroaurate (III) dihydrate (0.25 mM) was prepared and poured 
into three flasks (9 ml into flask ‘A’, 9 ml into ‘B’ and 45 ml into ‘C’).  Freshly prepared 
L-ascorbic acid (0.1 M) was then added to each flask (50 µl to ‘A’ and ‘B’, 250 µl ml to 
‘C’) and shaken.  To flask ‘A’ the seeds solution (0.4 ml, see method A) was added and 
mixed.  After 15 s, solution ‘A’ (1 ml) was added to flask ‘B’, 30 s later solution ‘B’ (5 ml) 
was added to flask ‘C’ and the reaction mixture was left overnight at 35 °C.  The formation 
of gold nanowires was indicated by the solution colour change from colourless to red 
[18].  
Nanowires were purified by two steps of centrifugation/decantation (10’000 rpm, 10 min.), 
redispersed in 5 ml of Milli-Q water, characterised (see chapter 4) and kept at 4 °C.   
3.1.3.  Synthesis of silica/gold core/shell NPs. 
Silica/gold core/shell NPs were prepared by Halas method 
[21,23,26,47] (see chapter 2 for 
reaction mechanism), involving four steps: a) synthesis of silica NPs (by Stӧber method 
[19,20,22,28]); b) functionalisation with 3-(aminopropyl)trimethoxysilane (APTMS, Scheme 
27A);  c)  attachment  of  gold  seeds  (stabilised  with  tetrakis(hydroxymetyl)phosphonium 
chloride – THPC, Scheme 27B; prepared by Duff method 
[24,25]) and d) growth of the gold 
shell.  
 
 
 
 
 
Silica NPs were prepared by mixing ammonia solution (30 %, 3 ml) with absolute 
ethanol (50 ml), to which tetraethyl orthosilicate (TEOS, 6.7 mmol, 1.5 ml, see Scheme 
28) was added dropwise.  Smaller silica NPs were prepared by a modified protocol, as 
reported by Liu and co-workers  
[20].  Specifically, absolute ethanol (50 ml) was mixed 
N
CH3
CH3
CH3 Br-
+
Scheme 26.  Chemical structure of CTAB surfactant. 
A  B 
Scheme 27.  Chemical structures of: APTMS (A) and THPC (B).  
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with Milli-Q water (3.03 ml) and ammonia solution (30 %, 2.25 ml).  Under vigorous 
stirring, TEOS (8.7 mmol, 1.94 ml) mixed with absolute ethanol (5 ml) was added quickly.   
Both,  sol-gel  mixtures  were  stirred  for  30  min.  and  purified  by  two  steps  of 
centrifugation/decantation  (10’000  rpm,  10  min.).    Silica  NPs  were  redispersed  by 
sonication in ethanol (50 ml).  To vigorously stirred silica NPs, APTMS (2.8 mmol, 0.5 
ml) was added and the reaction mixture was allowed to react for 2 h.  APTMS-silica NPs 
were  purified  by  two  steps  of  centrifugation/decantation  (10’000  rpm,  10  min.)  and 
redispersed by sonication in 100 ml of Milli-Q water.   
 
 
 
 
 
 
 
Meanwhile, gold seeds were prepared by mixing sodium hydroxide solution (1 M, 0.5 
ml) with THPC (0.067 mmol, 1 ml) and Milli-Q water (45 ml), followed by the injection of 
sodium  tetrachloroaurate (III) dihydrate solution (1 %, 0.75 ml).  Colour change  from 
colourless to yellowish/light brown indicated the formation of small gold NPs (seeds) 
[44,45] 
(see  chapter  4  for  physicochemical  characterisation).    Gold  seeds  were  purified  by 
overnight  dialysis  against  Milli-Q  water  (1’000  ml;  12  ‚  14  k  cellulose  membrane, 
CelluSep).  Fresh solution of seeds (5 ml) was added to APTMS-capped silica NPs (0.5 
ml) and  the reaction mixture was  allowed to sit  for 2 h at room temperature.  Seeds-
APTMS-silica NPs were purified by two steps of centrifugation/decantation (1’000 rpm, 
10 min.) and redispersed in Milli-Q water (5 ml) prior to shell growth.   
In a separate flask, potassium carbonate (25 mg, MW = 138.2) was dissolved in Milli-
Q water (100 ml) by 5 min. stirring at room temperature.  Next, sodium tetrachloroaurate 
(III) dihydrate solution (1 %, 1.5 ml) was added and the mixture was stirred for 30 min. 
then cooled down to 4 °C.  To the cold growth solution (4 ml), seeds-APTMS-silica NPs 
(200 µl) were added.  While stirring, formaldehyde (0.36 mmol, 10 µl) was injected and 
the mixture was allowed to react for 5 min. until colour change from colourless to blue.  
The growth was terminated by the addition of thiol containing molecule (100 µl, 5 mg/ml, 
MW = 526.7, see section 3.2.1. for the chemical structure and chapter 2 for reaction 
mechanism), which binds to the gold surface and prevents further growth of NPs 
[39,40,48-51].  
Scheme 28.  Chemical structure of TEOS.  
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Silica/gold  core/shell  NPs  were  purified  by  three  steps  of  centrifugation/decantation 
(10’000  rpm,  10  min.),  redispersed  in  sodium  borate  buffer  (0.01  M,  pH  9,  1  ml), 
characterised  (see  chapter  4)  and  kept  at  4  °C  prior  to  further  surface  modifications 
(section 3.2.). 
3.1.4.  Synthesis of hollow gold NPs. 
Hollow gold NPs were prepared by a protocol involving two steps.  First, spherical silver 
NPs were grown by the seed mediated method, developed by Oh 
[35].  Silver NPs were then 
utilised as templates in the galvanic replacement reaction between silver (Ag
0 atoms) and 
gold (Au 
3+ ions) 
[30,31,33,34,52-54].  This method introduced by Xia, resulted in the formation 
of gold NPs with hollow interiors (see chapter 2 for reaction mechanism).  
The growth solution was prepared by mixing in the following order: CTAB (0.2 M, 80 
ml), silver nitrate (0.05 M, 400 µl) and freshly prepared L-ascorbic acid (0.1 M, 2 ml).  
Silver seeds were prepared separately by the reduction of silver nitrate (2.5 mM, 1 ml), 
mixed with trisodium citrate (2.5 mM, 1 ml) and Milli-Q water (8 ml), with an ice cold 
solution of sodium borohydride (0.001 M, 25 µl).  Colour change from colourless to pale 
yellow indicated the formation of small silver  NPs 
[35,44,45,55] (seeds, see chapter 4 for 
physicochemical characterisation).  A fresh solution of seeds (400 µl) was added to the 
growth solution, followed by the injection of sodium hydroxide  solution  (1 M, 2 ml).  
Colour  change  from  colourless  to  deep  yellow  indicated  the  formation  of  silver  NPs 
[35,44,45].    The  reaction  mixture  was  left  overnight  at  35  °C,  then  purified  by 
centrifugation/decantation (1’000 rpm, 10 min.). 
Silver NPs were redispersed in Milli-Q water (40 ml), characterised (see chapter 4) 
and used as templates in the galvanic replacement reaction.  The solution of silver NPs (10 
ml) was brought to boil and refluxed for 10 min.  While stirring, sodium tetrachloroaurate 
(III) dihydrate aqueous solution was added dropwise (1 mM, 0.25 ml).  Colour change 
from yellow to blue indicated the formation of hollow NPs 
[33,34,52-54,56,57].  The reaction 
mixture was refluxed for an additional 20 min. then cooled to room temperature.  NPs were 
characterised (see chapter 4) and kept at 4 °C prior to surface capping (section 3.2.).  
3.2.  NPs surface capping. 
Gold NPs were capped with several types of ligands, including OEG ligand 
[50] (section 
3.2.1.), DA-PEG ligand 
[48] (section 3.2.2.) and CALNN peptide 
[58-61] (section 3.2.3.).  All  
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listed molecules were chemisorbed on the surface of gold NPs via thiol anchoring groups 
[39,40,62,63]  (see  chapter  2  for  theoretical  background).    OEG-capped  NPs  were  further 
modified  with  octa-peptides  (section  3.2.4.)  by  the  EDC/s-NHS  coupling  chemistry 
method 
[64-66]. 
3.2.1.  NPs surface capping with OEG ligands. 
Freshly  prepared  OEG  (monocarboxy  (1-mercaptoundec-11-yl)  hexaethylene  glycol, 
Scheme 29) aqueous solution (5 mg/ml, 200 µl, MW = 526.7) was added to a solution of 
gold nanospheres (10 ml, 5 nM), while stirring.  The mixture was incubated for 2 h at room 
temperature,  then  overnight  at  4  °C.    Capped  NPs  were  purified  by  three  steps  of 
centrifugation/decantation (16’400 rpm, 15 min) and redispersed by sonication in sodium 
borate buffer (10 ml, 0.01 M, pH 9) prior to physicochemical characterisation (see chapter 
4) or growth media (1 ml) prior to experiments with cells (see chapter 5).  NPs were 
stored at 4 °C.  
 
 
 
 
Anisotropic (rod-like, hollow or core/shell) gold NPs were capped with OEG ligands 
according to a slightly modified procedure.  A fresh solution of OEG (5 mg/ml, 200 µl, 
MW = 526.7) was injected into an aqueous solution of gold NPs (5 ml; optical density, OD 
= 0.5), whilst sonicating at 4 ºC, this was immediately followed by the addition of sodium 
borate buffer (5 ml, 0.02 M, pH 9).  Gradually over an 1 h, the temperature was increased 
to  room  temperature,  then  held  at  room  temperature  for  2  h  with  stirring.    This  was 
followed by 30 min. of sonication at room temperature and overnight incubation at 4 °C.  
Capped NPs were purified by three steps of centrifugation/decantation and redispersed by 
sonication in sodium borate buffer (10 ml, 0.01 M, pH 9) prior to characterisation (see 
chapter 4) or growth media (1 ml) prior to experiments with cells (see chapter 5; Note: 
supernatants left at each step of purification were combined and stored at 4 ºC prior to 
quantification of the thiol content, as described in section 3.3.2.).  NPs were stored at 4 °C. 
 
 
Scheme 29.  Chemical structure of OEG.  
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3.2.2.  NPs surface capping with DA-PEG ligands. 
Freshly  prepared  DA-PEG  (46-mercapto-22,43-dioxo-3,6,9,12,15,18-hexaoxa-21,44-
diazahexatetraconta-31,33-diyn-1-oic acid,  Scheme 30) solution in methanol (5 mg/ml, 
100 µl, MW = 729.0) was added to an aqueous solution of gold NPs (5 ml, 5 nM), whilst 
stirring in the dark at room temperature.  After 10 min., sodium phosphate buffer (5 ml, 0.2 
M;  0.3  M  sodium  chloride;  pH  8)  was  introduced  and  the  reaction  mixture  was  left 
overnight at 4 °C in the dark.  NPs were purified from the excess of DA-PEG ligand by 
triple centrifugation (16’400 rpm, 15 min.), followed by decantation (Note: supernatants, 
from each step of purification were combined prior to the thiol quantification; see section 
3.3.2.).  NPs were redispersed in sodium phosphate buffer (10 ml,0.1 M, pH 8) and UV-
irradiated for 15 min. (254 nm light wavelength, 35 W lamp power, 10 cm from the UV-
lamp) to photo-crosslink DA-PEG monomers 
[48].  The colloidal solution was purified from 
small  aggregates  by  centrifugation  (5’000  rpm,  5  min.).    The  supernatant  containing 
dispersed NPs was placed in a clean vial prior to the second step of capping.   
A fresh portion of DA-PEG solution (5 mg/ml, 10 µl, MW = 729.0, in methanol) was 
introduced and the reaction mixture was incubated overnight at 4 °C in the dark.  NPs were 
purified by triple centrifugation/decantation (16’400 rpm, 15 min.), redispersed in sodium 
phosphate buffer (10 ml, 0.1 M, pH 8) and UV-crosslinked using the same irradiation 
conditions.    After  purification  (centrifugation  5’000  rpm,  5  min.),  the  supernatant 
containing dispersed photo-polymerised NPs was characterised (see chapter 4) and stored 
at 4 °C.  
 
 
 
 
 
 
 
3.2.3.  NPs  surface  capping  with  CALNN  based  peptides  and 
assembly on oligodeoxynucleotide templates. 
The surface of spherical gold NPs was functionalised with CALNN and CALNN-Ahex-
FQGII  (c-FQGII,  Fig.  3A;  Ahex  is  aminohexanoic  acid)  peptides  through  the  thiol 
Scheme 30.  Chemical structure of DA-PEG.  
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[39,40,58,61]  (see  chapter  2  for  chemical  structures  and  theoretical 
background).    CALNN/c-FQGII  capped  NPs  were  assembled  on  two  types  of 
oligodeoxynucleotide templates (ODN) 
[60].  From which, one was composed of a short 
palindromic  sequence  (ODN3,  Fig.  3B),  while  second  formed  pseudo-infinite  duplexes 
(ODN1+2,  Fig.  3C).    As  stated  in  chapter  2,  NPs  bound  to  ODN  templates  via  the 
interaction between AT-rich regions of ODN and FQGII sequence in the outer shell on 
NPs 
[60,67,68]. 
 
 
 
 
 
 
 
 
 
A mixture of CALNN and c-FQGII (5 ‚ 25 % of c-FQGII, 0.5 mg/500 µl) in sodium 
phosphate buffer (0.2 M, pH 8) was added to an aqueous solution of gold NPs (0.5 ml, 5 
nM), whilst stirring.  The reaction mixture was sonicated for 20 min. at room temperature, 
then incubated overnight at 4 °C.  Colloids were purified from the excess ligands by triple 
centrifugation (16’400 rpm, 15 min.) followed by decantation, then redispersed in sodium 
phosphate buffer (0.5 ml, 0.1 M; 0.1 M sodium chloride; pH 8) prior to the characterisation 
(see chapter 4) and assembly on ODN templates (see chapter 4).  NPs were stored at       
4 °C. 
ODNs were synthesised by Dr Eugen Stulz group members: Miss Danielle Coomber, 
Dr  Simon  R.  Gerrard  and  Miss  Sarah  Tyas  (School  of  Chemistry,  University  of 
Southampton, Southampton, UK) on an ABI Expedite 8909 synthesiser 
[60].  Standard solid 
supported  phosphoramidite  cycle  (1  mol)  of  acid  catalysed  detritylation,  coupling, 
capping  and  iodine  oxidation  was  used.    ODNs  were  deprotected/cleaved  from  solid 
support by heating in concentrated ammonium hydroxide at 35 C for 15 h, then purified 
using  Glen-Pak  purification  column  following  standard  protocols  (Glen  Research  or 
Cambio Ltd.). 
NPs (2 nM) and templates ODN1+2 or ODN3 (1 μM or 0.5 μM) were suspended in 
sodium phosphate buffer (0.1 M, 1 ml; 0.1 M sodium chloride, 1 mM EDTA, pH 8).  
A 
C 
B 
Figure 3.  The structure of c-FQGII (A), short ODN3 self-complimentary sequence 
(B) and pseudo-infinite ODN1+2 sequence (C). 
5’ - CG TAG CGC  TAC GCG AAA TTT G - 3’ 
3’ – CGC TTT AAA CGC ATC GCG ATG - 5’ 
5’ - CG TA GC GC TA CG - 3’ 
3’ - GC AT CG CG AT GC - 5’  
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An approximate 1:1 molar ratio between single AT binding region within ODN and 
FQGII  was  achieved  (Note:  assuming  80  %  of  NPs  surface  covarage 
[61,69],  2000 
surface atoms would be bound to CALNN or c-FQGII, which is equal to 500 c-FQGII’s 
for 25 % c-FQGII content).  Heating up to 85 °C and cooling down to 18 °C cycle was 
performed  to  ensure  the  formation  of  ODN-NPs  assemblies.    The  formation  of 
assemblies  was  monitored  by  transmission  electron  microscopy  and  UV-visible 
spectroscopy techniques (see chapter 4 for results).  
3.2.4.  Further modifications of NPs surface. 
Three different octa-peptides (P1, P2 and P3; see chapter 2 for chemical structures) were 
conjugated to OEG-coated gold NPs using EDC/s-NHS coupling method 
[64-66].  In this 
method, an amide bond was formed between an amine and a carboxylic group; hence, 
between carboxy terminated OEG NPs (see chapter 2 for a schematic illustration and the 
reaction mechanism) and amine containing octa-peptides.  EDC/s-NHS coupling resulted 
in the formation of peptide-OEG conjugated colloids.   
In detail, a peptide solution (100 µl, 1 mg/ml, MWP1/P2 = 922.1, MWP3 = 968.2, in 0.01 
M sodium borate buffer, pH 9) was added to OEG-coated NPs solution (5 ml, 1.5 nM for 
spherical or OD = 0.3 for anisotropic; in 0.01 M sodium borate buffer, pH 9) and mixed.  
To  which,  aqueous solutions of coupling agents: EDC (1-(3-(dimethylamino)propyl)-3-
ethyl-carbodiimidemethiodide, 50 µl, 0.2 M) and s-NHS (N-hydroxysulfosuccinimide, 100 
µl, 0.2 M) were introduced.  The reaction mixture was stirred for 24 h at room temperature.  
Conjugates were purified by triple centrifugation/decantation (16’400 rpm, 15 min.) and 
redispersed  in  sodium  borate  buffer  (100  µl,  0.01  M,  pH  9)  prior  to  physicochemical 
characterisation (see chapter 4) or in growth media (100 µl) prior to experiments with 
cells (see chapter 6 and chapter 7).  NPs were stored at 4 °C. 
Further functionalisation of P1-OEG conjugated spherical NPs with HiLyte Fluor 680 
amine fluorescent dye (HiLyte, Anna Spec Inc.) was conducted using the same EDC/s-
NHS coupling method.  Briefly, HiLyte dye solution (100 µl, 1 mg/ml, MW = 1197.5; 0.01 
M borate buffer, pH 9) and coupling agents (50 µl, 0.2 M of EDC and 100 µl, 0.2 M of s-
NHS) were added to P1-OEG NPs solution (5 ml, 1.5 nM, in 0.01 M borate buffer, pH 9) 
and stirred for 24 h at room temperature.  HiLyte-P1-OEG conjugates were purified by 
triple  centrifugation/decantation  (16’400  rpm,  15  min.)  and  redispersed  in  phosphate  
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buffered saline (1 x PBS, 100 µl, 0.1 M, pH 7.2) prior to characterisation (see chapter 4) 
and experiments with cells (see chapter 6).  NPs were stored at 4 °C in the dark.  
3.3.  NPs characterisation techniques. 
Several complimentary  techniques were  employed to characterise gold  NPs, including: 
Raman, UV-vis-NIR and fluorescence spectroscopy (section 3.3.1.), transmission electron 
microscopy, dynamic light scattering, ξ-potential (zeta potential) and gel electrophoresis 
(section  3.3.3.) 
[48,60,70-74].    NPs  surface  coverage  with  ligands  was  quantified  (section 
3.3.2.) and the colloids stability against aggregations was tested (section 3.3.4.) 
[48,75,76]. 
3.3.1.  Spectroscopy techniques. 
UV-visible and fluorescence spectra of gold NPs were collected from aqueous colloidal 
solutions, using a black quartz cuvette (1 cm, Hellma).  
UV-visible spectra were measured using a Cary 300 Bio UV-vis spectrophotometer 
from  400  to  900  nm  or  Jasco  UV/VIS/NIR  spectrophotometer  from  400  to  1300  nm.  
Emission  spectra  of  HiLyte  tagged  NPs  were  collected  using  Varian  Cary  Eclipse 
Fluorescence Spectrophotometer from 650 to 800 nm with 633 nm excitation wavelength.  
The  concentration  of  spherical  gold  colloid  was  estimated  from  the  maximum 
absorbance  value,  following  the  Beer-Lambert  law  and  the  subsequent  equation 
[44,45,73,74,77]: 
   
          
   , where 
c – concentration of NPs [mol/l] 
Abs
max – maximum absorbance value  
1 – light pathway [cm] 
D – sample dilution factor 
ε – extinction coefficient [l·mol
-1·cm
-1]; 3.64 · 10
8 for 15 nm gold NPs  
Raman spectra were collected using a Renishaw Raman 2000 equipped with a 633 nm 
helium-neon (He-Ne) laser with a maximum power of 5 mW and spectral resolution of 4 
cm
–1.  A 50 x objective was used.  Spectra were recorded from 400 cm
–1 to 3400 cm
–1 
wavenumber shift with a maximum 10 s accumulation time.  Surface enhanced Raman  
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spectra (SERS) of gold NPs were collected from air dried aqueous samples deposited on 
colloidal crystal templated ‘inverse opal’ nanostructured gold films 
[78].  
3.1.1.  NPs surface coverage quantification. 
The  number  of  OEGs  per  one  nanoparticle  was  estimated  using  Ellman’s  thiol 
quantification method (Scheme 31) 
[75].  In this method, Ellman’s reagent (5,5’-dithiobis(2-
nitrobenzoic acid), DTNB) reacts with a thiol and releases a chromogenic compound (5-
thio-2-nitrobenzoic acid, TNB), which absorbs at 412 nm at pH 7.6 ‚ 8.6. 
 
 
 
 
 
 
 
 
 
 
 
The  quantification  buffer  (0.5  ml,  0.1  M  sodium  phosphate,  pH  8;  1  mM 
ethylenediaminetetraacetic acid – EDTA) was mixed with Ellman’s reagent (10 µl, of solid 
DTNB dissolved in 1 ml of quantification buffer).  To which, the thiol containing solution 
(50 µl of combined supernatants, left after each step of purification; 0.1 ‚ 1 mM range) 
was  introduced  and mixed.    The  reaction  mixture  was  incubated  for  15  min. at  room 
temperature and the maximum absorbance value was measured at 412 nm.  Thiol content 
was calculated from the calibration curve (prepared by measuring a series of dilutions with 
a given concentration of the quantified thiol, ranging from 0 ‚ 1.5 mM).  Since, the pH of a 
quantified solution affects the intensity of the maximum absorbance 
[79,80], two separate 
calibration curves were prepared.  One for DA-PEG and the other for OEG ligand, each 
with the same type of buffer (see section 3.2. for NPs surface capping details) as used in 
the capping procedure.  Calibration curves are shown in Fig. 4. 
thiol 
DTNB 
chromogenic TNB 
mixed disulfide 
+  + 
Scheme 31.  Schematic illustration of the Ellman’s method.  
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From  the  appropriate calibration curve, the concentration of ligand in  a quantified 
sample (supernatant) was estimated.  The moles of ligand were calculated from the total 
volume of the supernatant.  The initial amount of ligand introduced into the NPs solution 
(see section 3.2.) was known, thus the quantity of ligand which was chemisorbed onto the 
NPs surface was deliberated.  Taking the molecular weight of ligand, allowed the actual 
number of ligand molecules chemisorbed on NPs, to be calculated.  The concentration of 
NPs (as well as the number of moles) was calculated using UV-vis spectroscopy (spherical 
NPs,  see  section  3.3.1.)  or  mass  spectroscopy  (anisotropic  NPs,  ICP-MS,  see  section 
3.5.3.).  Having estimated the average number of atoms per nanoparticle (see chapter 4 
and Appendix B), the total number of NPs in the sample was calculated.  The number of 
chemisorbed ligands was divided by the number of NPs in the sample, to give the number 
of ligands per each nanoparticle.     
The number of peptides per nanoparticle was estimated using FluoroProfile Protein 
Quantification Kit (Sigma-Aldrich) 
[76].  In this method, a fluorescent regent called the 
epicocconone,  reacts  with  a  side  chain  of  lysine  residues  from  peptides  or  proteins 
(Scheme 32), resulting in a shift of the fluorescent signal from 530 nm to 600 nm. 
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Figure 4.   Calibration curves for Ellman’s quantification of OEG (A) and DA-PEG 
(B) ligands.  
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As suggested by the  manufacturer of  FluoroProfile (Sigma-Aldrich),  the  ‘working 
reagent’ was prepared by mixing the fluorescent reagent, quantification buffer and water in 
the  ratio  volume:  1:1:8.    The  ‘working  reagent’  (50  µl)  was  added  to  the  quantified 
solution (50 µl, supernatant left after colloids purification, see section 3.2.) and shaken.  
The reaction mixture was incubated for 30 min. at room temperature in the dark.  The 
maximum emission value at 620 nm was measured with 510 nm excitation wavelength and 
used  to  calculate  the  number  of  peptides  from  the  calibration  curve  (Fig.  5).    Since, 
FluoroProfile reagent reacts selectively with the side chain of lysine residues 
[76] and each 
of the octa-peptide sequences contained only one N-terminus lysine, the quantities of all 
three octa-peptides in solutions were estimated from the same calibration curve, following 
analogues strategy as in the above thiol quantification method.   
epicocconone 
Scheme 32.  Schematic illustration of the FluoroProfile method, taken from 
[76]. 
lysine-containing 
peptide 
epicocconone-peptide 
complex  
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3.1.1.  NPs size, shape and net charge measurements. 
The shape and size of the metallic core of NPs was determined by transmission electron 
microscopy  (TEM).    Images  were  obtained  with  Hitachi  H7000  transmission  electron 
microscope operating at a bias voltage of 75 kV.  All samples were prepared by deposition 
of a colloid droplet, which was then air dried, onto a Carbon Film 400 Mesh Copper (50) 
grid.  Several images of each sample were taken.  Statistical analyses of representative 
images were drawn onto size distribution histograms. 
Hydrodynamic diameters of NPs and their net charge were measured with a Zetasizer 
Nano ZS (Malvern Instruments Ltd.) using colloids dispersed in Milli-Q water or buffer.  
Disposable cuvettes (Malvern Instruments Ltd.) were employed in dynamic light scattering 
(DLS)  measurements  or  disposable  capillary  cells  in  ζ-potential  measurements.    DLS 
measurements (overall diameter of NPs) in conjunction with histograms representing the 
size of an inorganic core allowed, the thickness of organic layers: OEG, DA-PEG and octa-
peptides (chapter 4), to be calculated. 
Gel electrophoresis was also employed to determine the differences in charge and size, 
deriving from the outer shell of NPs 
[70,71].  A horizontal agarose gel system was used in all 
experiments.    The  agarose  gel  (0.75  %)  was  prepared  by  dissolving  agarose  (0.45  g, 
Sigma-Aldrich) in Tris-Borate-EDTA buffer (0.5 x TBE, 60 ml, pH 8) by heating up to          
90 °C in a microwave and shaking.  Liquid agarose was poured into a gel-tray (10 x 7 cm, 
Bio-Rad) fixed within the gel-caster (Bio-Rad).  Next, an 8-teeth comb (Bio-Rad) was 
placed  in  the  middle  slot,  the  gel  was  left  to  cool  and  solidify  for  30  min.  at  room 
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Figure 5.   Calibration curves for FluoroProfile quantification of P1, P2 and P3 octa-
peptides.  
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temperature.  The gel caster was levelled up, ensuring formation of evenly thick (1 cm) 
matrix with 8 identical wells (well capacity 41.6 µl).  The solidified gel was placed in 
Mini-Sub Cell GT Base (Bio-Rad) along with sufficient TBE buffer (0.5 x) for submersion 
of the gel, beneath 5 mm of liquid.  The colloids (16 µl, 50 nM, in 0.5 x TBE buffer) mixed 
with glycerol (4 µl, 30 %, in 0.5 x TBE buffer) were gently loaded into the wells.  The 
safety lid was placed onto the base, and electrical cables were plugged into the power 
supply (Bio-Rad).  The gel was run for 1 h, using 10 V (steady current) per 1 cm of gel.  
Digital images of gels were taken with a Cannon Power Shot A480 digital camera. 
3.3.4.  Stability tests of colloids. 
The stability of spherical colloids was tested at a range of pH and temperatures, as well as 
in the presence of thiol containing molecules 
[39,40,48].  The formation of NPs aggregates 
was monitored by colorimetric assays.  These included macroscopic observations of the 
solution colour change and UV-visible spectroscopy 
[43,44,48,81]. 
The  stability  of  NPs  against  ligand  exchange  reactions  was  studied  in  prolonged 
incubation  with  thiol  containing  molecules,  such  as:  mercaptoethanol,  dithiothreitol, 
cysteamine,  cysteine,  α-lipoic  acid  and  11-amino-1-undecanethiol.    In  a  typical 
experiment,  the  colloidal  solution  (100  µl,  1.5  nM)  was  incubated  for  72  h  in  10  % 
mercaptoethanol (1:1, Milli-Q water : methanol), at room temperature, between pH 3 ‚ 9.  
The stability of colloids (100 µl, 1.5 nM) at variable pH, ranging from 1.2 ‚ 12, was tested 
over a 48 h incubation time at room temperature.  
The  stability  of  colloids  at  high  temperatures  was  tested  in  five  repeated 
heating/cooling  (100  °C  /  room  temperature)  cycles.    Low  temperature  stability  was 
monitored  over  three  freezing  (down  to  -20  °C)  /  thawing  (room  temperature)  cycles.  
Extinction spectra of NPs were collected after each cycle. 
3.4.   Cells isolation and culturing. 
Research efforts of this project were focused on the interactions between colloidal gold 
NPs and human umbilical vein endothelial cells (HUVECs, see chapter 2 for theoretical 
background).  Primary HUVECs were obtained from umbilical cords.  Cells isolation (and 
culturing) will be described in the following sub-section.  Except of HUVECs, malignant 
cell line (HeLa) was employed in some experiments (flow cytometry, chapter 6).  These 
cells show very different physiology compared to HUVECs (see chapter 2 for theoretical  
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background),  therefore were cultured according to an individual protocol, described in 
section 3.4.3.   
3.4.1.  HUVECs isolation. 
HUVECs were harvested from human umbilical veins by Dr Timothy M. Millar from the 
School of Medicine, University of Southampton, Southampton, UK.  The isolation method 
involved collagenase digestion, as previously reported 
[82,83] .  
Umbilical cords and placentas were harvested at term following natural delivery at the 
Princess Anne Hospital, Southampton, UK following local ethically approved procedures 
(Ethics submission number: 07/H0502/83).  Umbilical cords were typically stored at 4 °C 
until use, within 24 h of delivery.  Cords were perfused with Type 1 collagenase solution 
(1 mg/ml, Worthington) for 10 min. at 37 °C, before endothelial cells were harvested by 
centrifugation, then seeded onto T-75 cm flasks.  Flasks and subsequent culture plastic 
were pre-coated with porcine gelatin (0.2 % in Hank's Buffered Salt Solution – HBSS, 
Sigma-Aldrich).  Cells were passaged by trypsin digestion and grown to confluence in 
M199 (Invitrogen) media containing 20 % human serum (Autogen Bioclear) and penicillin 
/ streptomycin (Invitrogen) at 37 C in a humidified 5 % carbon dioxide (CO2) balanced air 
incubator.   Endothelial lineage was confirmed by cobblestone appearance in culture, by 
distinct  punctate  expression  of  von  Willebrand  factor  (vWF)  and  by  Cluster  of 
Differentiation molecule number 31 (CD31) expression (data not shown). 
3.4.2.  HUVECs culturing. 
HUVECs were grown on porcine gelatin (0.2 % in HBSS) pre-coated culture dishes, in a 
media growth (M199) containing 20 % human serum (full-serum).  Typically, HUVECs 
were seeded onto a culture dish, filled with a sufficient volume of growth media (Table 1) 
and incubated in 5 % CO2 air balanced incubator at 37 °C.  Every two to three days, the old 
medium was decanted, cells were gently washed twice with PBS buffer (1 x) and fresh 
medium growth was poured into the culture dish.  All reagents were pre-warmed to 37 °C 
before use and kept sterile. 
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HUVECs  grown  to  a  confluence  on a Petri  dish  were  passaged  by  trypsinisation.  
After medium growth was decanted, cells were washed three times with PBS buffer (1 x) 
and trypsin solution (1.5 ml, 0.25 % trypsin 0.01 % EDTA solution, Sigma-Aldrich) was 
added.  Cells were incubated at 37 °C in 5 % CO2.  The harvesting time was approximately 
5 min.  To block trypsin and prevent further digestion of cells, serum containing medium 
growth (5 ml) was added.  The cell suspension was transferred into a plastic tube and 
centrifuged (2’000 rpm, 5 min., 4 °C).  Cells were resuspended in medium growth (1 ml) 
and counted.  The desired number of cells was placed in a fresh culture dish along with the 
sufficient volume of growth media.  HUVECs only from second passage were used in all 
experiments. 
3.4.3.  HeLa cells culturing. 
HeLa cells (see chapter 2 for theoretical background) were used as a negative control in 
several experiments (flow cytometry, chapter 6).  These cells were grown as attached to 
culture  dishes  in  DNEM  media  growth  (Gibco)  supplemented  with  10  %  fetal bovine 
serum  (FBS,  Sigma-Aldrich),  and  penicillin  /  streptomycin  (Invitrogen)  at  37  C  in  a 
humidified CO2 balanced air incubator.  Typically, HeLa were grown to 80 % confluence, 
then passaged by trypsinisation (see the previous section).  The doubling time of HeLa is 
approximately 24 h 
[85-89], therefore cells were split few times a week in small portions.  In 
all experiments, cells from the second to tenth passage were used. 
3.5.  Biological  samples  characterisation  techniques  and  experimental 
methods. 
Standard techniques commonly used in biomedical  and physicochemical  sciences were 
applied  to  study  the  interactions  of  colloidal  gold  NPs  and  cells.    These  included 
Culture dish   Number of cells  Growth media volume   
[ml] 
Petri dish, 10 cm  2.0 · 10
6  10.0 
12-well plate  1.0 · 10
5  1.0 
96-well plate  2.5 · 10
4  0.2 
Table 1.  HUVECs culturing.  
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transmission  electron  microscopy  (section  3.5.1.),  flow  cytometry  (section  3.5.2), 
inductively coupled plasma mass spectrometry (section 3.5.3.), laser treatment (section 
3.5.4.), in vitro angiogenesis (section 3.5.5.) and gene expression profiling (section 3.5.6.) 
assays.   
3.5.1.  Transmission  electron  microscopy  of  biological  specimens 
incubated with NPs. 
For  electron  microscopy  purposes,  HUVECs  were  either  grown  on  membrane  culture 
inserts,  then  fixed  with  the  membrane,  or  on  gelatin  pre-coated  culture  dishes,  then 
harvested and fixed as a pellet 
[90,91].  All samples were embedded in resin, cut to ultra-thin 
sections, then stained and imaged with Hitachi H7000 transmission electron microscope 
operating at a bias voltage of 75 kV. 
In detail, HUVECs (1 · 10
5) grown on porcine gelatin (0.2 % in HBSS) pre-coated 12-
well micro-plate, were incubated with OEG-coated NPs (1000 µl, 5 · 10
12 NP, in a full-
serum growth media) for 4 h at 37 °C in a humidified 5 % CO2 balanced air incubator.  
After treatment, cells were washed three times with PBS (1 x), then trypsinised (0.75 ml, 
0.25 % trypsin 0.01 % EDTA solution, Sigma-Aldrich) for 5 min. at 37 °C in 5 % CO2.  
The cell suspension was transferred to a plastic tube (1.5 ml, Eppendorf) and centrifuged 
(2’500 rpm, 5 min, 4 °C).  The solution was decanted and the cell pellet was redispersed in 
a main fixative: glutaraldehyde / formaldehyde (3 % / 4 %, in 0.1 M piperazine-1,4-bis(2-
ethanesulfonic  acid  –  PIPES  buffer,  pH  7.2),  then  incubated  for  15  min.  at  room 
temperature.  Cells were centrifuged (2’500 rpm, 5 min, 4 °C) and decanted.  To the cell 
pellet a drop of sodium alginate (5 % in water) was introduced with a mixture of PIPES 
buffer (0.5 ml, 0.2 M) and calcium chloride solution (0.5 ml, 0.2 M in water).  When the 
alginate settled (15 min.), the supernatant was removed and the embedded cell pellet was 
transferred into a glass vial and fixed with post fixative: osmium tetroxide (1 %, 0.1 M 
PIPES buffer) for 1 h.  The fixed pellet was washed twice with water (for 5 min.) and 
stained with uranyl acetate (2 %, in water) for 20 min.  The specimen was then washed 
with 30 %, 50 %, 70 % and 95 % ethanolic solutions for 10 min. each, then absolute 
ethanol  for  20  min.  twice.    Dehydrated  cells  were  embedded  in  TAAB  resin  (Agar 
Scientific Ltd.) and polymerised at 60 °C for 24 h.  Resin blocks were cut using Leica RM 
2255 microtome to obtain ultrathin sections (~ 100 nm thickness).  Sections were deposited 
on TEM grids and stained with Reynolds lead stain 
[92] prior to imaging.  
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 HUVECs in experiments with pep-OEG NPs were processed according to a modified 
protocol.  Firstly, cells (2.5 · 10
4) were grown on polyethylene terephthalate (PET) inserts 
(BD Biosciences) pre-coated with poly-D-lysine (10 µg/ml in 1 x PBS) and incubated with 
pep-OEG NPs for 4 h at 37 °C in full-serum media growth in a humidified 5 % CO2 
balanced air incubator.  The colloidal solution (1000 µl, 1 · 10
12 NPs, in a medium growth) 
was placed in a well under the PET insert along with additional volume of colloid (300 µl, 
same solution) placed inside the insert.  After treatment, cells were washed three times 
with  PBS  (1  x)  and  fixed  before  imaging  using  the  main  fixative:  glutaraldehyde  / 
formaldehyde (3 % / 4 %, in 0.1 M PIPES buffer) and post fixative: osmium tetroxide              
(1 %,  in tetradecafluorohexane  –  FC-72 solvent).    Fixed  specimens were washed with 
absolute ethanol, stained with uranyl acetate (1 %, in ethanol), embedded in Spurr resin 
(Agar Scientific Ltd.) and polymerised at 60 °C for 24 h.  Resin blocks were cut using 
Leica RM 2255 microtome to obtain ultrathin sections (~ 100 nm thickness).  Sections 
were deposited on TEM grids and stained with Reynolds lead stain 
[92] prior to imaging.  
3.5.2.  Flow cytometry. 
LL-RPE tagged P1 peptides (P1-LL-RPE) and HiLyte-P1-OEG NPs were employed in 
flow  cytometry  assays.    HiLyte-P1-OEG  NPs  were  prepared  according  to  a  protocol 
described  in  section  3.2.4.,  while  P1  peptides  were  labelled  with  LL-RPE  (Innova 
Biosciences Ltd.) fluorescent molecules according to a standard protocol supplied by the 
manufacturer 
[93]. 
Typically, live cells (1 · 10
5) suspended in a blocker (0.2 ml, 0.1 % sodium azide, 5 % 
FBS, in 1 x PBS) were incubated with P1-LL-RPE (15 µl, 8.7 μM) or HiLyte-P1-OEG NPs 
(10 µl, 1 μM, in 1 x PBS) for 1 h on ice.  In competition experiments, free P1 or P2 peptide 
solutions (15 µl, 1 mg/ml, in 1 x PBS, MW = 922.1) were introduced 15 min. before 
incubation with P1-LL-RPE or HiLyte-P1-OEG NPs.  Cells were washed twice with PBS 
(1 x) and gently redispersed in PBS (0.2 ml, 1 x) prior to measurements.   
Scattered and emitted light was recorded with FACS calibur (BD BioSciences) flow 
cytometer, using 488 nm excitation wavelength and orange channel detector or 633 nm 
excitation wavelength and infrared channel detector for P1-LL-RPE or HiLyte-P1-OEG 
NPs, respectively. 
All  results  deriving  from  the  measurements  of  emitted  light  were  presented 
simultaneously as one parameter, known as the binding index (BI).   
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       , where 
BI – binding index [%] 
Fl  – measured fluorescence value [a.u] 
Mn – measured mean value [a.u.] 
100 – factor deriving from referring to BI
max [%] 
BI
max  –  maximum BI value related to cells incubated with HiLyte-P1-OEG NPs 
3.5.3.  Inductively coupled plasma mass spectrometry (ICP-MS). 
ICP-MS  measurements  were  performed  by  Dr  Simone  Nitti  from  Istituto  Italiano  Di 
Tecnologia (IIT), Nanobiotechnology Department, Genova, Italy and by Dr J. Andy Milton 
from  the  National  Oceanography  Centre  (NOC),  School  of  Ocean  and  Earth  Science, 
University of Southampton, Southampton, UK. 
Prior to measurements, HUVECs (1 · 10
5) were grown on porcine gelatin (0.2 % in 
HBSS) pre-coated 12-well micro-plate and incubated with OEG-coated NPs (1000 µl, 5 · 
10
12 NP, in a full-serum media growth) for 4 h at 37 °C in a humidified 5 % CO2 balanced 
air incubator.  After treatment, cells were washed three times with PBS (1 x) and trypsin 
solution  (0.75  ml,  0.25 % trypsin 0.01  % EDTA  solution, Sigma-Aldrich) was added.  
HUVECs were incubated for 5 min. at 37 °C in 5 % CO2, then PBS (5 ml, 1 x) was added 
and the cell suspension was transferred into a plastic tube (15 ml) and centrifuged (2’500 
rpm, 5 min., 4 °C).  The cell pellet was redispersed in  PBS (1 ml, 1 x), counted and 
transferred into a glass vial.  Sealed vials were transported to IIT or NOC, where Dr Nitti 
or Dr Milton performed digestion of cells (and NPs) with aqua regia (9 ml) and ICP-MS 
measurements of a series of dilution using gold standards. 
The amount of gold atoms in each sample was measured in ppm, while the number of 
cells  was  counted.    This  was  referred  to  the  total  amount  of  introduced  NPs  and  the 
background level of gold in cells, both measured by ICP-MS.  The number of gold atoms 
per nanoparticle was ‘roughly’ estimated from the average size of NPs (measured by TEM, 
see Appendix B), the distances between atoms in the fcc crystal structure and the volume 
of a gold atom.  The average number of NPs per cell was then calculated.  At least three 
independent experiments were performed to estimate these average numbers. 
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3.5.4.  Photo-thermal treatment (laser-hyperthermia). 
The  experimental  set-up  (Scheme  33)  consisted  of  two  major  components: 
Supercontinuum  SC450  Laser  light  source  (Fianium)  and  IX81  Motorized  Inverted 
Microscope (Olympus), equipped with an environmental chamber, temperature controller, 
CO2 controller, as well as bright field and phase contrast imaging system.  The set-up was 
assembled in the Biomedical Imaging Unit, General Hospital, Southampton, UK by Dr 
Otto L. Muskens from the School of Physics and Astronomy, University of Southampton, 
UK.    
In a typical experiment,  HUVECs (2.5 · 10
4) were seeded on porcine gelatin pre-
coated 96-well microplate and incubated for 24 h at 37 °C in full-serum growth media in a 
humidified 5 % CO2 balanced air incubator.  Cells were treated for 4 h with OEG-coated or 
P1-OEG anisotropic NPs (100 µl, 1 · 10
13, in a medium growth).  After treatment, cells 
were washed twice with PBS (1 x) and kept in PBS (1 x) prior to the laser illumination. 
Cells were first imaged (phase contrast filter, 4 x objective) and then illuminated with 
near-infrared (NIR) laser light for  10 min. using variable laser power density (5  ‚ 32 
W/cm
2)  and  200  µm  laser  spot  size.    Bandpass  filters  were  employed  to  cut  off  any 
wavelength shorter than 680 and longer than 720 nm, to create a narrow (40 nm) band gap 
falling within NIR region (suitable for photo-thermal treatment of biological tissue 
[94-98]; 
see  chapter  2  for  theoretical  background).    SC450  Laser  is  a  powerful  pulsed  laser, 
sending 4 ps pulses.  The repetition rate is 40 MHz.  
After  laser  illumination,  buffer  was  removed  from  the  wells  and  the  cells  were 
incubated for 1 h or 24 h in fresh medium growth, prior to viability studies.  Cells washed 
once with PBS (1 x) were stained with trypan blue 
[99] (10 min., 0.1 % in 1 x PBS at 37 °C 
in a humidified 5 % CO2 balanced air incubator).  Stained cells were washed twice with 
PBS (1 x) prior to phase contrast and bright field imaging with 4 x objective.  The same 
spot was imaged before and after treatment.  Stained (damaged) and unstained (intact) cells 
were counted.  Cell viability was presented as a percent of stained cells to the total number 
of cells and plotted on a graph against the increasing laser power density (see chapter 7).  
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3.5.5.  Gene expression profiling. 
Gene expression profiling assays (see chapter 6 and 7 for results) involved four major 
steps: a) treatment of cells with NPs; b) mRNA isolation (the product of activated genes); 
c) reverse transcriptase polymerase chain reaction (RT-PCR, synthesis of c-DNA on the 
mRNA templates) and d) quantitative polymerase chain reaction (Q-PCR) using specific 
primers (oligodeoxynucleotides complimentary to the sequence encoding selected gene) 
equipped with a fluorescent TaqMan probe 
[100].  Since, RT-PCR, Q-PCR and TaqMan 
primers  are  well-established  and  commonly  used  in  genes  products  quantification, 
associated reaction mechanisms will not be discussed in this thesis.   
For  treatment  with  pep-OEG  spherical  NPs,  HUVECs  (1  ·  10
5)  were  seeded  on 
porcine gelatin pre-coated 12-well micro-plates and incubated for 24 h at 37 °C in serum-
depleted growth media (0.2 % of human serum, 100 times less than full-serum growth 
media)  or  additionally  hypoxia  mimicked  (100  µM,  cobalt  II  chloride  –  CoCl2 
[101]) 
conditions in a humidified 5 % CO2 balanced air incubator.  Cells were treated for 6 h with 
VEGF-B167 (150 ng, 10 µl, in 1 x PBS; PeproTech, Inc.), free P1 and P2 (7.3 ng, 10 µl, in 
1 x PBS, MW = 922.1), free P3 (7.7 ng, 10 µl, in 1 x PBS, MW = 968.2) or pep-OEG 
conjugated to spherical NPs (1.5 nM, 10 µl in 1x PBS), prior to mRNA isolation.  
laser light 
source 
IX81 microscope with the 
environmental chamber 
mirror  
filters  
focusing 
lens 
focusing 
lens 
optical 
fibres 
laser               
power-meter  CO2 controller 
temperature 
controller 
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Scheme 33.   Schematic illustration of the laser set-up. 
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Cells, washed twice with PBS (1 x) were lysed directly in a culture dish by adding 
TRIzol  reagent  (0.5  ml,  Sigma-Aldrich).    Homogenised  samples  were  incubated  with 
chloroform (0.1 ml) at room temperature for 5 min. and centrifuged (13’300 rpm, 30 min., 
4 °C).  The aqueous phase was transferred to a fresh tube and mixed with isopropanol (0.25 
ml)  and  glycogen  (5  µl,  20  mg/ml).    Samples  were  incubated  for  10  min.  at  room 
temperature, 10 min. at -80 °C, then centrifuged (13’300 rpm, 30 min., 4 °C).  RNA pellets 
were  washed  once  with  chilled  ethanol  (75  %),  incubated  on  ice  for  10  min.  and 
centrifuged (13’300 rpm, 15 min., 4 °C).  Washed pellets were air-dried and dissolved in 
nuclease-free water (100 µl).  
RNA solution (10 µl, 10 ng) was mixed with 10 x RT buffer (2 µl), random primers  
(2  µl),  RNAsin  (1  µl),  dNTPs  (0.8  µl),  nuclease-free  water  (3.2  µl)  and  reverse 
transcriptase (1 µl, Applied Biosystems).  Samples were incubated for 10 min. at 25 °C, 30 
min. at 45 °C and then for 5 min. at 95 °C.  RT-PCR was then followed by Q-PCR.  In 
detail, 10 times diluted c-DNA (2.5 µl, in nuclease-free water) was mixed with nuclease-
free water (2 µl), 2 x PCR mix (5 µl) and TaqMan primer (0.5 µl, Applied Biosystems) in 
384-well microplate.  DNA was amplified (35 cycles) and quantified using Thermo-cycler 
equipped with the TaqMan probe. 
 For  the  treatment  with  P1-OEG  or  OEG  anisotropic  NPs  followed  by  laser-
hyperthermia,  HUVECs (2.5 · 10
4) were seeded on porcine gelatin pre-coated 96-well 
microplate and incubated for 24 h in media growth at 37 °C in a humidified 5 % CO2 
balanced air incubator.  Next, the old medium was removed and OEG-coated or P1-OEG 
conjugated anisotropic NPs were introduced (100 µl, 1 · 10
13 in a medium growth).  Cells 
were incubated for 4 h, then washed twice with PBS (1 x) and kept in PBS (1 x) prior to 
laser irradiation.  
Four spots per sample were exposed to laser light to maximise the surface area of 
treatment, thus the number of irradiated cells.  After the irradiation, buffer was removed 
and cells were stimulated with TNF-α (100 ng/ml) for 5 h 
[102,103] in fresh growth media 
prior to mRNA isolation, RT-PCR and Q-PCR (detailed above). 
3.5.6.  In vitro angiogenesis. 
The formation of capillary-like structures by HUVECs on basement membrane matrix gel 
(Geltrex, Gibco; according to a protocol supplied by the manufacturer 
[104]) was studied 
after treatment with pep-OEG NPs.   
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The matrix gel was thawed overnight on ice, then mixed gently by pipette (avoiding 
air bubbles).  The homogenous gel (50 µl) was placed in a well (48-wells micro-plate) and 
polymerised  at  37  °C  in  a  humidified  5  %  CO2  air  balanced  incubator  for  30  min.  
HUVECs (4 ·10
4) suspended in growth media (200 µl, serum-depleted) mixed with VEGF-
B167 (150 ng/well), octa-peptides (7.3 ng/well of P1 or P2, MW = 922.1; 7.7 ng/well of P3, 
MW = 968.2) or pep-OEG conjugated spherical gold NPs (15 fmol/well) were seeded per 
well and incubated at 37 °C in a humidified 5 % CO2 air balanced incubator for 2 ‚ 20 h.  
Phase  contrast  images  of  capillary-like  structures  were  taken  with  IX81  Olympus 
microscope using 4 x objective.  
Statistical analysis of the capillaries formed were performed by measuring the overall 
length of capillaries per image (the field of view was 0.216 mm
2) using ImageJ software 
(see chapter 6).  The number of branching points per each image was counted manually.  
At least three view points per well were analysed.  Variations in tubules morphologies 
were reflected by error bars on associated graphs (see chapter 6).  Assuming that untreated 
cells (control) represent the background level of regulation (minimal capillaries length), 
while  VEGF-B167  stimulated  cells  show  the  maximum  level  of  regulation  (maximum 
capillaries length; hence equal to 100 %), the regulation index (RI) was calculated from the 
subsequent equation: 
 
    
               
               , where 
RI – regulation index [%] 
CL – capillaries length 
CL
cont – background subtraction (capillaries length quantified in untreated cells; control)  
100 – factor deriving from referring to CL
max [%] 
CL
max   – maximum CL value quantified in cells treated with VEGF-B167 
Analogously, if untreated cells formed the background number of branching points 
(minimal), while VEGF-B167 stimulated cells the maximum, the branching index (BrI) was 
calculated following the subsequent equation: 
 
     
                 
                 , where 
BrI – branching index [%]  
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BPs – branching points 
BPs
cont – background subtraction (number of BPs in untreated cells; control)  
100 – factor deriving from referring to BPs
max [%] 
BPs
max   – maximum BPs number obtain in cells treated with VEGF-B167 
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4.  Synthesis, surface capping and assembly of NPs. 
Over the course of the presented research a variety of water soluble nanomaterials were 
synthesised.  Water solubility along with stability against aggregations in buffered media is 
required for every appliance of nanocomposites in biomedicine 
[1-19]. 
Nanocomposites were prepared according to well-established protocols, described in 
chapter 3.  The size and shape of NPs and effectively the physicochemical properties of 
nanomaterials 
[20-24]  (see  chapter  2  for  theoretical  background)  were  manipulated 
chemically.  Spherical, rod-like, hollow gold NPs, as well as silica/gold core/shell hetero-
nanostructures (composed of more than one element) were prepared 
[25-33] (section 4.1.).  
The surface of NPs was coated with various organic molecules 
[2,4,6,34-36] (section 4.2.).  
Previously reported capping ligands (e.g. CALNN peptide 
[4], section 4.2.1.) and newly 
developed diacetylene based molecule 
[6] (section 4.2.3.) were utilised during this project.  
The  resulted  mono-layer  of  ligands  was  further  modified  with  bioactive  peptides 
[37] 
(section 4.2.2.).  Surface capping led to stable and water soluble colloids 
[6] (see section 
4.2.4.).  
4.1.  Synthesis of NPs. 
The  citrate  reduction  method,  developed  by  Turkievich 
[26,30,31,38-40]  was  utilised  in  the 
synthesis  of  spherical  gold  NPs  (section  4.1.1.).    Gold  nanorods  (section  4.1.2.)  were 
prepared either by a method introduced by El-Sayed’s group 
[28] (method I) or a protocol 
reported by Murphy 
[25] (method II).  Following a synthetic route introduced by Halas and 
co-workers led to silica/gold core/shell hetero-structures 
[29] (section 4.1.3.).  Gold NPs 
with  hollow  interiors  were  produced  according  to  a  method  developed  by  Xia 
[32,33] 
(section 4.1.4.).  One more type of anisotropic gold NPs with multiple arms (branched 
shape) was obtained with a new method, established during a master project of Mr Hugo 
Day (the University of Southampton, School of Physics and Astronomy, Southampton, 
UK).  The author of this thesis actively participated in this development, which led to a 
publication 
[41] (see Author’s Declaration for the full list of articles published from this 
project).    These  results  however,  will  not  be  further  discussed  in  the  thesis,  because 
branched NPs were not employed in any surface capping experiments nor in the biological 
part of the research (chapters 5 ÷ 7).  
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4.1.1.  Synthesis of spherical gold NPs.  
Gold NPs, spherical in shape and relatively mono-dispersed in size, were obtained using 
the  citrate  reduction  method 
[26,30,31,38-40]  (see  chapter  2  for  reaction  mechanism  and 
chapter 3 for protocol).  Representative TEM image is shown in Fig. 6A.  At least five 
TEM images of a colloid were analysed.  Diameters of NPs on each image were measured 
to  determine  major  size  groups.    The  overall  number  of  NPs  in  each  size  group  was 
counted  and  referred  to  the  overall  number  of  NPs  on  the  micrograph  (to  give  the 
population as percentage).  Obtained populations plotted against size groups (Fig. 6B) gave 
the NPs size distribution in the sample.  Estimated average diameter of the colloid was 15 
± 2 nm.  
The optical signature of the colloid was determined using UV-vis spectroscopy (Fig. 
6C).  The extinction peak reached maximum at around 520 nm (characteristic feature of 15 
nm spherical gold NPs 
[21-24,42,43]).  The single and sharp peak suggested a mono-dispersed 
colloid 
[21,23,24]. 
 
 
  
 
 
 
 
 
 
 
 
It is possible to vary the size of NPs with the citrate reduction method, simply by 
adjusting the molar ratio between the gold precursor (Au
3+) and the citrate reductant (Ct
3-) 
in the reaction mixture 
[38,39].  When the ratio between Au
3+ and Ct
3- was 1 : 3.9 (see 
chapter 3 for experimental details), NPs shown in Fig. 6 were produced.  Larger NPs were 
prepared  with  a  reduced  amount  of  Ct
3-.    As  an  example,  TEM  images  of  gold  NPs 
synthesised using 1 : 1.95 and 1 : 0.39 of Au
3+ to Ct
3- ratios are shown in Fig. 7A and B, 
respectively.  
Figure 6.  TEM  image  (A),  size  distribution  histogram  (B)  and  UV-vis  spectra  of 
citrate stabilised colloidal gold NPs prepared with 1 : 3.9, Au
3+ to Ct
3- ratio.  
Scale bar is 100 nm. 
A  B  C  
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It can be concluded from the images above that, a decrease in the quantity of Ct
3- 
introduced into the reaction mixture, generally leads to the formation of larger particles.  
One possible explanation is that, decreasing the quantity of citrate reduces the number of 
nucleation sites 
[38,39].  The less the gold precursor is involved in the nuclei, the more Au
3+ 
is available for growth stage.  Larger amount of unconsumed precursor (which remains in 
solution),  can  now  be  employed  in  further  development  of  NPs,  leading  to  larger 
structures.  Increase in the size of NPs boosts the ratio between the NPs diameter and the 
ligand length.  This, in conjunction with the reduction of the overall number of capping 
molecules (citrate), can lead to insufficient stabilisation of the NPs surface.  Destabilised 
NPs  would  clump  together  and  ripen 
[35,36,38,44,45],  which  can  effectively  result  in  the 
formation of even larger structures.  
In general, the size distribution of NPs produced, increases with decreasing molar ratio 
between the gold precursor and Ct
3-.   A decrease in the amount of Ct
3- by a factor two, 
leads  to  the  formation  of  colloids  with  a  broader  plasmon  band  (Fig.  8,  violet  line); 
possibly attributed to the poly-dispersed (non-uniform) sizes of NPs 
[21,23,24], as seen on the 
TEM image (Fig. 7).  Slight red-shifting of the extinction peak of NPs is most likely 
derived from their larger size, as in agreement with Mie’s theory 
[24] (see chapter 2).   
Further reduction of the amount of Ct
3- (factor 10) resulted in a significant decrease in 
the intensity of the maximum  extinction peak (Fig.  8, blue line).   This, along  with  a 
significant  broadening  (possibly  light  scattering  effect 
[22,46],  see  chapter  2  for  related 
theoretical background) and red-shift (to around 540 nm), suggests the formation of larger 
NPs and/or aggregates of NPs 
[21-24].  Both can be seen on the associated TEM image (Fig. 
Figure 7.   TEM images of citrate stabilised colloidal gold NPs prepared with Au
3+ to Ct
3- 
ratio of: 1 : 1.95 (A) and 1 : 0.39 (B).  Scale bars are 100 nm. 
A  B  
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7B);  as  explained  by  the  reduced  amount  of  citrate  ligand,  which  cannot  sufficiently 
stabilise the NPs surface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peng and co-workers proposed that trisodium citrate has a triple role in the citrate 
reduction 
[38] (see chapter 2 for detailed reaction mechanism).  Trisodium citrate not only 
acts as a gold reductant and NPs capping agent, but also as a pH modulator.  Reaction pH, 
according to Peng, has a significant effect on the reaction time and the size of NPs.  Below, 
TEM images of NPs prepared with pH adjusted to pH 6 (Fig. 9A) and pH 7 (Fig. 9B) are 
shown.    As  can  be  seen,  an  increase  in  the  pH  value  to  6  and  7  (images  A  and  B 
respectively) generally leads to the formation of larger NPs.   At lower pH values, the 
overall  size  distribution  of  NPs  seems  narrower,  as  indicated  by  both,  TEM  and  the 
extinction peak (shaper peak, Fig. 9C, pink line).  According to Peng and co-workers, 
depending on the pH, the reaction  can undergo one of two possible pathways,  with  a 
switching point at pH 6.5 
[38].  Slow nucleation and growth occur at high pH, while fast 
nucleation and intra-particle ripening at low.  At low pH (fast reaction) more nuclei are 
formed leading to smaller NPs.  
   
Figure 8.   UV-vis  spectra  (A)  and  a  corresponding  digital  image  (B)  of  citrate 
stabilised colloidal gold NPs prepared with Au
3+ to Ct
3- ratio of: 1 : 3.9 
(standard protocol, dashed line – A; left vial – B), 1 : 1.95 (violet line – A, 
middle vial – B) and 1 : 0.39 (blue line – A, right vial – B). 
A 
B  
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In general, citrate stabilised NPs easily aggregate in buffered environments and change 
their  optical  properties 
[7,21,24,35,36,47]  (see  chapter  2  for  theoretical  background).    This 
aggregation is irreversible and is due to a weak electrostatic stabilisation of the NPs surface 
with  the  citrate  capping  agent 
[35,36].    Negative  charge  of  citrate  NPs  is  screened  in  a 
presence of salts (e.g. sodium chloride, NaCl), bringing NPs closer (they no longer repel), 
until they finally stick together and form aggregates.  To increase the stability of NPs, their 
surfaces can be capped with ‘stronger’ ligands (interacting more strongly with the gold 
surface) via ligand exchange reactions 
[7,35,36]; e.g. BSPP ligand (developed by Lehnert’s 
group 
[48])  provides  NPs  with  a  strong  electrostatic  stabilisation,  as  demonstrated  by 
Alivisatos and co-workers 
[49].  As a result, the aggregation of NPs with NaCl is reversible 
[45,47,49].    NPs  can  be  brought  back  to  solution  upon  addition  of  pure  water.    Most 
importantly, their optical signatures are fully restored. 
A  B 
Figure 9.   TEM images (A and B), UV-vis spectra (C) and a digital image (D)  of 
citrate stabilised colloidal gold NPs prepared by a standard protocol (dashed 
line – C, left vial – D) with pH adjusted (with sodium hydroxide) to pH 6 
(A, violet line – C, middle vial – D) and pH 7 (B, blue line – C, right vial – 
D).  Scale bars are 100 nm.  
C 
D  
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Following this idea, to increase the storage stability, spherical citrate stabilised NPs 
with an average diameter of 15 nm, were capped with BSPP (see chapter 2 for schematic 
illustration and chapter 3 for experimental protocol).  The capping with BSPP resulted in a 
minor change in the refractive index of the colloid.  This, as expected from Mie’s theory 
[24], led to a slight red-shift of the plasmon band 
[21] (from 520 to 522 nm, Fig. 10C).  
Sharpness of the extinction peak suggests that BSPP capped NPs remained dispersed in 
solution 
[21-24,42,43,45].   The size and shape of the  metallic core of  BSPP  NPs  were not 
affected, as illustrated by the TEM image (Fig. 10A) and a corresponding size distribution 
histogram (Fig. 10B). 
  
 
 
 
 
 
   
 
 
4.1.2.  Synthesis of gold nanorods. 
Nanorods were grown in solution from the gold precursor and small gold NPs (seeds), 
entrapped  within  micelles  formed  by  surfactant  molecules  (CTAB) 
[25,28,50,51].    Two 
different  methods  (I 
[28]  and  II 
[25])  were  used  (see  chapter  3  for  details).    Method  I 
required additive silver ions (Ag
+), which undergo under-potential deposition (UPD) on the 
sides of a growing nanorod, promoting longitudinal axis elongation 
[28,52].  The overall 
length of the obtained nanorods depends on the introduced quantity of silver, as will be 
demonstrated in this section.  
Gold seeds were prepared by previously reported borohydride reduction method 
[28].  
In this method, gold precursor was reduced with sodium borohydride in the presence of 
CTAB (see chapter 2 for reaction mechanism and chapter 3 for experimental details).  
Resulting, CTAB stabilised seeds had a typical diameter of 2 ÷ 4 nm (as can be seen on the 
TEM image, Fig. 11A).  Colloidal solution had a brown colour and a typical shoulder-like 
A  B  C 
Figure 10.   TEM image (A), size distribution histogram (B) and UV-vis spectra of BSPP 
stabilised colloidal gold NPs.  Scale bar is 100 nm.  
 
Chapter 4 – Synthesis, surface capping and assembly of NPs 
 
 
87 
 
0
0.5
1
400 600 800
E
x
t
i
n
c
t
i
o
n
 
Wavelength [nm]
plasmon band at around 510 nm 
[21-24,28] (Fig. 11C and B, respectively; see also chapter 2 
for theoretical background).  These NPs served as seeds in both methods (I and II) used for 
the preparation of nanorods. 
 
 
 
 
 
 
As  already  mentioned,  the  dimensions  of  NPs  synthesised  by  method  I,  were 
controlled by simply varying one reaction parameter – the quantity of introduced silver 
(silver nitrate solution) into the reaction mixture 
[28].  An increase of silver nitrate solution 
volume from    .0.15 ml to 0.40 ml resulted in the formation of nanorods with a length-to-
width aspect ratio extended from around 2.2 to 5.2  (Fig. 12A and D, respectively).    
Figure 11.   TEM  image  (A),  UV-vis  spectra  (B)  and  a  digital  image  (C)  of  CTAB 
stabilised colloidal gold NPs.  Scale bar is 100 nm. 
A 
B  C  
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Figure 12.   TEM  images  and  the  representative  size  distribution  histograms  of  gold 
nanorods prepared with: 0.15 ml (A), 0.21 ml (B), 0.30 ml (C) and 0.40 ml (D) 
of silver nitrate solution.  Aspect ratios are around: 2.2 (A), 2.9 (B), 4.4 (C) and 
5.2 (D) respectively.  Scale bars are 100 nm. 
A 
B 
C 
D  
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As can be seen on the TEM images, the reaction yield (percent of rod-like structures to 
the total number of NPs) has reached over 90 %, as the majority of produced NPs were 
rod-like in shape, with only few spheres (Fig. 12A) or cubes (Fig. 12C).  Synthesised 
nanorods were narrow in size distribution and had an average dimension of 11 by 24 nm to 
11 by 57 nm (size distribution histograms, Fig. 12). 
It is widely accepted that, the optical properties of NPs strongly depend on their size 
[21-24,53-55].  In fact, the longitudinal plasmon band of rod-like gold NPs is sensitive to the 
nanorod  aspect  ratio  and  can  be  red-shifted  to  the  near-infrared  (NIR)  spectral  region 
[21,22,53-55] (as already explained in chapter 2).  Consequently, the maximum absorbance 
peak of nanorods with a width fixed at about 11 nm and length increased from 24 to 57 nm 
was shifted from 650 to 850 nm in wavelength, respectively (Fig. 13A).  These variations 
in the optical properties of rod-like colloids were also perceptible macroscopically, as seen 
in the solution colour change from violet to brown (Fig. 13B). 
 
 
 
 
 
 
 
 
 
 
More  elongated  nanostructures,  called  nanowires  were  synthesised  by  a  slightly 
modified reaction scheme 
[20,25,50,56-59] (method II, see chapter 3 for experimental details).  
In method II silver nitrate was discarded from the growth solution and NPs were grown in 
three steps.  This led to the synthesis of gold wires with a high aspect ratio and a length 
above 100 nm.  As an example, up to 300 nm long and 25 nm thick nanowires are shown 
on TEM micrographs (Fig. 14A ÷ B).  The corresponding UV-vis spectrum is presented in 
Figure 13.   UV-vis spectra (A) and a digital image (B) of gold nanorods prepared with: 
0.15 ml (violet: line – A and solution – B), 0.21 ml (blue: line – A and 
solution – B), 0.3 ml (green: line – A and solution – B) and 0.4 ml (brown: 
line – A, brown and solution – B) of silver nitrate solution. 
A 
B  
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Fig. 14D.  Clearly, the presence of wire-like structures in colloidal solution resulted in 
even greater red-shift of the plasmon band (to 1150 nm).  Broad longitudinal peak suggests 
poly-dispersed  NPs 
[21-24,55],  as  indicated by  the  TEM  images.   Higher  intensity of  the 
transverse band at 525 nm, along with the red colour of the solution, indicated the presence 
of spherical NPs 
[21,23-25].  This was confirmed by the TEM microscopy (Fig. 14C).  The 
overall reaction yield was calculated from five representative TEM images with only 10 % 
of nanowires among shapes of obtained NPs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
As explained in chapter 2, the growth of nanorods is predominantly controlled by 
basic components of the reaction mixture: CTAB, seeds and silver nitrate* (*when method 
I is utilised) 
[25,28,50-52,56-64].  Murphy’s group investigated the effect of different types of 
seeds on the final product of the reaction 
[50], e.g. nanorods grown via method II from 
citrate stabilised NPs, had Au{111} facets at the tips and a combination of Au{100} and 
Au{110} facets on the sides. 
A  B 
C  D 
Figure 14.   TEM images (A – C) and UV-vis spectrum of gold nanowires.  Scale bars 
are 100 nm.  
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The crystal structure of the final reaction product was studied by Guyot-Sionnest and 
co-workers 
[52].  They demonstrated that nanorods synthesised by method I exhibit Au 
{100} facets in the ends and Au {110} on the sides.  The different crystal structure was 
attributed to the UPD of silver, which according to Guyot-Sionnest, is favourable on Au 
{110} facets (the sides), rather than on Au {100} facets (nanorod ends). 
Except of the crystal structure, UPD also explains why the aspect ratio of nanorods 
produced, can be controlled by adjusting the quantity of the introduced silver nitrate 
[28,52].  
Higher concentrations of silver nitrate result in larger amounts of silver deposited on the 
nanorod-sides.  Larger surface area passivated with silver, leads to more excessive growth 
of nanorods ends and higher aspect ratio (width-to-length) of synthesised NPs 
[28,52,58,59].  
Elongation  of  the  longitudinal  axis  is  additionally  promoted  by  the  strong  binding  of 
CTAB  to  silver  (probably  via  bromide 
[58]),  which  usually  follows  the  silver  UPD 
[28,52,58,59].  
In the absence of silver (method II) the growth is mainly surfactant mediated.  As 
proposed by  Mulvaney  and co-workers,  CTAB  micelles  form  complexes  with  reduced 
AuCl
2- anions 
[63,64].  CTAB-AuCl
2- complexes collide with CTAB stabilised seeds.  The 
collision rate is faster at tips, rather than sides, thus promoting the growth in one direction.  
The overall yield of the reaction can be controlled by adjusting the pH of the environment, 
as demonstrated by Murphy and co-workers 
[56,58].  A slight increase of the reaction pH 
results in an increase of the ascorbate mono-anion fraction (effective reductant).  Ascorbate 
binds to the growing nanorod ends and reduces Au
3+ cations to Au
+ more efficiently, thus 
promoting the growth along the longitudinal axis. 
4.1.3.  Synthesis of silica/gold core/shell NPs. 
Silica/gold  core/shell  hetero-nanocomposites  were  prepared  according  to  a  method 
developed by Halas  and co-workers 
[29,65,66] (see chapter 3 for experimental protocol).  
This method involves three major steps; a) preparation of silica NPs (Fig. 15A); b) to 
which small gold NPs (seeds) are subsequently attached (Fig. 15B) and finally c) slow 
growth of gold shells around silica cores (Fig. 15C).  
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Silica NPs, prepared by a standard sol-gel method developed by Stöber et al. 
[67-70], 
were  spherical  and  uniform  in  size,  with  an  average  diameter  around  97  nm,  as 
demonstrated in  Fig. 16A and B.  The size of NPs synthesised by this method can be 
varied by adjusting the amount of water added into the reaction environment 
[67-70].  Water 
participates  in  precursor  hydrolysis  and  condensation  (see  chapter  2  for  detailed 
mechanism).  The amount of ammonia solution introduced into the reaction also has a 
strong effect on the final size of NPs 
[67-70].  As demonstrated by Vrij and co-workers, a 
synergetic effect of water and ammonia concentration regulate the final diameter and poly-
dispersity  of  silica  NPs 
[68].    Water  is  a  key  reagent  for  the  precursor  hydrolysis  and 
condensation, therefore reducing the water quantity slows down the reaction rate and leads 
to the formation of larger NPs.  Higher concentrations of ammonia result in larger average 
diameters and a narrower size distribution.  Consequently, smaller silica NPs (around 45 
nm  in  diameter,  Fig.  16C  and  D)  were  prepared  with  increased  water  and  decreased 
ammonia quantities 
[68,69] (see chapter 3 for experimental details). 
   
A  B  C 
Figure 15.   TEM images of: silica nanoparticle (A), silica nanoparticle with attached 
gold seeds (B) and a complete silica/gold core/shell (C); representing the 
three major steps in the synthesis of core/shell nanostructures.  
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The  surface  of  silica  NPs  was  functionalised  with  APTMS  (see  chapter  3  for 
experimental  details),  to  generate  a  monolayer  with  amine  groups  extending  outwards 
[29,66].  Available amine groups served as binding sites for small gold NPs in the following 
step of the synthesis of silica gold hetero-nanostructures. 
Three different  sizes  of gold  NPs  (seeds) were prepared by  the Duff  method (see 
chapter 3 for experimental details) 
[71,72].  Simply by changing the amount of the gold 
precursor (1 % aqueous solution of sodium tetrachloroaurate (III) dihydrate) added into the 
reaction mixture from 1.5 ml to 0.75 ml, the largest or the smallest seeds were obtained, 
respectively.    UV-vis  spectra  of  seeds  solutions  are  shown  in  Fig.  17A.  The  largest 
colloids exhibit a shoulder-like plasmon band (red line), while the maximum absorbance 
peak  of  the  smallest  seeds  (yellow  line)  is  nearly  invisible 
[22-24]  (see  chapter  2  for 
theoretical background on the optical properties of gold NPs).  A corresponding digital 
image of colloidal solutions is show in Fig. 17B. 
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Figure 16.   TEM images (A and C) and size distribution histograms (B and D) of silica 
NPs.  Scale bars are 100 nm. 
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As seen on TEM images (Fig. 18A ÷ C), the size of produced seeds varied from 3 ÷ 5 
nm of the largest (Fig. 18A), 2 ÷ 4 nm of the medium size (Fig. 18B), to 1 ÷ 3 nm of the 
smallest colloid (Fig. 18C).  Moreover, the largest seeds were the least uniform in size and 
shape, as some larger (up to 10 nm) and elongated structures were also present in solution.  
Despite that, all three colloids were attached to APTMS-functionalised 100 nm silica NPs 
(Fig. 18D ÷ F) and served as seeds in the synthesis of gold shells.  The smallest (yellow) 
seeds, attached to large silica NPs, were barely visible on the TEM micrograph (Fig. 18F), 
possibly due to their decreased contrast 
[23]. 
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Figure 17.   UV-vis spectra (A) and a corresponding digital image (B) of THPC coated 
gold NPs.  Yellow line and solution represent the smallest seeds, brown line 
and solution – medium size and red line and brownish-red solution – the 
largest.  
A 
B  
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In the final step of the synthesis of silica/gold hetero-nanocomposites gold shells were 
grown around silica cores from the gold precursor 
[29,65,66,73] (sodium tetrachloroaurate (III) 
dihydrate).  Gold seeds attached to the cores served as nucleation sites, therefore their 
initial size affected the thickness of produced shell and the optical properties of the final 
core/shell  NPs 
[29,65,66,74].    UV-vis  spectra  (Fig.  19A)  of  silica/gold  hetero-structures 
showed a significant red-shift of the plasmon band, from around 580 nm to 700 nm, for the 
core/shells grown from the largest or the smallest seeds, respectively.   Silica/gold NPs 
grown from the medium  size seeds  absorbed  at  around 605 nm.   The broad  shape of 
extinction peaks can be explained by the scattering effect deriving from the large overall 
diameter of NPs (100 nm silica cores), possibly in conjunction with the non-uniform size 
distribution 
[21,22,46,65].  Changes in the colour of the colloidal solutions were also observed 
macroscopically, as demonstrated on the associated digital image (Fig. 19B). 
   
A  B 
D  E 
C 
F 
Figure 18.   TEM images of THPC coated gold NPs (A ÷ C) and gold seeds attached to 
silica NPs (D ÷ F); the smallest gold seeds (A, D), medium size (B, E), the 
largest (C, F).  Scale bars are 100 nm.  
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Significant differences in the optical properties between synthesised colloids derived 
from the variation in thicknesses of gold shells grown on silica cores.  Assuming that the 
average core size was about 97 nm, the thickest shells (around 45 nm, Fig. 20A) were 
produced from the largest seeds (Fig. 18).  The medium size seeds resulted in thinner 
shells (around 33 nm, Fig. 20B), while the smallest seeds lead to the formation of the 
thinnest  gold  shells  (around  20  nm,  Fig.  20C).    It  is  also  worth  highlighting  that  the 
surfaces of the shells produced were not perfectly smooth, with the thickest shells having 
the largest bumps.  
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Figure 19.   UV-vis  spectra  (A)  and  a  corresponding  digital  image  (B)  of  silica/gold 
core/shell nanostructures.  Pink line represents pink solution (thickest shell), 
violet line – violet solution and blue line – blue solution (thinnest shell). 
A 
B 
Figure 20.   TEM  images  of  silica/gold  core/shell  nanostructures,  with  variable 
thicknesses of gold shell: the thickest (A), medium (B) and the thinnest (C).  
Scale bars are 100 nm. 
A  B  C  
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It is widely accepted that the optical properties of silica/gold core/shells depend very 
strongly on three major parameters: the shell thickness, the core size and ratio between 
them, as described by Halas and co-workers 
[29,65,66,74].  These parameters can be controlled 
by  slight  modifications  of  the  reaction  conditions 
[29,65-74].    As  already  mentioned,  a 
decrease in the amount of water and an increase in the amount of ammonia in the reaction 
environment, during the synthesis of silica NPs via sol-gel method, result in larger NPs 
[67-
70].  Consequently, larger silica cores lead to larger diameters of gold shells, which results 
in greater red-shifting of the plasmon band 
[22,29,65,66,74,75]. 
  Another important parameter is the thickness of the gold shell 
[22,29,65,76].  Except of 
the seed sizes (Fig. 18), the actual number of seeds attached to each silica core can also 
affect the thickness of produced gold shell 
[29,65,66].  This can be controlled by, e.g. the type 
of functional groups attached to silica NPs.  Halas and co-workers showed that thiol or 
amine terminated silica had the highest number of attached seeds 
[66].  Larger quantity of 
seeds per silica nanoparticle results in a thinner shell, because less surface area of silica 
core  is  left  to  cover  with  gold.    As  also  demonstrated  by  Halas  and  co-workers,  the 
thickness of the gold shell can be additionally regulated by adjusting the amount of gold 
salt present in the growth solution 
[29,65,66].  Reduced concentration of the precursor leads to 
the formation of a thinner shell.  In general, maximum red-shift of the plasmon band is 
usually achieved by thin shells (5 to 20 nm) grown around large cores (100 to 200 nm) 
[65].  
However,  larger  overall  size  of  NPs  leads  to  enhanced  scattering  properties  and  a 
predominantly  scattering  mode  of  silica/gold  hetero-nanostructures 
[22,77].    This  is 
particularly important in biomedical applications of NPs, which are based on absorption 
and scattering properties of silica/gold core/shells (e.g. laser-hyperthermia 
[78], see chapter 
7).    Consequently,  when  predominantly  absorbing  NPs  are  required,  thin  gold  shells 
(approximately 5 nm) can be grown around small silica cores (45 nm, see chapter 3 for 
experimental protocol) to form silica/gold hetero-structures absorbing in the NIR spectral 
region (see section 4.2.2. for UV-vis spectra of such NPs).   
4.1.4.  Synthesis of hollow gold NPs. 
Hollow gold NPs were synthesised by the method developed by Xia and co-workers and 
consisting  of  two  steps:  preparation  of  silver  NPs  (templates),  followed  by  galvanic 
replacement reaction between templates and the gold precursor 
[32,33,79-81] (see chapter 2  
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for  theoretical  background).    The  shape  and  size  of  hollow  gold  nanostructures  are 
determined by the type and size distribution of the silver templates.  
One-step seed mediated protocol developed by Oh and co-workers was employed in 
the synthesis of silver NPs 
[82] (see chapter 3 for experimental details).  In this method 
spherical or rod-like silver NPs can be synthesised in the presence of CTAB from small 
citrate capped silver NPs.  Citrate stabilised silver seeds were prepared by a borohydride 
reduction method at room temperature.  Silver seeds from 4 to 7 nm in diameter were 
obtained, as demonstrated on a TEM image (Fig. 21A).   
 
 
 
 
  
 
 
 
The UV-vis spectrum (Fig. 22A) with the characteristic peak (around 400 nm), in 
conjunction with yellow coloured solution (Fig. 22B), indicated the presence of colloidal 
silver 
[23,24,32,82].    The  final  product  of  the  seed  mediated  synthesis  (CTAB  stabilised 
spherical  NPs)  was  orange-yellowish  in  colour  (Fig.  22B).    NPs  were  81  ±  9  nm  in 
diameter (Fig. 21B) with an extinction peak around 440 nm (Fig. 22A).  The broadness of 
the plasmon band can be attributed to scattering effects and/or wide size distribution of 
NPs 
[21,23,24,54].  
 
   
Figure 21.   TEM images of citrate stabilised silver seeds (A) and CTAB coated silver 
NPs (B).  Scale bars are 100 nm. 
A  B  
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In the final stage of the synthesis of hollow gold NPs silver atoms were exchanged to 
gold during the galvanic replacement reaction 
[32,33,79,83].  The optical properties of the 
resulting  gold  NPs  depend  strongly  on  type  of  nanostructures  produced,  thus  can  be 
adjusted chemically 
[10,22,27,32,33,76,79-81,83-87].  The quantity of the gold precursor (1 mM 
sodium  tetrachloroaurate  (III)  dihydrate)  injected  into  the  boiling  solution  of  silver 
nanocrystals was crucial.  A decrease from 0.5 to 0.25 ml resulted in the formation of 
nanoshells or nanocages, respectively (Fig. 23A ÷ C) with around 10 nm wall thickness.  
The presence of holes in the wall resulted in a red-shift of the plasmon band from around 
700 nm (for nanoshells) to 800 nm (for nanocages, Fig. 23D).  Significant differences in 
the optical properties of colloids were also observed macroscopically, as demonstrated on 
the associated digital image (Fig. 23E).  
   
Figure 22.   UV-vis  spectra  (A)  and  a  corresponding  digital  image  (B)  of  citrate 
stabilised silver seeds (yellow line – A and solution on the left – B) and 
CTAB coated silver NPs (orange line – A and solution on the right – B).  
A 
B  
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Several different methods of the synthesis of monodispersed silver NPs have been 
developed in recent years, e.g. Xia and co-workers reported a polyol method, which lead 
to the formation of a variety of shapes of silver NPs, from spherical, cube-like to rice-like 
[27,81,84,86-88].  This method however, involves high temperatures (up to 160 °C).  As an 
alternative,  Oh  and  co-workers  developed  a  seed  mediated  surfactant  guided  method, 
which  was  initially  designed  to  synthesise  silver  nanorods 
[82].    Nonetheless,  as 
demonstrated in this section, with minor modifications (see chapter 3 for experimental 
protocol)  this  method  can  be  employed  in  the  synthesis  of  relatively  monodispersed 
spherical NPs.  
The very simple method of synthesising hollow gold NPs (developed by Xia and co-
workers) involves only two reagents: gold precursor and silver NPs 
[32,33,79,83].  A type of 
the final product and its optical properties can be easily modified, by varying the amount of 
precursor or by using different silver templates; e.g. Oh and co-workers demonstrated the 
 
Figure 23.   TEM images (A ÷ C), UV-vis spectra (D) and a corresponding digital image 
(D) of hollow gold NPs; nanoshells (A, blue line on D and solution on the 
left on E) and nanocages (B and C, brown line on D and solution on the right 
on E).  Scale bars are 100 nm.  
D 
E 
B  C  A  
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use of silver nanorods, which led to the formation of hollow gold nanorods with a plasmon 
band around 800 nm 
[82].  Whilst the utilisation of silver nanocubes resulted in hollow gold 
nanocubes or nanocages with  plasmon band shift to 1000 nm, as demonstrated by Xia and 
co-workers 
[14,27,32,33,79-81,83-85,87,89]. 
4.2.  Surface capping and assembly of NPs. 
Gold  NPs  were  coated  with  three  types  of  ligands:  CALNN  based  peptides 
[4,34], 
oligoethylene glycol (OEG) based ligands 
[2] and diacetylene based molecules 
[6,90,91].  NPs 
capped  with  diacetylene  based  monomers  were  photo-polymerised  (section  4.2.3.)  to 
create firm polymeric shell, which protects the metallic core and enhances NPs stability in 
aqueous environments 
[6].  Gold colloids coated with CALNN based peptides were utilised 
in the formation of NPs assemblies (section 4.2.1.) on oligodeoxynucleotide templates 
[34].  
OEG  capped  NPs  were  further  modified  with  octa-peptides 
[37]  (section  4.2.2.)  and 
employed in the selective targeting of HUVECs (see chapter 5 and 7) towards regulation 
of basic cellular functions (chapter 6 and 8).  Stability tests of gold colloids are shown in 
section 4.2.4. 
4.2.1.  NPs  surface  capping  with  CALNN  based  peptides  and 
assembly on oligodeoxynucleotide templates. 
Gold NPs were capped with CALNN based 
[4,92] oligopeptides and assembled on short 
synthetic  oligodeoxynucleotides  (ODNs) 
[34].    Selective  binding  between  FQGII  penta-
peptide and AT-rich regions of ODNs 
[93,94] resulted in a range of gold NPs arrays.  The 
size and shape of  NPs  assemblies  were  adjusted by  changing  the  composition of NPs 
capping layer and varying the architecture of ODN templates.  Specifically, short self-
complementary  sequences  of  ODN3  contained  two  AT-regions,  while  long  staggered 
duplex of ODN1+2 had AT-rich regions at regular intervals along its entire length (see 
chapter 2 for theoretical background and chapter 3 for schematic illustration).  
Spherical 15 nm gold NPs were coated with a mixture of CALNN and CALNN-Ahex-
FQGII (c-FQGII, see chapter 2 for chemical structures and chapter 3 for experimental 
details) peptides 
[34].  As reported by Brust and co-workers, the CALNN moiety provides 
NPs with sufficient stability in buffered environments 
[4,9,92,95] (see chapter 2 for schematic 
illustration and more details on CALNN capping ligand).  The percentage of c-FQGII to 
CALNN attached to the surface of gold NPs was varied between 0 and 25 % to obtain  
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increasing ODN binding sites per nanoparticle.  UV-visible spectra of gold colloids (Fig. 
24A)  with  varying  c-FQGII  content  showed  sharp  plasmon  bands  with  typical  peaks 
(around 525 nm), representing stable and dispersed in solution 15 nm NPs 
[21-24,42].  A 
decrease in electrophoretic mobility (Fig. 24B) of colloids represented an increase in the 
amount of c-FQGII attached to NPs 
[96,97]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The formation of gold NPs assemblies on ODN templates was monitored by electron 
microscopy and UV-vis spectroscopy.  TEM micrographs (Fig. 25) of NPs, incubated with 
ODN templates, showed clear organisation of NPs-ODN complexes.  Dimers and trimers 
were formed on both templates (ODN3 and ODN1+2), when 5 % c-FQGII coated NPs were 
used.  Short chains of NPs were formed on both templates when the number of ODN 
binding sites increased to 10 % c-FQGII.  Longer, single chain-like arrangements of 15% 
c-FQGII coated NPs can be observed on ODN3, while double chains of NPs were formed 
on ODN1+2 duplexes.  Up to 3 µm long chains showed about 100 nm long helical twists, as 
indicated by red arrows.  Much shorter double chains of NPs were formed with 25 % c-
FQGII on ODN1+2 templates, while when ODN3 templates were employed, highly complex 
three  dimensional  networks  of  NPs  were  created  (for  more  TEM  images,  see  related 
publication listed in Author’s Declaration).  
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Figure 24.   UV-visible spectra (A)  and a  gel  electrophoresis image  (B) of  gold  NPs 
with: 0 % (black line, lane 1), 5 % (pink line, lane 2), 10 % (blue line, lane 
3), 15 % (green line, lane 4) and 25 % (orange line, lane 5) c-FQGII content.  
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Statistical analysis of TEM micrographs showed a gradual increase in the number of 
assembled NPs, with an increase in the amount of binding sites per nanoparticle (Table 2).  
Consequently, it can be hypothesised that the probability of binding is directly correlated 
with the c-FQGII content. 
The optical properties of NPs assembled on ODN templates depend strongly on the 
size and shape of aggregates, as well as distances between NPs 
[21-24,54,98].  The presence of 
small  structures  (e.g.  dimers  and  trimers)  is  usually  indicated  by  broadening  and/or 
decreasing  intensity  of  the  plasmon  band,  while  additional  red-shifting  suggests  the 
c-FQGII 
 [%] 
Assembled NPs  
[%] 
ODN1+2  ODN3 
5  32 ± 5  42 ± 3 
10  53 ± 4  64 ± 4 
15  67 ± 7  95 ± 6 
25  84 ± 6  100 ± 2 
5 % c-FQGII  10 % c-FQGII  15 % c-FQGII  25 % c-FQGII  0 % c-FQGII 
TEM images 
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Figure 25.   TEM images of gold NPs with variable amount of c-FQGII assembled on 
ODN templates.  Scale bars are 100 nm. 
Table 2.   Statistical analysis of the NPs assemblies.  
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formation of larger aggregates (Fig. 26).  Plasmon bands of 5% and 10% c-FQGII coated 
NPs assembled on ODNs do not show any notable shifts.  In contrast, major decrease in the 
intensity, broadening and red-shifting of plasmon bands, can be observed for NPs with 
higher c-FQGII content.  Red-shifts of up to 11 nm were observed for 25 % c-FQGII NPs 
assembled on ODN1+2 templates, while up to 21 nm for ODN3, albeit the UV-vis spectra 
represent  an  average  between NPs  involved  in assemblies  and  those remaining free in 
solution.  
 
 
 
 
 
 
 
 
 
 
 
 
 
DNA based scaffolds have been employed in the past to arrange NPs, as reported by 
several  research  groups 
[49,98-101].    These  approaches  either  require  a  high  level  of 
sophistication in design and synthesis, or are limited to fabrication of small quantities of 
material.  A system developed during this project, is based on specific recognition between 
penta-peptide  and  short  ODN  based  sequences.    It  is  simple  in  design  and  easy  in 
preparation  (see  chapter  3  for  experimental  protocols).    Sasaki  and  co-workers 
demonstrated that the FQGII sequence selectively binds to an AT-rich region of a short 
target DNA duplex with high binding constants 
[93,94].  This idea was employed in the 
fabrication of NPs assemblies.  Hence, FQGII penta-peptide was used in the preparation of 
the  minimal  NPs-ODN  building  blocks.    This  new  strategy  of  NPs  assembly  was 
developed over the course of this project in a close collaboration with Stulz’s group from 
the School of Chemistry, University of Southampton, Southampton, UK. 
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Figure 26.   UV-visible spectra of gold NPs with: 0 % (black line), 5 % (pink line), 10 % 
(blue  line),  15  %  (green  line)  and  25  %  (orange  line)  c-FQGII  content 
assembled on ODN1+2 (A) and ODN3 (B) templates.  
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4.2.2.  NPs  surface  capping  with  OEG  ligand  and  further 
modifications. 
Brust and co-workers developed a method for preparation of water soluble and stable in 
buffered  environments  gold  NPs,  capped  with  amphiphilic  thioalkyl  based  ligand: 
monohydroxy  (1-mercaptoundec-11-yl)  tetraethylene  glycol 
[2].    A  slightly  modified 
molecule,  extended  by  two  steps  of  ethylene  glycol  and  terminated  with  a  functional 
carboxylic group (OEG, see chapter 3 for structure and capping protocol) was employed 
here as a capping ligand for spherical (15 nm in diameter) and anisotropic (rod-like, hollow 
and core/shell) gold NPs (see chapter 2 for schematic illustration).  
NPs  were  capped  with  OEG  (monocarboxy  (1-mercaptoundec-11-yl)  hexaetylene 
glycol) through the thiol anchoring group 
[2,35,36].  The long (C11) carbon chain of OEG 
provided  NPs  with  a  uniform  hydrophobic  layer,  due  to  Van  der  Waals  interactions 
between neighbouring ligands 
[2,7].  The hydrophilic part of OEG (-(EG)6-OCH2-COOH) 
ensured  water  solubility  and  a  functional  carboxylic  group 
[2,7,36,102,103].    Carboxyl  was 
employed in further modifications of NPs with octa-peptides (P1, P2 or P3, see chapter 2 
for  chemical  structures)  and  a  fluorescent  tag  (HiLyte)  via  the  EDC/s-NHS  coupling 
method 
[37]  (see  chapter  2  for  reaction  mechanism  and  chapter  3  for  experimental 
protocols).  This conjugation technique was employed in the past to couple transferrin and 
antibodies to mercaptoacetic acid coated quantum dots or carboxy terminated PEG dithiol 
capped gold NPs, as reported by Nie and co-workers and Mason’s group, respectively 
[104,105].  The reaction conditions used here (see chapter 3) were adjusted and optimised, to 
match the requirements of the octa-peptide based system, which resulted in up to 31 % 
reaction yield, as will be discussed further in the text.  
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OEG  coated  NPs,  as  well  as  P1-OEG,  P2-OEG,  P3-OEG  and  HiLyte-P1-OEG 
conjugates, were stable in buffered environments and did not form any large aggregates.  
As an example, TEM micrographs and size distribution histograms of OEG coated and P1-
OEG conjugated 15 nm spherical NPs are shown in Fig. 27A ÷ D (see section 4.1.1. for 
BSPP caped NPs).  It is evident that the metallic core has not been affected by the ligand 
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Figure 27.   TEM images (A and C), size distribution histograms (B and D) and UV-vis 
spectra (E and F) of: OEG NPs (A, B and red line) and P1-OEG NPs (C, D 
and green line), P2-OEG NPs  (blue  line) and  P3-OEG NPs  (black  line).  
Scale bars are 100 nm. 
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exchange or EDC/s-NHS coupling procedures.  In addition, sharp plasmon bands without 
shoulders (Fig. 27E and F) suggested dispersed NPs of typical sizes in solution 
[21-24].  
Slight shifts between peaks representing OEG coated and peptide conjugated (pep-OEG) 
colloids  were  observed.    This  indicated  minor  changes  in  the  refractive  indexes,  most 
likely derived from the presence of an additional organic layer composed of octa-peptide 
[21,24,42].  
Spherical NPs served as a model system and were employed in studies regarding non-
specific interactions with mammalian cells (see chapter 5), specific targeting of desired 
cell types and regulation of certain cellular functions (see chapter 6).  However, because 
of the optoelectronic properties of spherical NPs (plasmon band around 520 nm), they 
could not be applied in laser induced photo-thermal treatment 
[106-108] (see chapter 2 for 
theoretical  background).    Instead,  anisotropic  NPs  (rod-like,  hollow  and  core/shell) 
absorbing in the NIR spectral region were used 
[78,80,109-111] (see chapter 7).  All three types 
of anisotropic NPs were successfully stabilised with OEG capping ligand and conjugated 
to P1 peptide.  UV-visible spectra (Fig. 28) indicated stable colloids of typical shapes and 
sizes 
[21-24,42,43].  The character of the peaks was not affected, suggesting that the metallic 
cores of OEG NPs and P1-OEG NPs remained unaltered and that the NPs did not form any 
aggregates.  
 
 
 
 
 
 
 
 
 
 
 
 
Both, UV-vis spectroscopy and TEM imaging cannot give sufficient information about the 
exact overall size of NPs, including the organic shell and the net charge of the particle.  
Therefore dynamic light scattering (DLS) and ζ-potential measurements were performed to 
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Figure 28.   UV-visible spectra of OEG NPs – red line and P1-OEG NPs – green line. 
Nanorods – full line, hollow NPs – dotted line and core/shells – dashed line.  
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determine  these  parameters  (see  chapter  3  for  experimental  details).    Changes  in  the 
hydrodynamic diameter between OEG and pep-OEG coated NPs are shown in Fig. 29.  
OEG NPs had an average size of 24.7 ± 1.8 nm, while the average size of P1-OEG NPs 
was 30.7 ± 0.9 nm.  Assuming that the average diameter of the gold core was 15 nm (TEM 
images,  Fig.  27),  the  width  of  OEG  monolayer  was  calculated  at  4.85  nm,  while  the 
peptide layer was found to be 3 nm thick.  The layers of P2 and P3 octa-peptides had 
similar thicknesses.  A strong negative charge (-27.53 ± 1.5 mV) of OEG coated NPs 
derived from the presence of carboxylic groups in the organic layer.  The net charge of P1-
OEG conjugates changed by 4 mV (-23.40 ± 2.3 mV), due to the formation of amide bonds 
between  carboxylic  groups  from  the  outer  shell  of  OEG  and  N-terminus  lysines  form 
positively charged peptides.  P2-OEG conjugates had a similar ζ-potential, while P3-OEG 
NPs had slightly lower, which might be a result of a slightly smaller number of peptides 
attached to each nanoparticle.  
 
 
 
   
 
 
 
 
 
 
   
This is in a good agreement with quantitative analysis of OEG NPs and pep-OEG NPs.  
The average number of OEGs attached to each nanoparticle was estimated with Ellman’s 
method 
[112,113] and the amount of conjugated peptides was found with a lysine specific, 
FluoroProfile  protein  quantification  kit 
[114]  (see  chapter  3  for  experimental  details).  
Overall, it was calculated that 1876 ± 156 OEG ligands (see Appendix B for tables with 
data from 10 independent measurements) were chemisorbed on the surface of 15 nm spherical 
NPs.  An average of 436 ± 44 P1 or P2 and 417 ± 10 P3 octa-peptides was conjugated to 
the  outer  shell  of  each  nanoparticle.    Variable  peptide  coverage  can  be  derived  from 
differences in amino acids content between P1 (or P2) and P3 (see chapter 2 for chemical 
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Figure 29.   Dynamic light scattering (A) and ζ-potential (B) of: OEG coated NPs – red 
line, P1-OEG NPs – green line, P2-OEG NPs – blue line and P3-OEG NPs – 
black line. 
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structures), possibly affecting the diffusion rate in an aqueous environment and the yield of 
the  coupling  reaction 
[37,115].   P3  peptide  consist  of  25  %  hydrophilic  residues  and  its 
average hydrophilicity is 0, while P1 and its scrambled (mutated) version P2 contain twice 
as  much  (50  %)  hydrophilic  amino  acids,  what  makes  them  slightly  more  hydrophilic 
(average 0.6).  Nevertheless, all three pep-OEG NPs showed equally good water solubility. 
Similar measurements (DLS and ζ-potential) and quantification assays were performed 
on  anisotropic  core  based  NPs.    DLS  and  ζ-potential  spectra  are  shown  in  Fig.  30.  
However, the hydrodynamic width and length of nanorods could not have been measured 
with this method, due to the difficulty of distinguishing the peaks representing longitudinal 
axis from the nanorod thickness.  
 
 
 
 
 
 
 
 
 
 
 
 
 
The average number of OEGs and P1 peptides attached to anisotropic core based NPs 
was estimated following Ellman’s 
[112,113] and FluoroProfile 
[114] methods, respectively.  In 
all cases the number of capping ligands seemed to be sufficient to provide appropriate 
surface stabilisation.  Between 21 to 32 % of the available carboxylic groups on the outer 
shell of NPs were consumed for the covalent attachment of P1 peptides.  This can be 
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Figure 30.   Dynamic light scattering (A – C) and ζ-potential (D – F) of: OEG coated 
NPs – red line and P1-OEG NPs – green line.  Core/shells (A, D), hollow 
NPs (B, E) and nanorods (C). 
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considered as  a relatively good reaction  yield.  All measured and calculated values of 
spherical and anisotropic NPs are shown in Table 3. 
 
 
Gel electrophoresis was used for qualitative examination of the EDC/s-NHS coupling 
products to determine the differences in size and net charge between the resulting colloids 
[96,97] (Fig. 31).  Notable delay of colloid in lane 4 (Fig. 31A) in comparison to OEG NPs 
(lane  1)  and  control  samples  (lanes  2  and  3),  indicated  successful  conjugation  of  P1 
peptides to OEG NPs.  There are no significant differences between P1, P2 and P3 pep-
OEG NPs (Fig. 31B), which indicates similar yields of these coupling reactions, as the 
sizes and net charges of these colloids are comparable.   
 
 
 
 
 
 
 
 
 
 
 
Gel electrophoresis was also performed on anisotropic core based OEG and P1-OEG 
NPs (Fig. 32).  As expected OEG NPs (lanes 1, 3, 5 and 7) showed higher electrophoretic 
mobility than P1 conjugates (lanes 2, 4, 6 and 8) and travelled further in the gel for all 
types the NPs cores.  On the other hand, it is evident that the smallest spherical NPs (lanes 
P1-OEG NPs 
type 
Metallic 
core 
[nm] 
Hydrodynamic 
diameter  
[nm] 
Net charge 
[mV] 
Number of 
OEGs 
Number of 
P1s 
spherical  15 ± 2  31 ± 1  -23 ± 2  1876 ± 156  436 ± 44 
rod-like  16 ± 3/47 ± 3  -  - 26 ± 1  6820 ± 877  1457 ± 149 
hollow  92 ± 8/9 ± 3  98 ± 4  -32  ± 2  55871 ± 570  17514 ± 1904 
core/shells  43 ± 6/6 ± 3  56 ± 3  -29  ± 2  21368 ± 830  6931 ± 300 
2  3  1  2 
+ 
4  1  - 
+ 
-  3 
A  B 
Lane 1 – P1-OEG NPs  
Lane 2 – P2-OEG NPs  
Lane 3 – P3-OEG NPs 
 
Lane 1 – OEG NPs            
Lane 2 – OEG NPs / free P1  
Lane 3 – OEG NPs / EDC, s-NHS  
Lane 4 – OEG NPs / free P1/  EDC, 
s-NHS   
 
Figure 31.   Gel electrophoresis showing: qualitative analysis of EDC/s-NHS coupling 
(A) and the differences between pep-OEG NPs (B). 
 
Table 3.   A summary of physiochemical properties of P1-OEG NPs.  
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1 and 2) migrated the furthest, while the largest hollow NPs (lanes 5 and 6) delayed the 
most in the gel.  Hollow NPs smeared in the gel, rather than migrated as one homogenous 
band, which can be a size related effect. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presence  of  the  fluorescent  tag  on  HiLye-P1-OEG  NPs  (see  chapter  3  for 
experimental  details)  was  confirmed  by  fluorescence  spectroscopy  (Fig.  33A)  and  gel 
electrophoresis (Fig. 33C).  A slight red-shift in the emission spectra of HiLyte-P1-OEG 
NPs (around 695 nm) in a comparison to free fluorescent dye (680 nm) 
[116] was observed.  
This  slight  shift  in  emission  can  be  attributed  to  stretching,  deriving  from  covalent 
attachment of HiLyte molecules 
[117].  Distances from 4.85 to 7.85 nm (OEG or P1-OEG 
layers,  respectively)  between  fluorophore  and  the  gold  surface  sufficiently  prevented 
quenching of the fluorescent signal.  No changes in visible light absorption characteristics 
(Fig. 33B) suggest the HiLyte-P1-OEG NPs remained stable and dispersed in solution after 
conjugation 
[21-24,42].  Significant differences in electrophoretic mobility between colloids in 
lanes  1  ÷  3  (Fig.  33C)  provide  an  additional  confirmation  of  successful  conjugation 
between HiLyte dye molecules and P1-OEG NPs. 
   
  1    2        3     4        5     6        7     8 
Lane 1 – OEG NPs 
Lane 2 – P1-OEG NPs  
Lane 3 – OEG NPs 
Lane 4 – P1-OEG NPs 
Lane 5 – OEG NPs 
Lane 6 – P1-OEG NPs 
Lane 7 – OEG NPs 
Lane 8 – P1-OEG NPs 
+ 
- 
Figure 32.   Gel electrophoresis of colloidal gold NPs: spherical (1, 2), rod-like (3, 4), 
hollow (5, 6) and core/shell NPs (7, 8).  
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Kamat and co-workers showed that the deactivation of excited states in fluorophore-
gold NPs composites most likely derives from electron or energy transfer from fluorophore 
to the metallic core, or inter-molecular interactions between fluorophores 
[117].  Within the               
HiLyte-P1-OEG NPs, the quenching of the fluorescent signal was sufficiently prevented 
using appropriate selection of critical parameters.  Fluorophore molecules were separated 
from the gold surface (quencher) by 4.85 ÷ 7.85 nm distance created by OEG or OEG-P1 
layers.    Relatively  high flexibility of P1  and hexa-ethylene  glycol  moieties 
[7,102,118] in 
conjunction with discrete positions of HiLyte dyes on the outer shell of the organic corona, 
prevented inter-molecular quenching of fluorophores.   Since, HiLyte dye emits (and is 
excited) in NIR region, the fluorescent signal could not be disrupted by NPs, absorbing in 
the visible range. 
   
A 
C 
Figure 33.   Emission (A) and extinction spectra (B); P1-OEG NPs (red line), HiLyte-P1-OEG 
NPs (blue line) and free HiLyte dye (black dashed line, emission only).  A digital 
image of a gel electrophoresis (C). 
+ 
-  1 
Lane 1 – OEG NPs 
Lane 2 – P1-OEG NPs / HiLyte 
/ EDC, s-NHS  
Lane 3 – P1-OEG NPs  2  3 
B  
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4.2.3.  NPs surface capping with diacetylene based (DA-PEG) ligand. 
A new type of capping ligand (DA-PEG, see chapter 3 for structure) based on diacetylene 
group was employed in the NPs surface capping 
[6].  DA-PEGs were attached to the surface 
of NPs through thiol anchoring groups 
[35,36] and polymerised by UV-irradiation 
[91,119,120] 
(see chapter 2 for schematic illustration and chapter 3 for experimental details).  Fine 
packing between neighbouring monomers was assured by the hydrophobic part of DA-
PEGs,  where  long  carbon  chains  interacted  with  each  other  via  van  der  Waals  forces 
[7,35,36,121,122].  The hydrophilic unit containing oligoethylene glycol ensured water solubility 
and provided a functional carboxylic group for further modifications 
[2,7,37,102,103]. 
The idea to use diacetylene based molecules as NPs capping ligands only recently 
appeared  in  the  literature,  e.g.  Dellepiane  and  co-workers  reported  that  thiolalkyl-
diacetylenes  can  be  utilised  in  the  synthesis  of  small  gold  NPs  in  organic  solvents 
[91,120,123,124].  Here, diacetylene based ligands (DA-PEG) were employed in the capping of 
water soluble 15.5 nm spherical gold NPs (BSPP stabilised; see section 4.1.1.). 
After photo-polymerisation NPs remained dispersed in solution, showing no sign of 
aggregation, as can be seen on TEM micrographs (Fig. 34A and C).  No changes in the 
average diameter of NPs after photo-crosslinking (size distribution histograms, Fig. 34B 
and D) indicated that the inorganic core remained stable under the irradiation conditions.  
Another proof of the core stability comes from the sharpness of the extinction spectrum of 
photo-polymerised NPs 
[23,24] (Fig. 34E and F).  Dispersed colloids of typical sizes are 
indicated by a single extinction peak in the visible spectral range 
[21-24].  Slight red-shifting 
in the plasmon band position from 522 to 526 nm (in comparison to BSPP NPs) suggested 
only minor changes in the refractive index after capping 
[21,24,42].  The polymerised form of 
the  diacetylene  moiety  does  not  show  any  feature  on  the  UV-vis  spectra  of  colloids, 
because  the  extinction  coefficient  of  gold  NPs  is  much  higher  than  of  polymerised 
diacetylenes (≥ 10
3)  
[42,125].    
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The  overall  size  of  DA-PEG  capped  NPs  (including  the  organic  corona)  was 
determined by DLS, while the net charge by ζ-potential measurements (see chapter 3 for 
experimental details).  It was possible to detect changes in the hydrodynamic diameter of 
DA-PEG capped NPs before and after photo-polymerisation (Fig. 35).  Monomeric NPs 
0
20
40
13.5 15.5 17.5
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Figure 34.   TEM images (A, C), size distribution histograms (B, D) and UV-vis spectra 
(E, F) of 15.5 ± 1.5 nm, DA-PEG coated gold NPs before (A, B and green 
line) and after (C, D and black line) UV-polymerisation; BSPP capped NPs 
– red line.  Scale bars are 100 nm. 
A 
C 
B 
D 
F 
E  
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had an average size of 25.9 ± 1.9 nm, while DA-PEG NPs after polymerisation were 24.3 ± 
1.0 nm.  Assuming that the gold core was 15.5 nm in diameter (from TEM images, Fig. 
34), the width of the monomeric shell was calculated at 5.2 nm, while the polymeric shell 
was found to be 4.4 nm thick.   The decrease in size of photo-crosslinked NPs can be 
attributed to stretching and bending of photo-crosslinked poly-diacetylenes in comparison 
to  the  monomeric  form 
[91,119,120,123,126,127].    DA-PEG  capped  NPs  were  in  general 
negatively charged.  The strong charge was derived from the presence of carboxylic groups 
in the outer shell of ligands.  Notable increases in the charge strength of photo-crosslinked 
NPs (-30.4  ±  1.5 mV) in comparison to unpolymerised  NPs (-28.6 ±  1.5 mV)  can be 
attributed to an additional amount of ligands attached to NPs throughout the second step of 
capping (see chapter 3 for experimental details).  
 
 
 
 
 
 
 
 
 
 
 
The average number of DA-PEG monomers per each 15.5 ± 1.5 nm nanoparticle was 
quantified  with  Ellman’s  method 
[112,113]  at  2073  ±  250  DA-PEGs  (see  chapter  3  for 
experimental  details  and  Appendix  B  for  a  table  with  data  from  10  independent 
measurements).  Consequently, more than 80 % of NPs surface was covered with DA-
PEG, resulting in high proximity between diacetylene groups.  According to the literature, 
only  distances  not  exceeding  5  Å  (Angstrom),  lead  to  successful  polymerisation  of 
diacetylenes 
[119,120].   Polymerisation criteria were  met within  the  presented system, as 
indicated by surface enhanced Raman spectroscopy (SERS, Fig. 36).  
The SERS spectrum (Fig. 36) of a colloid capped with DA-PEG monomers clearly 
presented typical fingerprints of the non-polymerised diacetylene group (b – diacetylene 
vibrations; a – carbon-carbon triple bonds) 
[91,120,124].  The polymeric form of DA-PEG can 
be  seen  on  a  SERS  spectrum  of  UV-irradiated  colloid  (remaining  a  band),  while  no 
40  
    
      
20 
            
0  
Figure 35.   Dynamic light scattering (A) and ζ-potential (B) of DA-PEG coated NPs, 
before – black line and after – red line photo-polymerisation. 
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characteristic feature can be attributed to the non-polymerised diacetylene stretch (b).  The 
additional  peak  at  around  1556  cm
-1  (c)  was  assigned  to  carbon-carbon  double  bond 
vibrations,  produced  upon  the  polymerisation  process  (see  chapter  2  for  schematic 
illustration).    It  can  be  concluded  that  most  of  the  available  diacetylene  groups  were 
successfully  photo-crosslinked  on  the  surface  of  NPs.    Tight  photo-crosslinked  shell 
provided NPs  with  enhanced stability against aggregation in  aqueous  environments, as 
demonstrated by stability tests in the following section. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DA-PEG ligands can be employed to coat the surfaces of other types of NPs, e.g. 
small 2 ÷ 4 nm spherical gold NPs (related publication is listed in Author’s Declaration) 
were capped with DA-PEG monomers.  In this case however, the polymerisation process 
was  not  fully  completed.    Partial  polymerisation  was  attributed  to  the  high  surface 
curvature  of  small  NPs 
[118],  which  possibly  resulted  in  larger  distances  between 
neighbouring  diacetylene  groups  (Note:  distances  between  neighbouring  monomers  are 
critical  for  the  polymerisation  process).    Nonetheless,  DA-PEG  capped  NPs  both, 
polymerised (15 nm NPs, see the next section) and partially polymerised (3.25 ± 1.5 nm 
NPs, see related publication) showed very good stability in aqueous environments. 
a 
b  a 
c 
Figure 36.   SERS spectra of DA-PEG coated gold NPs before (red line) and after (black 
line)  UV-irradiation,  where  (a)  [2150  cm
-1]  represents  the  stretching 
vibration of carbon-carbon triple bonds, (b) [2257 cm
-1] a feature band of the 
diacetylene group and  (c) [1556 cm
-1] the stretching vibration of carbon -
carbon double bond. 
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4.2.4.  Stability tests of colloids. 
The efficiency of several capping strategies, including BSPP, OEG and DA-PEG ligands in 
NPs surface stabilisation was assessed 
[6].  Specifically, capped colloids were exposed to 
various  chemical  conditions,  including  low  pH,  high  concentration  of  thiol  containing 
molecules and elevated temperatures.  
Stability of 15 nm spherical gold NPs coated with BSPP (A), OEG (B) and DA-PEG 
(monomeric – C and polymerised – D) was tested over a wide range of pH (see chapter 3 
for experimental details).  Changes in the colour of colloidal solutions upon aggregation 
[22-
24,45,49,128] (blue colour) were observed macroscopically, as shown on a digital image (Fig. 
37) and by UV-visible spectroscopy (Fig. 38).  
 
 
 
 
 
 
 
 
 
 
 
 
 
It  is  evident  that  at  pH  lower  than  2,  DA-PEG  was  the  only  ligand  capable  of 
providing NPs with sufficient surface stabilisation.  It can be hypothesised that enhanced 
stability of colloids derived from a presence of diacetylene groups, which in conjunction 
with long carbon chains can maximise the Van der Waals interactions between ligands.  
This would lead to a higher surface coverage (see sections 4.2.3. for physicochemical 
characterisation)  and  better  stability.    Improved  stability  of  polymeric  over  non-
polymerised DA-PEG coated NPs was reviled at pH lower than 1.6.  Here, the presence of 
an additional covalent bond between neighbouring ligands seems to be necessary for the 
ultimate stabilisation of colloids. 
   
 1.2  1.4  1.6  2.0  3.0  4.0  5.0  7.0  9.0   
A
B 
C 
D
   
pH values 
Figure 37.   A digital image of gold NPs coated with: BSPP (A), OEG (B), monomeric 
DA-PEG (C) and polymerised DA-PEG (D).  NPs were incubated at various 
pH for 48 h.  
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Stability of colloids against ligand exchange reactions with thiol containing molecules 
was tested in the presence of 10 % mercaptoethanol at pH 3 to 9 (Fig. 39).  After 72 h 
incubation, monomeric DA-PEG NPs (C), OEG coated (B) and BSPP stabilised NPs (A) 
aggregated,  while  polymerised  DA-PEG  NPs  (D)  remained  stable.    Once  again,  firm 
polymeric  shell  with  additional  covalent  bonds  between  ligands  provided  enhanced 
resistance to thiolated ligands in exchange reactions.  
   
Figure 38.   UV-visible  spectra  of  gold  NPs  coated  with:  BSPP  (A),  OEG  (B), 
monomeric  DA-PEG  (C)  and  polymerised  DA-PEG  (D).    NPs  were 
incubated at various pH for 48 h. 
A  B 
C  D  
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In addition to pH and ligand exchange stability tests, temperature stability analysis 
were  performed  on  the  most  stable  DA-PEG  coated  polymerised  NPs.    Repeated 
heating/cooling  and  freezing/thawing  cycles  were  carried  out  (see  chapter  3  for 
experimental  details)  and  the  stability  of  colloid  was  monitored  by  UV-visible 
spectroscopy (Fig. 40).  Polymeric DA-PEG NPs remained stable even after five heat/cool 
(100/25 °C) cycles, as no red-shifting of the plasmon band was observed.  DA-PEG capped 
NPs were also frozen then thawed and showed no sign of aggregation in at least 3 cycles.  
 
 
 
 
 
 
 
 
 
 
  
 
Figure 40.   UV-visible  spectra  of  gold  NPs  coated  with  polymerised  DA-PEG  after 
freeze/thaw (A) and heat/cool (B) cycles. 
A  B 
Figure 39.   UV-visible  spectra  of  gold  NPs  coated  with:  BSPP  (A),  OEG  (B), 
monomeric  DA-PEG  (C)  and  polymerised  DA-PEG  (D).    NPs  were 
incubated with 10 % mercaptoethanol, at various pH for 72 h; control – NPs 
in water. 
A  B 
C  D  
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A variety of capping ligands for NPs surface stabilisation have been reported in recent 
years,  including:  oligonucleotides 
[49,118,129],  peptides 
[4,92,95],  lipids 
[130],  polyethylene 
glycols 
[102-104,121], silica shells 
[131] and amphiphilic molecules such as alkylthiols 
[122], 
poly(acrylic  acid) 
[132]  and  poly(maleic  anhydride  alt-1-tetradecene) 
[133].    However, 
research efforts were focused on searching for universal capping ligand for the preparation 
of unconditionally stable colloids.  DA-PEG ligand established during this project meets 
some of the stability criteria.  NPs coated with polymerised shell of DA-PEG are stable at 
elevated temperatures, low pH and in the presence of high concentration of thiols.  Despite 
such enhanced stability, the preparation of DA-PEG capped colloids is fairly simple, fast 
and does not require any sophisticated equipment (see chapter 3 for experimental details).  
Clearly, polymeric DA-PEG NPs show an opportunity for a number of applications 
that  require  storage  in  a  frozen  form,  reactions  at  high  temperatures  or  low  pH 
environments.    However,  NPs  capped  with  other  thiolated  ligands  (e.g.  OEG)  show 
satisfactory  stability  in  standard  buffered  environments,  thus  can  still  be  utilised  in 
biomedical sciences (see chapters 5 and 6).   
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5.  Cellular fate of OEG NPs. 
As emphasised in the introductory part of the thesis (chapter 1), key motivation of this 
research was to achieve highly controllable regulation of biological functions in selected 
type of mammalian cells (HUVECs) with colloidal gold NPs.  The first mile stone towards 
realisation of this aim was to identify and understand the basic mechanisms controlling 
common interactions between colloids and HUVECs.  
Hence,  the  use  of  OEG  capped  NPs  (Note:  synthesis  and  physicochemical 
characterisation of OEG capped colloidal NPs was demonstrated in chapter 4).  These NPs 
can interact with cells only in a non-selective manner, since no molecules showing any 
biological  activity  were  incorporated  in  the  capping  layer 
[1-7]  (see  Scheme  34).    The 
employed  mono-layer  of  OEG  provides  NPs  with  a  strong  negative  charge,  which 
determines the cellular fate of the colloid 
[8].  As will be demonstrated in this chapter, OEG 
NPs were taken-up by cells.  To realise how the uptake rate is affected by other parameters, 
e.g. size and shape of NPs, four types of OEG capped NPs were employed in these studies: 
spherical gold NPs (SP, 15 ± 2 nm), gold nanorods (NR, 16 ± 3 / 47 ± 3 nm), hollow gold 
NPs  (HG,  92  ±  8  /  9  ±  3  nm)  and  silica/gold  core/shell  nanostructures                                   
(CS,  43  ±  7  /  6  ±  3  nm).    Previously,  15  nm  SP  have  been  used  to  investigate  the 
interactions of NPs with various types of cells 
[1,2,5,6,8-17].  Consequently, OEG capped SP 
served here as a ‘reference’ NPs for an easier comparison with the literature data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
endocytosed  
OEG NPs 
OEG NPs 
Scheme 34.   Schematic illustration of non-specific uptake of OEG NPs by HUVECs.  
cellular 
membrane  
 
Chapter 5 – Cellular fate of OEG NPs  
 
 
127 
 
Chen and co-workers demonstrated that the uptake of NPs (citrate stabilised, spherical 
gold NPs) by HeLa cells (see  chapter 2 for more information about HeLa) reached a 
plateau after 4 ÷ 7 h of treatment 
[9].  Based on these findings, the minimal 4 h treatment 
time of HUVECs with OEG NPs was selected.  Cells were treated with OEG capped SP, 
NR, HG or CS in serum containing (20 % serum proteins – full-serum) growth media       
(5 · 10
12 NPs in 1 ml; see chapter 3 for more details).  After treatment with NPs cells were 
either imaged live with an inverted light microscope (OEG SP only), or fixed and imaged 
with  a  transmission  electron  microscope  (all  types  of  NPs).    For  electron  microscopy 
purposes cells were fixed according to the protocol described in chapter 3. 
TEM micrographs of HUVECs incubated with OEG coated SP are shown in Fig. 41.   
NPs  were  taken-up  by  the  cells,  since  they  are  confined  within  cytoplasmic  vesicles 
(circles); most likely endosomes 
[17,18].    The  well-preserved  double  membrane  of  these 
vesicles is indicated by arrows.  There are no OEG SP outside endosomes ‘free’ in the 
cytoplasm.  Since OEG SP did not contain any bioactive molecules, specific interactions 
between them and the cells were unlikely to happen.  Consequently, non-selective (charge 
mediated) endocytosis can be considered as the most probable pathway of internalisation.  
The internalisation of colloidal NPs by mammalian cells by engulfing with the cellular 
membrane (endocytosis) was previously reported by many research groups 
[6-9,12,17-24].  
 
 
 
 
 
 
 
 
 
 
 
 
 
High ionic strength and acidic pH can be found within intra-cellular vesicles, like 
endosomes 
[25].  In the endosomes, thiolated biomolecules, e.g. proteins or peptides can 
B  A 
Figure 41.   TEM images of HUVECs after 4 h incubation with OEG coated NPs (A and 
B).  Circles represent NPs locked inside the organelles.  A square indicates 
magnified area of an image (B, insert).  Double membrane is shown by arrows.  
Scale bars are 100 nm.  
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also be present
 [25,26] (Note: side chain of cysteine contains thiol group, which can bind to 
gold surface 
[27-29]; see chapter 2 for theoretical background).  Such conditions can affect 
the  stability  of  colloids,  in  extreme  cases  leading  to  aggregation  and  changes  in  NPs 
properties (e.g. optical signatures) 
[30-33].  Pacey and co-workers observed colour changes 
of citrate stabilised gold SP solutions from red to blue (aggregation) deriving from the 
adsorption of various cationic salts 
[32].  Brust and co-workers reported the uptake of citrate 
stabilised gold SP by HeLa cells and their aggregation within endosomes 
[17].  In both 
cases,  instability  of  gold  colloids  in  biological  environments  derived  from  insufficient 
(electrostatic)  NPs  surface  stabilisation  with  sodium  citrate.    To  enhance  the  stability 
against aggregation of gold NPs, their surfaces can be capped covalently 
[27,28,30], e.g. with 
OEG  ligand  (see  chapter  2  for  schematic  illustration  and  chapter  3  for  experimental 
details).  As demonstrated in chapter 4, OEG capped NPs remain stable in buffered and 
low pH (down to pH 3) environments.  Therefore, it was expected that the OEG capping 
layer would provide NPs with sufficient stability against aggregations inside endosomes. 
Within  endosomes,  mostly  single  (non-aggregated)  OEG  SP  were  found  (TEM 
images, Fig. 41).  However, larger groups and/or agglomerates of NPs were also denoted.  
The presence of these on TEM micrographs can be explained by NPs overlaying on two 
dimensional  images.    In  theory,  up  to  four  OEG  SP  (hydrodynamic  diameter  around         
25 nm, see chapter 4) can be fitted on top of each other in 100 nm thick cell sections, 
which were imaged by TEM (see chapter 3 for experimental methods).  To verify whether 
observed groups of NPs are indeed just overlaid NPs, or rather real aggregates, colour 
changes of uptaken NPs were observed (Note: changes in NPs colour suggest aggregation 
[31-34]).  The simplest method involved macroscopic observations of the cell suspension.  A 
more advanced technique based on phase contrast and bright field microscopy of cells 
grown on a surface was also employed (see chapter 3 for experimental details).  
 A digital image of HUVECs suspension after treatment with OEG SP is shown in         
Fig. 42.  Prior to imaging, cells (with NPs) were washed with buffer (until the solution was 
colourless)  to  remove  excess  of  non-internalised  (or  non-interacting)  OEG  NPs,  then 
harvested from the culture dish and suspended in a buffered solution (see chapter 3 for 
experimental details).  Differences between untreated cells (left) and cells, which have 
uptaken  NPs  (right)  are  evident.    Reddishness  of  the  cell  suspension,  indicating  the 
presence of stable NPs 
[33,35,36], was perceivable to the naked-eye.  Since colloidal gold has 
a high extinction coefficient value 
[35,37] (ɛ = 3.64 · 10
8 for 15 nm SP), even pico-molar  
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(pM) concentration of OEG SP can be detected.  Possibly, the colour intensity of cells 
loaded with NPs was additionally enhanced, due to increased local concentration of OEG 
NPs within endosomes.   
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Moreover, the intense colour of HUVECs (with associated NPs) was observed by light 
microscopy techniques.  The quantity of endocytosed OEG coated NPs was high enough to 
permit detection by bright field microscopy.  Phase contrast images of cells and bright field 
images of the same area of the culture dish are presented in Fig. 43.  The differences 
Figure 42.   A digital image of HUVECs suspension: control sample (cells only, left) and 
cells treated with OEG coated NPs for 4 h (right). 
Figure 43.   Phase contrast (A and B) and bright field (C and D) images of HUVECs after      
4 h treatment with: OEG coated NPs (B and D); control sample (HUVECs 
only, A and C).  Scale bars are 10 μm. 
A 
C 
B 
D  
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between control sample (C) and HUVECs loaded with NPs (D) are evident.  The red 
colour (D) deriving from uptaken OEG NPs indicated that NPs remained stable within 
cellular matrix 
[32,33,35,36].  
As suggested recently by Levy and co-workers, even though there are many reports on 
the uptake of NPs by cells, some questions regarding the role of basic parameters such as: 
size,  shape  and  surface  chemistry  of  NPs,  still  remain  answered 
[6].    Consequently, 
additional experiments following systematic approaches were recommended.  Following 
this idea, after the uptake of OEG SP and the colloidal stability inside endosomes were 
confirmed, the studies were extended to other types of NPs.  The intracellular fate of OEG 
capped anisotropic core based NPs (NR, HG and CS) in HUVECs was investigated.  As 
shown on TEM images (Fig. 44A and B), OEG NR were taken-up by HUVECs.  Double 
membrane surrounding NR is clearly presented on the image A, suggesting that OEG NR 
were locked inside organelles (endosomes).  As in case of OEG SP, endocytosis would be 
the most likely cell entry pathway.  Interestingly, it seems that the orientation of OEG NR 
within vesicles was random.  Some nanorods were aligned horizontally to the TEM grid 
and appeared as elongated structures on the image (white circle), while others were lined-
up vertically, giving the impression of more spherical shape (orange circle). 
OEG HG were also taken-up by HUVECs (TEM images, Fig. 44C and D).  A double 
membrane (arrows) surrounding NPs, suggesting their presence in the endosomal vesicles, 
was well preserved.  As expected, the fourth type of NPs: OEG CS was also confirmed 
inside HUVECs by the TEM microscopy (Fig. 44E and F).  It is clear that NPs were 
confined within organelles (arrows), even though the double membrane was not clearly 
presented.  Also, endocytosis seemed to be the most probable explanation of entrance route 
into the cells by both, OEG HG and OEG CS. 
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As seen from the TEM images above, the number of vesicles per cell, as well as the 
number of NPs  locked within each  endosome  varied.   Only thin (around 100 nm,  see 
chapter 3 for experimental details) slices of cells were imaged at a time (around 1 % of a 
cell).  Due to these reasons, it was unlikely to foresee the average number of uptaken NPs 
(per cell) with high accuracy, based only on statistical analysis of TEM images.  Therefore, 
B  A 
Figure 44.   TEM images of HUVECs after 4 h incubation with OEG NR (A and B), OEG 
HG (C and D) and OEG CS (E and F).  Double membrane is indicated by 
arrows.  White circle represents NR aligned horizontally, while orange circle – 
vertically.  Scale bars are 100 nm. 
B  A 
D  C 
F  E  
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another  relevant,  relatively  simple  and  efficient  technique:  inductively  coupled  plasma 
mass spectrometry (ICP-MS, see chapter 3 for more experimental details) was used 
[38].  
First, the number of cells in the sample was counted (100’000 cells).  The number of gold 
atoms  per  nanoparticle  and  the  weight  of  a  single  nanoparticles  were  calculated                     
(e.g.  105’448  gold  atoms,  equals  to  3.45  ·  10
-17  g  per  15  nm  spherical  NPs,  see                 
Appendix B for detailed calculations also for other types of NPs), while the weight of gold 
atoms in the sample was given by ICP-MS (ppm).  Taking the weight of gold atoms in the 
nanoparticle and the weight of gold atoms in the sample, the number of NPs in the sample 
was calculated, then divided by the number of cells in the sample, to give the number of 
NPs in each cell.  The results from three independent experiments are shown in Table 4. 
It is widely accepted that the cellular ability to uptake NPs depends on the size, shape 
and the net charge of NPs (positive, negative or neutral) 
[2,6-9,12,17-19,21,24,39-42].  Here, all 
types of OEG coated NPs were negatively charged, however larger NPs (e.g. OEG HG) 
had a slightly stronger charge than smaller ones (e.g. OEG SP).  This can be attributed to a 
larger number of OEG ligands chemisorbed on the surface of larger HG (see Table 4 and 
chapter 4 for physicochemical characterisation).  It seems that strongly charged OEG HG 
(-40 mV) were taken-up by HUVECs less effectively than OEG SP (-28 mV).  One can 
hypothesise  that  the  stronger  negative  charge  of  HG  makes  it  difficult  for  them  to 
physically  approach the cells, probably because HG were repelled  (even stronger than 
OEG SP) from negatively charged cellular membrane of HUVECs 
[9,42].  However, these 
differences in the charge strength between NPs can be treated as minor and not necessarily 
considered as a predominantly controlling constraint.  OEG NPs were significantly varied 
in other parameters, e.g. size and shape (Table 4).  These two parameters (rather than the 
charge strength) probably play a dominating role in regulating of the uptake rate.     
The smallest, OEG SP (hydrodynamic diameter around 25 nm) were most efficiently 
taken-up by HUVECs, while the largest OEG HG (96 nm) the least.  On the other hand, 
OEG  NR  were  endocytosed  in  much  larger  numbers  than  OEG  CS  with  a  diameter 
comparable to the NR length.  The uptake rate of OEG NR and OEG SP with the same 
diameter as the NR width was similar.   
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Chan and co-workers were investigating the shape dependent differences in the uptake 
of citrate stabilised gold NPs by HeLa cells and found that, NR (14 x 74 nm) were taken-
up less efficiently than both,  14 or 74 nm SP 
[9,21].   Chan’s  group performed a direct 
comparison between NR and their spherical length and width equivalents 
[9,21].  They found 
that HeLa took-up 500 and 375 % more of 74 and 14 nm SP than 74 x 14 nm rods, 
respectively.  The much lower uptake of NR was attributed to the CTAB capping layer, 
which may be toxic to cells.  Chan’s group also reported that 50 nm spherical gold citrate 
capped NPs were taken-up by HeLa cells more efficiently that 14 nm and 74 nm SP, also 
the uptake rate reached its half-life the fastest 
[9,21].  In case of HUVECs (Table 4), 50 nm 
(core/shells) were taken-up more efficiently than the largest NPs (HG), but less efficiently 
than the smallest 15 nm NPs.  Only slightly higher uptake rate of OEG NR, than their 
length equivalent (OEG CS), was observed.  While, very similar numbers of OEG NR and 
their width equivalent (OEG SP) were internalised by HUVECs.  Such variations can be 
explained  by:  a)  the  differences  in  cell  type  physiology  (Note:  HUVECs  are  primary 
culture cells, healthy mammalian non-malignant cells, as opposed to an immortalised and 
transformed cell line, like HeLa 
[43-45]); b) the differences in charge strength within OEG 
NPs  and/or c) the type  of  NPs surface capping  layer  (here OEG).   This  hypothesis  is 
supported by more recent literature reports, demonstrating the dependence of the uptake 
rate  on  the  composition  of  the  organic  corona  of  NPs  and  the  type  of  cells 
[2,3,5,6,9,11,14,15,17,19-21,23,24,40-42,46-53]. 
Several groups have investigated the differences in NPs uptake that derive from their 
functionality, e.g. Ghandehari and co-workers demonstrated that the uptake of 30 ÷ 90 nm 
‘bare’ gold SP (meaning citrate capped, natively charged) by prostate cancer cells (PC-3) 
OEG NPs 
type 
Metallic core 
[nm] 
Hydrodynamic 
diameter  
[nm] 
Net charge 
[mV] 
Number of NPs 
per cell 
spherical  15 ± 2  25 ± 2   -28 ± 2  2551 ± 343 
rod-like  16 ± 3/47 ± 3  -  -30 ± 1  2486 ± 460 
hollow  92 ± 8/9 ± 3  96 ± 4  -40  ± 2  363 ± 82 
core/shells  44 ± 7/6 ± 3  51 ± 3  -36  ± 2  901 ± 99 
Table 4.   A summary of physiochemical properties of OEG NPs.  
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was much higher than ‘PEGylated’ ones (meaning polyethylene glycol coated) 
[19].  On the 
contrary,  Brust  and  co-workers  reported  that  ‘PEGylated’  16  nm  SP  (meaning                         
1-mercaptoundec-11-yl tetraethylene glycol coated) were not taken-up by HeLa cells at all 
and  showed  that  the  same  NPs  but  citrate  or  CALNN  capped  were  endocytosed  very 
effectively 
[17].    The  differences  in  the  uptake  of  ‘PEGylated’  NPs  observed  by 
Ghandehari’s  and  Brust’s  groups  can  be  attributed  to  the  cell  type  (PC-3  and  HeLa, 
respectively).  Mirkin and co-workers investigated the differences in NPs uptake deriving 
purely from the cell type 
[14].  They tested the uptake of antisense oligonucleotide modified 
13 nm gold SP (ASNPs) by a mouse cell line (C-166) and two human cell models (HeLa 
and A594).  It was found that NPs were taken-up by all three cell types, but the absolute 
number of uptaken NPs varied by a factor of 20.  
The closest example of studies showing the behaviour of HUVECs in contact with 
NPs, is the work reported by McGrath’s group on 100 nm polystyrene SP, with various 
functional groups attached to the outer shell of the capping layer (e.g. carboxylic, methyl, 
lysine) 
[23].  It was demonstrated that the uptake rate of ‘carboxy’ NPs was the highest (up 
to 200 NPs per cell after 80 h of incubation), presumably because of the adsorption of 
serum proteins – albumin (Note: the adsorption of serum proteins was also demonstrated 
by Mirkin for ASNPs 
[14]).  McGrath reported that the proteins stayed adsorbed to NPs 
even after a wash 
[23].  On the contrary, ζ-potential measurements of OEG capped NPs 
(Fig. 45) after 24 h incubation with growth medium (20 % human serum, see chapter 3 for 
cell culturing protocol) and one wash (1 x PBS, centrifugation/decantation: 16’400 rpm,  
15 min.) did not show any changes in the net charge, which could have been assigned to 
the presence of serum proteins.  Consequently, it can be hypothesised that a very firm 
organic shell formed by OEG ligands (see chapter 4 for physicochemical characterisation 
and stability tests), sufficiently prevented the adsorption of serum proteins on the surface 
of gold NPs.  However, proteins can still interact with the negatively charged outer shell of 
OEG capping layer (e.g. weak electrostatic interactions), while NPs are suspended in a 
growth media (before wash and centrifugation steps). 
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Another method of controlling the uptake rate of NPs, is to coat their surface with 
appropriate  biomolecules,  e.g.  cell  penetrating  peptides 
[16,17,54,55],  proteins 
[5,21,56,57], 
antibodies 
[1,58-60], bacterial toxins 
[6], oligonucleotides 
[14,61] or liposomes 
[62,63].  A good 
example  would  be  a  family  of  octa-peptides,  as  developed  during  this  research  (see 
chapter 2 for chemical structures).  High control upon the cellular fate of colloids was 
gained  (see  the  following  chapter)  with  octa-peptide  conjugated  OEG  NPs  (pep-OEG 
NPs), even though pep-OEG NPs showed very similar physicochemical properties and 
varied  only  in  the  amino  acid  arrangement  (see  chapter  4  for  physicochemical 
characterisation).   
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Figure 45.   ζ-potential of: OEG coated NPs (red line) and OEG coated NPs incubated 
with growth media (blue line). 
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6.  Cell targeting and regulation with pep-OEG NPs. 
As explained in chapter 2, within the human body, interior layers of blood vessels in the 
circulatory  system  are  formed  by  endothelial  cells 
[1-3].    These  cells  are  involved  in 
important biological processes, including: the formation of blood vessels (angiogenesis and 
vasculogenesis), maintaining blood homeostasis, as well as regulating and being a part of 
the  immune  response  against  pathogens 
[2,4-7].    New  blood  vessels  (angiogenesis),  are 
grown during physiological processes (e.g. wound healing), but also in many pathological 
developments, like cancer 
[2,5,7-9].  Tumour progression, according to literature reports, can 
be suppressed by angiogenesis regulation 
[5,7,9-18]. 
In the presented research gold NPs were employed to achieve selective regulation of 
angiogenesis.  NPs were designed to target endothelial cells (HUVECs) via membrane 
receptors, specifically VEGFR-1 and NRP-1.  Selective targeting of VEGFR-1 or NRP-1 
was achieved with synthetic peptides attached to NPs (see section 6.1.).  VEGFR-1 was 
chosen because of its anti-apoptotic and pro-angiogenic functions 
[5,7,19-25].  Its selective 
targeting is a challenging task, since this receptor is less abundant than e.g. VEGFR-2.  
NRP-1 serves as a co-receptor regulating the formation of VEGFR-1-ligand complexes 
[5,7,19,23,24,26-28]. 
As described in chapter 3, NPs were prepared by standard wet chemistry methods, 
then capped with OEG ligand and further functionalised with peptides (see chapter 4 for 
results).    Each  of  the  peptides:  P1,  P2  or  P3  showed  similar  length,  charge  and 
hydrophilicity,  but  was  comprised  of  a  unique  primary  structure  (see  chapter  2  for 
chemical structures).  Different sequences of P1, P2 and P3 determined their bioactivity.  
P1 peptide (wild type) showed binding affinity towards VEGFR-1 (see section 6.1.1. for 
flow cytometry studies), while P3 preferably bound to NRP-1.  P2 peptide (mutant), a 
scrambled version of P1 could not form any active complexes with VEGFR-1 (see chapter 
2 for theoretical background).  
Once selective binding of pep-OEG NPs to HUVECs was confirmed by transmission 
electron microscopy (section 6.1.2.), the cellular response following the binding event was 
studied (section 6.2.).  A capability of pep-OEG NPs to activate or inhibit basic cellular 
functions  was  studied  at  the  molecular  level  (gene  expression  profiling  assay,  section 
6.2.1.)  and  by  in  vitro  angiogenesis  (capillaries  formation  assay,  section  6.2.2.).    See 
Scheme 35 for schematic illustration of the scientific content of this chapter. 
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6.1.  Selective targeting of HUVECs. 
HUVECs  were  targeted  with  NPs  through  octa-peptides  (incorporated  in  the  organic 
corona of NPs).  The level of selectivity (specificity) in binding of P1 and its mutated 
version (P2), as well as P1-OEG NPs to membrane receptors over-expressed by HUVECs 
was assessed by flow  cytometry  assays (section  6.1.1.).   Once binding  activity of  the 
peptides was confirmed, the cellular fate of P1-OEG NPs, P2-OEG NPs and P3-OEG NPs 
in  HUVECs  was  studied  by  transmission  electron  microscopy.    Differences  between 
specific (P1 or P3 mediated) and non-specific (P2 mediated) interactions between cells and 
NPs are demonstrated in section 6.1.2.  
6.1.1.  Cell receptors binding. 
To assess whether the newly designed artificial P1 octa-peptide exhibited binding affinity 
towards VEGFR-1 receptors, the peptide was labelled with a LL-RPE fluorescent tag 
[29] 
(see  chapter  3  for  experimental  details)  and  employed  in  flow  cytometry  assays.                      
P1-LL-RPE conjugates were incubated with live HUVECs, to allow binding to appropriate 
Scheme 35.   Schematic illustration of selective targeting of HUVECs with pep-OEG NPs 
resulting in controlled regulation of cellular functions. 
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cellular  receptors.    The  selectivity  of  binding  was  studied  in  a  series  of  competition 
experiments with untagged P1 and with respect to untreated cells.  HUVECs labelled with 
P1-LL-RPE conjugates were excited at 488 nm wavelength.  The orange channel was used 
to detect fluorescent signal and count positive cells.  Both, fluorescence intensity and the 
mean values were presented as one parameter, called the binding index (BI, see chapter 3 
for subsequent equation). 
To  study  only  receptor  mediated  interactions  between  HUVECs  and  fluorescent 
conjugates,  while  eliminating  non-specific  interactions  between  them  and  a  charged 
cellular membrane, cells were blocked with serum proteins 
[30-32] (FBS, see chapter 3 for 
experimental details).  HUVECs were incubated with conjugates on ice to avoid uptake of 
P1-LL-RPE and in the presence of sodium azide to prevent receptor circulation within cells 
[33-36]. 
Overlaid, LL-RPE intensity spectra and binding indexes are shown in Fig. 46.  It is 
evident that P1-LL-RPE were bound to HUVECs with high affinity, as BI of conjugates 
was 100 % referred to 0.5 % background coming from unlabelled cells.  The competition 
for binding sites allocated on the cellular membrane of HUVECs with free (unlabelled) P1 
resulted  in  a  significant  decrease  of  the  BI  value.    This  indicated  that  P1-LL-RPE 
conjugates and P1 peptides bind to the same spots on the cellular membrane in a sequence 
specific manner (P1 mediated).  It can be hypothesised that as designed, VEGFR-1 were 
indeed the binding sites for P1 sequence (RPL motif 
[37]).  
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Figure 46.   Overlaid LL-RPE intensity histograms (A) and binding index values (B) of 
unlabelled  cells  (red;  0),  HUVECs  incubated  with  LL-RPE-P1  conjugates 
(black; 1) and competition with free P1 (green; 2).  
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To verify whether P1 conjugated to OEG NPs have the same activity as free P1, P1-
OEG NPs were tagged with a fluorescent HiLyte dye (see chapter 3 for experimental 
protocol).    The  intensity  of  a  fluorescent  signal  of  HiLyte-P1-OEG  NPs  bound  to 
HUVECs, as well as the number of positive cells were measured using infrared channel 
detector (633 nm excitation wavelength).  These results are presented as BI’s. 
The population of HUVECs  (blocked for  non-specific interactions)  incubated with 
HiLyte-P1-OEG NPs showed high binding index (BI = 100 %).  Around two hundred 
times  higher  than  the  background  signal  (BI  =  0.5  %),  coming  from  unlabelled  cells             
(Fig. 47).  To confirm whether binding of HiLyte-P1-OEG NPs to membrane receptors 
was indeed peptide dependent, a series of competition experiments with free P1 peptide 
and  a  scrambled  (mutated)  P2  sequence  was  performed.    P1  peptide  was  expected  to 
compete HiLyte-P1-OEG NPs, whilst P2 should not (since the P2 peptide consists of the 
same amino acids as P1 but arranged in a different order; see chapter 2 for theoretical 
background).  
In the first series of competition experiments (Fig. 47A), HUVECs were incubated 
with  free  P1,  followed  by  the  fluorescent  colloid.    Considerably  lower  binding  index 
showing a 30 % decrease (in comparison to the maximum value of sample 1), suggested 
that P1 peptides were successfully competed out by HiLyte-P1-OEG NPs.  In contrast, the 
presence of P2 octa-peptide had no major effect on the binding (sample 3, BI = 95.3 %).  
Suggesting that both, florescent colloid and free untagged P1 peptide bind to the same 
receptors,  while  as  expected,  the  mutated  (P2)  sequence  shows  no  significant  binding 
activity.  
In the second series of competition experiments (Fig. 47B), HUVECs were incubated 
first with a fluorescent colloid and then with free octa-peptides (P1 or P2).  Competition 
with P1 peptides resulted in approximately 11.2 % decrease of the binding index (BI = 
88.8 %), referred to the maximum signal of sample 1.  Clearly, in this case the competition 
was by far less effective, as the BI index was 18.8 % higher (referred to sample 1) than in 
the  series  A  competition  experiments;  possibly  steric  hindrance  related  effects.  
Specifically,  it  can  be  hypothesised  that  VEGFR-1  were  no  longer  accessible  for  the 
peptides, because of a ‘blocking’ derived from the considerably larger HiLyte-P1-OEG 
NPs  (over  33  nm,  see  chapter  4  for  physicochemical  characterisation)  than  P1  (P1 
peptides are only about 3 nm) attached to them.  It is also possible for HiLyte-P1-OEG 
NPs  to  bind  to  more  than  one  receptor  (since  HiLyte-P1-OEG  NPs  contain  multiple 
binding sites).  Thus, even if one of the occupied (by a fluorescent nanoparticle) binding  
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sites  was  replaced  with  P1,  the  nanoparticle  would  still  be  attached  to  the  cellular 
membrane (via  other receptors).   Another possibility is that, NPs bind  stronger  to the 
receptors because of this multiplexing, thereby preventing competition with peptides.  The 
problem of steric hindrance to ‘incoming’ ligands from ‘resident’ ligands (bound to the 
receptors)  was  also  reported  by  Sklar  and  co-workers,  for  the  binding  studies  on 
fluorescein-biotin conjugates to streptavidin coated polystyrene beads 
[38].   
 
 
 
 
 
 
 
 
 
 
Besides the emitted light, flow cytometry also allows measurements of the scattered 
light.  Both, side scattered (SSC) and forward scattered (FSC) light of unlabelled HUVECs 
and cells incubated with HiLyte-P1-OEG NPs were measured.  As shown in Fig. 48, the 
population  of  HUVECs  incubated  with  a  fluorescent  colloid  moved  with  a  respect  to 
untreated  cells.    Both,  the  inner  complexity  (SSC)  and  the  cell  volume  (FSC)  values 
increased.  Indicating, HiLyte-P1-OEG NPs were attached to the cellular membrane of 
cells, rather than internalised and allocated within the cellular matrix (Note: experiment 
was performed on ice and in the presence of sodium azide). 
 
 
 
 
 
 
B 
Figure 47.   Binding index values of unlabelled cells (0),  or incubated with HiLyte-P1-
OEG  NPs  (1)  and  in  a  competition  with  free  P1  (2)  or  P2  (3)  peptides.  
HUVECs incubated with HiLyte-P1-OEG NPs first (A) or with free peptides 
(B). 
A  
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To confirm that the binding of P1 (and P1-OEG NPs) to HUVECs was based on the 
affinity towards the specific growth factor receptor, HeLa cells which do not over-express 
VEGFR-1 were employed as a negative control (see chapter 2 for more information about 
HeLa).  HeLa cells were incubated with a fluorescent colloid, as well as with free P1 or P2 
peptides in competition studies.  The background BI of HeLa cells (Fig. 49, sample 0) 
reached nearly 50 %, while the maximal BI value of cells incubated with HiLyte-P1-OEG 
NPs was double (BI = 100 %, sample 1).  HUVECs were approximately one hundred 
times more effectively labelled with a fluorescent colloid than HeLa cells.  It could be 
concluded  that  HiLyte-P1-OEG  NPs  bind  to  receptors,  which  are  over-expressed  by 
HUVECs,  but  are  infrequent  in  HeLa,  like  VEGFR-1 
[2,19,22,39,40].    Therefore,  it  was 
assumed that the binding event was selective to these receptors. 
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Figure 48.   Forward  (FSC)  and  side  (SSC)  scattered  light  by  HUVECs  (A)  and  cells 
incubated with HiLyte-P1-OEG NPs (B). 
Figure 49.   Binding index values of unlabelled HeLa cells (0), or incubated with HiLyte-
P1-OEG NPs (1) and in a competition with free P1 (2) or P2 (3) peptides.  
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As already discussed in chapter 2, Arap and co-workers developed a cyclic peptide 
(CPQPRPLC), which binds to the growth factor receptors 
[37].  The binding to VEGFR-1 
was  attributed  to  arginine  and  leucine  residues  in  RPL  motif,  based  on  a  series  of 
experiments with RPL tri-peptide.  These findings were implicated in a design of P1 octa-
peptide (KPQPRPLS,  see  chapter  2  for details).   As demonstrated by flow  cytometry 
assays, P1 peptide and P1-OEG NPs were capable of selective binding to receptors over-
expressed by HUVECs, presumably VEGFR-1.  
As demonstrated by Arap’s group, RPL tri-peptide (so as the cyclic peptide) binds to 
NRP-1 receptors, where the proline residue plays an important role 
[37].  On the contrary, 
Perret and co-workers reported the ATWLPPR sequence, which possess anti-angiogenic 
activity deriving from the inhibition of the VEGF165 binding to NRP-1 
[41].  It was found 
that  this  peptide  bound  to  NRP-1  through  LPPR  motif  and  demonstrated  that  the              
C-terminus arginine was crucial for its activity, deriving from its side chain (guanidine 
group) and free negatively charged carboxylic group (C-end peptide residue).  Also, both 
prolines were participating in binding to NRP-1.  The RPL sequence reported by Arap does 
not  contain  a  C-terminus  arginine  (with  free  carboxylic  group) 
[37],  however  an  easy 
accessible guanidine group may still be involved in binding.  The unique conformation of a 
cyclic peptide may also help in the presentation of the side chain of arginine and allowing 
the binding to NRP-1; despite the strong statement made by authors about the lack of 
importance of the secondary structure of this peptide.  Possibly  the proline and lysine 
residues play a similar role in determination of the structure of the RPL tri-peptide and a 
cyclic peptide,  as both prolines in LPPR motif and proline and lysine residues in the exon 
8 peptide (bicyclic), developed by Zachary and co-workers 
[28].  It is worth highlighting, 
that the non-cyclised version of the bicyclic peptide shows significantly reduced activity. 
The  ATWLPPR  sequence  developed  by  Perret  and  co-workers 
[41]  was  used  in  a 
design  of  NRP-1  binding  P3  peptide  (KATWLPPR,  see  chapter  2  for  details).    The 
following sections will show that P3-OEG NPs and P1-OEG NPs interact with HUVECs in 
a very different way, presumably via NRP-1 and VEGFR-1, respectively.  Meaning that, 
even  though  P1-OEG  NPs  contained  the  RPL  motif,  predominant  binding  was  to          
VEGFR-1 and not to NRP-1.  Another hypothesis (except these presented in the previous 
paragraph) is related to the conformation of peptides attached to the surface of NPs.  Dense 
packing  of  OEG  ligands  and  high  loading  of  peptides  (see  chapter  4  for  ligand 
quantification) may result in a three dimensional structure of P1-OEG NPs that prevents 
good presentation of the side  chain guanidines, between neighbouring ligands/peptides.   
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This hypothesis can also explain why the flow cytometry competition between LL-RPE-P1 
and free P1 was slightly more effective (Fig. 46) than between HiLyte-P1-OEG NPs and 
P1 (Fig. 47).  Specifically, free P1 and LL-RPE-P1 conjugates may still present a slight 
affinity towards NRP-1, even though P1 does not have a unique cyclic conformation 
[28].  
Here, the guanidine group may not be as easily accessible as in case of the cyclic peptide 
[28,37]  or  tri-peptide 
[37],  but  perhaps  it  was  not  completely  masked,  as  was  possibly 
happening in case of P1-OEG NPs.   
6.1.2.  Receptor mediated targeting. 
Possible  interactions  between  pep-OEG  NPs  and  HUVECs  were  investigated  by 
transmission electron microscopy, using spherical NPs as a ‘model’ system.  As explained 
earlier  (see  chapter  2  for  details),  P1-OEG  NPs  were  designed  to  bind  to  VEGFR-1 
endogenously over-expressed by HUVECs, while P3-OEG NPs were expected to bind to 
NRP-1.  A mutated peptide (P2), conjugated to OEG capped NPs were unable to bind to 
any of these receptors.  
The formation of a receptor-NPs complex with a typical tyrosine kinase VEGFR-1 
receptors activates the transduction of the  signalling cascade within the cell, while the 
complex  stays  attached to  the  cellular membrane 
[22,24]  (Scheme  36).    In  contrast,  the 
formation  of  NRP-1-NPs  complexes  is  followed  by  their  trafficking  on  the  cellular 
membrane  and  internalisation 
[26-28,41].    These  differences  in  mechanistic  pathways  of 
receptor complexes were reflected on TEM images.  Specifically, P1 conjugated colloids 
were found on the outer membrane of HUVECs, while P3 colloids within the cellular 
matrix.  P2-OEG NPs were interacting with cells non-specifically (endocytosis).    
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HUVECs were incubated with spherical pep-OEG NPs (5 · 10
12 NPs / 1 ml, 1.3 ml) in 
human serum containing (20 %, full-serum) growth media for 4 h.  Cells were grown on 
removable PET (polyethylene terephthalate) membrane inserts to avoid harvesting cells 
from the culture dish by trypsinisation (see chapter 3 for experimental details).  This was 
to prevent possible cleavage (by trypsin digestion) of membrane receptors with attached 
NPs (P1-OEG NPs), or dissociation of peptides from P1-OEG NPs.  After treatment with 
NPs, cells were fixed with PET membranes and imaged with the transmission electron 
microscope. 
TEM images (Fig. 50A) show that the spherical P1-OEG NPs were clearly bound to 
the cellular membrane of HUVECs (orange circles).  As expected, conjugated NPs mainly 
interacted with the external surface of HUVECs (VEGFR-1, see also section 6.1.1.) and 
rarely internalised (NPs pointed by white arrow).  
In contrast, P3-OEG NPs can be seen either agglomerated on the cellular membrane 
(most  likely  attached  to  NRP-1,  Fig.  50C  left),  or  internalised  and  locked  inside 
cytoplasmic vesicles (red arrow).  Even though the double membrane of vesicles was not 
clearly presented on the image, it  can be assumed that NPs were presumably confined 
within endosomes.  Most likely, P3-OEG NPs were taken-up by cells through specific 
receptor mediated endocytosis (RME, NRP-1 mediated 
[26-28,41]), since all stages of this 
cellular 
membrane 
VEGFR-1 
P1-OEG NPs 
endocytosed 
NPs 
P2-OEG NPs 
NRP-1 
P3-OEG NPs 
internalised                                     
NPs-receptor complex 
signalling 
cascade 
Scheme 36.   Schematic illustration of the possible interactions between pep-OEG NPs and 
cells.   
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process are presented on images.  Binding to the receptors and trafficking on the surface of 
HUVECs is showed in Fig. 50C left, orange circle.  The formation of vesicles and their 
internalisation is clearly presented in the middle, red circle.  Finally, travelling of the 
vesicles loaded with NPs inside the cell can be seen on the right, red circles. 
As presented on TEM images (Fig. 50B), P2-OEG NPs interacted with HUVECs in a 
very different way.  There were no NPs attached to the cellular membrane, while a vast 
number of P2-OEG NPs were seen within cellular matrix, locked inside vesicles.  The 
double  membrane  (red  arrows)  was  clearly  presented,  suggesting  endosomes  as 
cytoplasmic  vesicles.    NPs  were  probably  internalised,  following  the  non-selective 
endocytosis  pathway  (no  NPs  were  bound  to  membrane  receptors)  and  confined  in 
endosomes.  Clear similarities between the cellular fate of P2-OEG NPs and OEG NPs 
presented in chapter 5, suggest an analogues, non-selective mechanisms of uptake.  These 
are very different from both, RME (observed with P3-OEG NPs) and the receptor binding 
with P1-OEG NPs.  As previously mentioned, pep-OEG NPs were designed to show very 
similar physicochemical properties (size, charge, hydrophilicity and stability).  Only the 
amino  acids  arrangement  and  content  was  varied  within  octa-peptides,  resulting  in 
sequence dependent differences, which regulated the cellular fate of colloids.  The fate of 
NPs was qualitatively analysed using TEM.  Quantitfication experiments (e.g. competition 
with free peptides or cytokines) could not be performed with this technique, because: a) 
some NP might have been lost during the harsh and complex procedure of TEM fixation 
(see chapter 3); b) only small section of cell (and cellular membrane) can be seen per 
image, possibly leading to large errors. 
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Specific  targeting  of  cells  with  NPs  via  receptor  mediated  interactions  has  been 
intensively investigated in recent years 
[42-65].  A number of strategies following both, intra- 
and extracellular approaches, utilising either large (e.g. antibodies) or small (e.g. peptides, 
folic  acid)  molecules,  have  been  reported.    Richards-Kortum  and  co-workers  and                   
El-Sayed’s  group  established  spherical  gold  NPs  directly  capped  with  anti-epidermal 
growth  factor  receptor  antibodies  (anti-EGFR) 
[45,46,64].    They  demonstrated  that  anti-
EGFR-coated NPs selectively bound to EGFR over-expressing (endogenously) cells (e.g. 
Figure 50.   TEM images of HUVECs incubated with: P1-OEG NPs (A), P2-OEG NPs (B) 
and P3-OEG NPs (C).  Scale bars are 100 nm.  Orange circles indicate NPs 
bound to the external membrane of cells, while red represent internalised NPs.  
Double membrane is pointed by red arrows.  Internalised NPs are pointed by 
white arrows. 
A 
B 
C  
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SiHa cells) and stayed attached to the surface of cells, rather than internalised, as observed 
for P1-OEG NPs and HUVECs (Fig. 50).  Except of antibodies, other large proteins were 
also employed in the receptor mediated uptake of NPs 
[66,67] (the intracellular approach).  
Gu and co-workers showed that transferrin/PEG mixed layer capped gold nanorods were 
efficiently taken-up by HeLa cells expressing transferrin receptors 
[66].  
However, the use of small molecules in selective targeting of cells seems to be more 
advantageous,  mainly  because  of  reduced  immunogenicity  and  simplicity  of  their 
production, which could be easily scaled-up (e.g.  solid phase synthesis) 
[12,53,68,69].  As 
demonstrated by  Andres  and co-workers,  thioctic acid-PEG-folic acid capped spherical 
gold NPs were selectively taken-up by foliate receptor positive cancer cells, while their 
uptake was minimal in cells, which do not over-express these receptors 
[44].  Moreover, the 
presence of thiolated-PEG compartment within the organic layer, enhanced the stability of 
NPs in buffered environments; another advantage upon protein or antibodies stabilised NPs 
(electrostatic stabilisation 
[64,70-72]).  Often NPs based cellular targeting probes are designed 
to serve as imaging agents, therefore it is extremely important that the uptaken NPs retain 
their properties, e.g.  luminescent quantum dots and nanorods (QDs, QNRs) 
[56,73].   As 
reported by Pellegrino and co-workers, ‘PEGylated’ folic acid conjugated QNRs remained 
stable  (and  fluorescent)  after  selective  uptake  (mediated  by  foliate  receptors) 
[73].  
Presented here OEG capping layer provided NPs with a substantial stability in buffered 
environments, as demonstrated in chapters 4 and 5. 
Besides folic acid, the use of other small molecules (like peptides), for the preparation 
of  cell  targeting  nanocomposites,  gained  popularity  in  recent  years 
[47,53-55,57,62,74-80]; 
especially  cell  penetrating  peptides  (CPP)  are  very  attractive  biomolecules  and  were 
employed by several groups in the preparation of bioactive NPs 
[74,75,77].  Berry and co-
workers and Brust’s group demonstrated that TAT peptide functionalised NPs were not 
only taken-up by cells (e.g. HeLa) but were capable of escaping the endosomes, as they 
were found dispersed in the cytosol 
[74,75].  Except of that, the receptor targeting peptides 
have also been used to prepare NPs-peptide conjugates.  Very recently, Albericio and co-
workers reported that gold NPs capped with a mixed layer of targeting (bombesin gastrin 
releasing receptor peptide, BN/GRP) and drug (RAF) peptide analogues were successfully 
taken-up by GRP receptors expressing HeLa cells 
[53], while no NPs were found in the 
SHSY5Y cell line, which does not over-express GRP receptors.  As another example, RGD 
peptide was used by several research groups to functionalise NPs (e.g. QDs, magnetic NPs)  
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[13,81-83].    RGD-functionalised  NPs  were  specifically  taken-up  by  interleukin  αvβv 
expressing cells.  
As recently demonstrated by Levy and co-workers, endocytosis is usually followed by 
proteolytic digestion of peptides or proteins conjugated to NPs, carried out by cathepsin L 
protease  in  the  endosome 
[84].    Bearing  in  mind  that  the  properties  of  NPs  should  be 
retained even after digestion, to preserve their function (e.g. fluorescence) 
[56, 73, 83] and to 
avoid any intoxication (e.g. cadmium release from QDs) 
[85], the use of e.g. thiolated-PEG 
or OEG compartments in the organic layer is advantageous 
[73,  86] (Note: OEG capping 
layer provide NPs with sufficient stability in endosomes; see chapter 5).  Another way to 
solve the digestion issue 
[84] might be the utilisation of an extracellular approach in cell 
targeting and regulation.  P1 conjugated OEG NPs developed during this project meet both 
of  these  criteria  (good  stability  and  extracellular  method).    Also,  P3-OEG  NPs  were 
capable of triggering desired cellular response (even though they were internalised; section 
6.2.) simply by receptor binding (ahead of RME), which can also be considered as the 
extracellular approach.  
6.1.2.1.  Anisotropic pep-OEG NPs in selective interactions with 
HUVECs. 
As explained previously (see chapter 2), the applications of pep-OEG conjugates based on 
spherical gold cores (15 nm) in biomedicine are limited 
[87-90].  These limitations purely 
derive from the optical properties of NPs 
[91, 92] (e.g. plasmon band in the visible spectral 
range; see chapter 4 for physicochemical properties).  Therefore, these nanomaterials were 
only utilised to assess general bioactivity of pep-OEG NPs (section 6.2.) and were not used 
in laser induced photo-thermal treatment of cells (chapter 7 for results, chapter 2 for 
theoretical  background).    For  this  purpose,  pep-OEG  NPs  with  anisotropic  cores  were 
selected in respect  to their optical signatures 
[92-97], including  NIR extinction,  which  is 
required  for  in  vivo  treatment  of  a  deeper  tissue  (see  chapter  4  for  physicochemical 
properties of these nanomaterials).  
Three types of anisotropic NPs were used: nanorods (NR), hollow  gold (HG) and 
silica/gold  core/shell  (CS)  nanostructures.    Their  surfaces  were  capped  with  the  OEG 
ligands, and further modified with P1 or P2 octa-peptides (see chapter 3 for experimental 
details)  to  form  P1-OEG  and  P2-OEG  NPs  (NR,  HG  and  CS,  see  chapter  4  for 
physicochemical characterisation).  
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To confirm that anisotropic P1 conjugates interacted with HUVECs in the same way 
as  spherical  core  based  nanocomposites,  a  series  of  experiments  was  performed.  
Representative TEM images (Fig. 51) clearly demonstrated P1-OEG NPs attached to the 
cellular membrane HUVECs, most likely via VEGFR-1 receptors.  All three types (NR, 
HG and CS) of P1 conjugated NPs were found attached to the outer membrane of cells.  
 
 
 
 
 
 
 
 
The  average  number  of  P1-OEG  NPs  interacting  with  a  single  cell  can  be 
approximated from TEM images, assuming that the receptors were evenly distributed on 
the surface of cells 
[98].  Taking the thickness of the imaged specimen (100 nm slice) and 
the dimensions of the picture (scale bars), the surface area of the cell (cellular membrane) 
shown on the image can be calculated.  Simply by counting the number of NPs on the 
image (average from at least 10 representative images) and referring this to the observed 
membrane  area  (e.g.  1  nanoparticle  per  0.018  ‚  0.075  µm
2)  and  to  the  total  area  of 
HUVECs membrane (150 µm
2 was assumed, as the average diameter of cells in suspension 
–  ‘rounded  shaped  cells’  was  6.9  µm),  the  average  number  of  NPs  per  cell  was 
approximated.  Specifically, the average number of P1-OEG NPs (for all types of metallic 
cores) attached to each cell was found to be in a region between 2000 ‚ 8000. 
To show that the binding of P1-OEG NPs to cellular membrane is not random (non-
selective),  but  programmed,  receptor  selective  type  of  interactions,  a  series  of  control 
experiments was conducted.  Hence, HUVECs were incubated with P2-OEG NPs, unable 
to bind to VEGFR-1, but which can interact with cells non-specifically (demonstrated in 
the  previous  sections).   TEM images  (Fig.  52)  confirmed  NPs  within  the  intracellular 
matrix, locked inside vesicles – endosomes, as designated by circles.  Arrows indicated 
the double membrane of vesicles.  Rod-like, hollow and core/shell NPs have entered cells 
most likely following the endocytosis pathway. 
Figure 51.   TEM images of HUVECs incubated with: P1-OEG HG NPs (A), P1-OEG NR 
(B) and P1-OEG CS (C).  Scale bars are 100 nm.  
A  B  C  
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6.2.  Regulation of basic biological functions of HUVECs. 
As demonstrated in section 6.1., spherical pep-OEG NPs (P1 and P3) selectively bind to 
receptors  (VEGFR-1  and  NRP-1,  respectively)  allocated  on  the  cellular  membrane  of 
HUVECs.  Both receptors play a fundamental role in the regulation of basic physiological 
functions  of  HUVECs 
[2,5,7,19,22,23,26-28],  therefore  it  was  anticipated  that  following  the 
binding event, pep-OEG NPs would induce a certain cellular response.  P1-OEG NPs were 
expected  to  act  as  activators,  while  P3-OEG  NPs  as  inhibitors  (see  chapter  2  for 
theoretical background). 
The bioactivity of pep-OEG NPs was  studied by gene expression profiling assays.  
Three genes related to angiogenesis (blood vessels growth, basic function of HUVECs, see 
chapter  2  for  more  details)  and/or  hypoxia  (oxygen  deprivation,  see  chapter  2)  and 
regulated  by  the  binding  of  growth  factors  to  appropriate  receptors 
[5,10,37,41,84,85]  were 
examined.  Specifically, vascular endothelial growth factor A gene (VEGF A), hypoxia 
inducible factor 1 gene α subunit (HIF-1α), myelocytomatosis oncogene (C-MYC) were 
selected.    Since  the  selected  genes  are  critical  to  angiogenesis,  regulation  of  their 
expression levels in HUVECs (following treatment with pep-OEG NPs) would allow a 
control over cell physiology. 
On the other hand, even if a successful regulation of gene transcription in a population 
of cells is achieved, a control upon the whole physiological processes (e.g. angiogenesis) 
conducted  by  these  cells 
[86]  may  not  necessarily  be  gained.    Therefore,  once  it  was 
confirmed that pep-OEG NPs regulate the cellular response at the molecular level (section 
6.2.1.), the capability of colloids to stimulate or suppress the entire angiogenesis process 
was examined by in vitro capillary-like structures formation assays (section 6.2.2.). 
A  B  C  A  B  C 
Figure 52.   TEM images of HUVECs incubated with: P2-OEG HG NPs (A), P2-OEG NR 
(B) and P2-OEG CS (C).  Scale bars are 100 nm.   
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6.2.1.  Overview at the molecular level: gene expression profiling. 
As described in chapter 3 prior to gene expression profiling assays, HUVECs were treated 
for 6 h with pep-OEG NPs.  Environmental conditions, e.g. the quantity of serum proteins 
in growth media, were varied during treatment, to achieve the highest possible expression 
of VEGF A, HIF-1α and C-MYC genes.  The amount of expressed mRNA was quantified 
by Q-PCR reaction (see chapter 3 for experimental details) using primers equipped with 
TaqMan probes and c-DNA;  c-DNA was synthesised by reverse transcription (RT) on 
mRNA templates isolated from cells 
[87].  
To  optimise  environmental  conditions  for  VEGF  A,  HIF-1α  and  C-MYC  genes 
expression assay, a series of control experiments was performed.  In these experiments 
HUVECs were stimulated with a naturally existing cytokine – VEGF-B167 (see chapter 2 
for more information about VEGF-B167  and chapter 3 for experimental protocol).  As 
reported  by  Eriksson  and  co-workers,  VEGF-B167  selectively  binds  to  VEGFR-1 
[85].  
VEGF-B167 can also bind to NRP-1, as demonstrated by Alitalo’s group 
[27].  Following the 
binding event, activation of several genes, including VEGF A, HIF-1α and C-MYC in 
HUVECs was shown by Li and co-workers 
[10].  On account of previously reported up-
regulation  of  selected  genes 
[10],  as  well  as  the  binding  affinity  towards  both  chosen 
receptors 
[19-21,23] (Note: other cytokines, e.g. VEGF-A165, bind to different sets of growth 
factor receptors, see chapter 2), this cytokine was selected to serve as a positive control.   
VEGF  A,  HIF-1α  and  C-MYC  genes  expression  profiling  after  treatment  with            
VEGF-B167  is  shown  in  Fig.  53.    Presented  values  were  normalised  according  to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH, standard used in data normalisation 
[88], which is not regulated  by  VEGF-B167) expression  levels and referred to untreated 
HUVECs, which were incubated in full-serum (20 % human serum, see chapter 3 for cells 
culturing protocol) growth media.  In all tested conditions (Fig. 53, conditions 1 ÷ 3) three 
genes were up-regulated.  The highest up-regulation (nearly 60 fold, Fig. 53, conditions 1) 
was achieved for VEGF A gene, whilst the lowest (around 3 fold, same conditions) for        
C-MYC  gene.    It  is  evident  that  cells were  the  most effectively  stimulated  in  serum-
depleted  (0.2  %  human  serum,  100  times  less  than  in  a  standard  growth  media)  and 
hypoxia mimicked conditions (by the presence of cobalt II chloride, CoCl2 
[89]; see chapter 
3 for experimental details).  Moderate regulation (over 10 fold of VEGF A) was achieved 
in serum-depleted environment, while only minor effects on genes (0.7 fold of VEGF A) 
were observed, when cells were incubated in full-serum growth media.   
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It  can  be  concluded  (based  on  a  graph;  Fig.  53)  that  HUVECs  were  the  most 
effectively  stimulated  in  serum-depleted  conditions  and  this  effect  was  additionally 
enhanced by a CoCl2 mimicked hypoxia.  Consequently, it was anticipated that P1-OEG 
NPs would have similar activating effects on tested genes, even though P1-OEG NPs most 
likely bind to VEGFR-1, as demonstrated in section 6.1. (Note: VEBF-B167 binds to both, 
VEGFR-1 and NRP-1 
[19-23,26-28,85]).  Therefore, in response to P1-OEG NPs binding to 
HUVECs,  optimum  levels  of  genes  expression  were  expected  in  serum-depleted  and 
hypoxia mimicked environmental conditions. 
As already mentioned, P3-OEG NPs (NRP-1 binding) were expected to inhibit the 
expression of monitored genes.  Since hypoxic conditions (here, mimicked by CoCl2) can 
activate several genes, including VEGF A as demonstrated by Keshet’s group 
[90], there 
was a concern that in the presence of CoCl2, P3-OEG NPs mediated inhibition can be 
undermined or even masked.  To overcome this issue, a series of control experiments with 
HUVECs treated with free P3 octa-peptide under various conditions (Fig. 54, conditions 1 
÷ 3) was performed first.  The same conditions, showing a maximum gene inhibition with 
P3, would then be chosen and used in the cells treatment with colloidal P3-OEG NPs.   
P3 peptide showed inhibitory effects on all three angiogenesis related genes.  In the 
tested  conditions  VEGF  A  gene  was  down-regulated  the  most  efficiently,  while  the          
C-MYC gene was the least affected (as in case of VEGF-B167 mediated activation).  It is 
evident that the most efficient down-regulation (around -9 for VEGF A, and -8 for HIF-1α) 
was  achieved  in  serum-depleted  conditions  (Fig.  54,  conditions  2).    As  predicted,  the 
addition of CoCl2 had a positive effect on genes expression levels.  Joint outcome of both: 
Figure 53.   VEGF A, HIF-1α and C-MYC genes fold regulation in HUVECs after 6 h 
treatment with VEGF-B167 in reduced-serum with CoCl2 (1), reduced-serum 
(2) and full-serum (3) media growth.  
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serum starvation and hypoxia (conditions number 1), led to less effective down-regulation 
of VEGF A, HIF-1α (-8.5 and -7, respectively) and C-MYC genes (Fig. 54, conditions 1), 
than in conditions number 2.  Incubation in full-serum growth media (Fig. 54, conditions 
3)  resulted  in  a  minor  down-regulation of  tested  genes  (minimum  -0.6  for  VEGF  A).  
Moreover, the maximum effect on HUVECs (-9 down-regulation of VEGF A) was nearly 
6 times lower than VEGF-B167 induced effect (over 50 fold up-regulation of VEGF A) in 
number 1 conditions.  Possibly explained by the activation of the VEGF A gene in hypoxic 
conditions (here mimicked by CoCl2), which was also demonstrated by Keshet’s group 
[90].  
 
 
 
 
 
 
 
 
 
The activity of P1 and mutated P2 octa-peptides (activator, or no effect, respectively), 
as well as pep-OEG NPs (P1, P2 and P3) were assessed next.  The expression levels of 
VEGF A, HIF-1α and C-MYC genes in HUVECs, treated either with VEGF-B167 or free 
(P1, P2 or P3) peptides and their analogous pep-OEG NPs, were tested in the presence of 
CoCl2 in serum-depleted (Fig. 55), or without CoCl2 in serum-depleted (Fig. 56) or full-
serum (Fig. 57) growth media.  All three environmental conditions were applied in the 
experimentation  assays,  to  fully  assess  the  efficacy  of  both,  inhibitory  and  activating 
effects on cells, in respect to each other.    
 Overall, the VEGF A gene was affected the most by treatment with all tested gene 
regulators  (see  Fig.  55,  natural  cytokine,  octa-peptides  and  pep-OEG  NPs),  while  the 
smallest effect was observed on C-MYC gene.  Maximum up-regulation (nearly 50 fold) 
was  observed  for  VEGF  A  gene  after  the  cells  treatment  with  VEGF-B167  cytokine.  
Synthetic P1 octa-peptide and P1-OEG NPs up-regulated VEGF A gene by nearly 26 and 
Figure 54.   VEGF A, HIF-1α and C-MYC genes fold regulation in HUVECs after 6 h 
treatment with P3 in reduced-serum with CoCl2 (1), reduced-serum (2) and 
full-serum (3) media growth.  
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over 15 fold, respectively.  Interestingly, HIF-1α and C-MYC genes were stimulated more 
efficiently with P1 and P1-OEG NPs analogues than with the natural cytokine.  
On  the  contrary,  all  three  genes  were  significantly  down-regulated  with  P3  octa-
peptides and P3-OEG NPs.  VEGF A reached maximum down-regulation after treatment 
with P3-OEG NPs (over -10 fold).  The incubation with free P3 resulted in nearly -8 fold 
inhibition.  It is worth noticing that both, P1-OEG and P3-OEG NPs presented slightly 
stronger effects on tested genes, than free P1 and P3 octa-peptides, respectively (Note: the 
total quantity of introduced octa-peptides, those free in solution or attached to NPs was 
kept constant; see chapter 3 for experimental details).  One possible hypothesis which may 
explain this, can be an effect deriving from a higher local concentration of receptor binding 
epitopes on NPs (over 500 per each NP, see chapter 4 for peptide quantification) than on 
free peptides (only one binding site per each octa-peptide).  Meaning that, once a pep-OEG 
nanoparticle is bound to the appropriate receptor via one of its 500 octa-peptides, other 
epitopes are brought close to the surface of a cell, possibly inducing an additional binding 
event between the neighbouring receptor and another peptide (out of 499 still available for 
binding).  By this way the binding rate and the resulting gene expression levels can be 
increased.  
As predicted, a mutated P2 sequence and P2-OEG NPs did not induce any notable 
gene response.   This is  because P2  octa-peptide  cannot interact with any of the  listed 
receptors.  
 
 
 
 
 
 
 
 
 
 
Figure 55.   VEGF  A, HIF-1α and C-MYC genes fold regulation in HUVECs after 6 h 
treatment in serum-reduced growth media and with CoCl2.  
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 In  serum-depleted  conditions  (Fig.  56) similar  trends  were  observed.    VEGF-B167 
cytokine, as well as P1-OEG NPs and free P1 octa-peptide up-regulated, while P3-OEG 
NPs and free P3 octa-peptides down-regulated VEGF A, HIF1-α and C-MYC genes.  Both, 
P2 and P2-OEG NPs had no effect on the genes tested.  VEGF A gene responded the 
strongest to the tested factors, while C-MYC gene the least.  The highest fold regulation 
(over 14 fold up-regulation of VEGF A) was achieved after treatment with the natural 
cytokine.  Overall inhibitory effects seem to be much stronger in these conditions, than in 
the presence of CoCl2.  Over -12 fold down-regulation of VEGF A gene (and -8 fold of 
HIF1-α; -3 of C-MYC) was observed after treatment with P3-OEG NPs.  At the same time, 
the relative value of activation was much weaker, than in CoCl2 containing environment.  
Here, only 10 fold up-regulation of VEGF A (and 5 fold of HIF1-α; 1.5 of C-MYC) was 
achieved with P1-OEG NPs.  Possibly explained by the activation deriving from CoCl2, 
which mimics the hypoxic conditions, as already suggested  in the text  and previously 
demonstrated  by  several  research  groups 
[89,90].    CoCl2  based  activation  could  have 
enhanced the VEGF-B167, P1 and P1-OEG NPs mediated induction and at the same time 
suppressed the P3 or P3-OEG NPs mediated inhibition.    
 
 
 
 
 
 
 
 
 
 
 
 
The natural cytokine, as well as octa-peptides and pep-OEG NPs showed only minor 
level  of  genes  fold  (between  0.7  and  -0.7  fold)  regulation  in  full-serum  conditions                  
(Fig. 57).  However, the general trends (genes up-regulation with VEGF-B167, P1 and P3-
Figure 56.   VEGF A, HIF-1α and C-MYC genes fold regulation in HUVECs after 6 h 
treatment in serum-reduced growth media.  
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OEG NPs and down-regulation with P3 and P3-OEG NPs), observed after treatment in 
serum-depleted (Fig. 56) and serum-depleted with CoCl2 (Fig. 55) growth media, were 
preserved.  
Minor effect on genes in full-serum conditions can be attributed to the presence of 
growth  factors  among  serum  proteins.    Consequently,  the  control  sample  (cells  only), 
which served as a reference point (background correction) for data normalisation, as well 
as samples treated with gene regulators were stimulated.  That is why relative heights of 
bars representing genes fold regulation are not as elevated as in case of the serum-depleted 
environment.  
 
 
 
 
 
 
 
 
 
 
 
 
To  summarise,  generally  the  strongest  effects  on  genes  were  observed  in  hypoxia 
(CoCl2 mimicked) and serum-depleted conditions (Fig. 55).  However, down-regulation 
with P3 octa-peptide or analogues P3-OEG NPs seemed to be more efficient in the serum-
depleted environment only (Fig. 56).  Moreover, in CoCl2 free environment the effects 
deriving  from  P3  and  P3-OEG  NPs  treatment  are  stronger  than  P1  and  P1-OEG  NPs 
mediated  stimulation.    Treatment  in  full-serum  conditions  did  not  lead to  any  notable 
effects on tested genes 
[10,84].  Nonetheless, it was successfully  demonstrated that both 
synthetic sequences (P1 and P3), as well as P1-OEG and P3-OEG NPs conjugates show 
desired activity and can regulate the response of HUVECs at the molecular level. 
Figure 57.   VEGF A, HIF-1α and C-MYC genes fold regulation in HUVECs after 6 h 
treatment in full-serum growth media.  
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A different cell line, which does not over-express VEGFR-1 and/or NRP-1 (e.g. HeLa) 
was not used as an additional control in gene profiling assays.  In these assays, regulatory 
effects of colloids on cell metabolism (following the receptor binding event) were studied.  
Since no receptor binding was denoted in HeLa (flow cytometry, see the previous section), 
no major effects on genes could have been observed.  Consequently, HeLa were discarded 
from gene expression profiling experiments. 
As previously reported by Li and co-workers, treatment with VEGF-B167 cytokine up-
regulates many post-survival genes, including VEGF A, HIF1-α and C-MYC in a number 
of vascular cells 
[84].  Similar effects (activation) were observed in HUVECs treated with 
P1 or P1-OEG NPs.  It can be hypothesised that the binding of cytokine or octa-peptide 
derivatives to VEGFR-1 receptor induces tyrosine kinase phosphorylation cascade and a 
signal  transduction  within  cells,  which  led  to  up-regulation  of  monitored  genes.    The 
activation of VEGF A gene could have resulted in the secretion of VEGF-A protein, e.g. 
VEGF-A165 and its isoforms (see chapter 2 for more details).  Consequently, produced 
VEGF-A  factor  (along  with  growth  factors  present  in  growth  media;  serum-depleted 
environment  still contained  0.2  %  serum  proteins)  could  have  bound  to  growth  factor 
receptors (e.g. VEGFR-1 and VEGFR-2) and further activated the signalling cascade and 
increased the expression levels of selected genes.  
In general, tested genes were activated slightly stronger with VEGF-B167 than by P1 
derivatives.  A possible explanation could be that the natural cytokine can bind to both, 
VEGFR-1 and NRP-1 receptors 
[10,19,27,84,85] (and perhaps with higher affinity), while P1 
octa-peptide and P1-OEG NPs predominantly to VEGFR-1 (see section 6.1.).  Activated 
NRP-1 (by cytokine) can mediate more stable physical association between VEGF-A165 
and VEGFR-2, as demonstrated by Zachary and co-workers 
[28].  This is required for full 
activation  of  the  receptor  and  its  signaling  pathways 
[27,28,91],  thus  can  enhance  the 
expression levels of the tested genes.  It is also worth highlighting that the increased fold 
up-regulation of VEGF A gene after treatment with VEGF-B167 in serum-depleted growth 
media with CoCl2, can be explained by the stimulating effects of hypoxia (mimicked by 
CoCl2) on this gene 
[89,90] (already mentioned in the text). 
The  mechanism  of  P3  and  P3-OEG  NPs  mediated  inhibition  seems  to  be  more 
complicated and harder to explain than the regulatory effects of P1 and analogous P1-OEG 
NPs.  One can hypothesise that the association of P3 and P3-OEG NPs with NRP-1 can 
prevent  the  binding  of  growth  factors  (present  in  the  growth  media;  serum-depleted 
contained 0.2 % serum proteins) to this receptor.  Consequently, since co-binding to NRP- 
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1 is required for stable binding of VEGF-A to VEGFR-2 (shown by Zachary’s group)
 [28], 
the  effective  blocking  of  NRP-1  (with  P3  or  P3-OEG  NPs)  could  inhibit  the 
phosphorylation signalling cascade within cells, thus the expression of associated genes.  
On the other hand, the formation of complexes between NRP-1 and VEGFR-2 enhances 
the binding of growth factors, as reported by Klagsbrun and co-workers 
[91].  Therefore, it 
is possible that, if NRP-1 is bound to P3 or P3-OEG NPs, the formation of complexes with 
another growth factor receptor is suppressed and so is the efficiency of the growth factor 
binding events.  Consequently, it can be hypothesised that genes tested, including VEGF 
A, could not have been effectively stimulated and that growth factors could not have been 
secreted.  This resulted in genes down-regulation (referred to untreated cells).  It seems to 
be in agreement with hypoxia related effects on genes in HUVECs treated with P3 or P3-
OEG NPs.  Less effective gene fold regulation was indeed observed in the presence of 
CoCl2.    However,  CoCl2  induction  could  not  outweigh  inhibition  by  P3  derivatives, 
because  of  binding  to  NRP-1,  which  (as  already  explained)  possibly  suppressed  the 
association of growth factors with VEGFR-2 and the phosphorylation cascade.      
6.2.2.  In vitro angiogenesis regulation. 
As demonstrated in the previous section, pep-OEG colloids regulate several angiogenesis 
related genes in HUVECs.  This section will assess whether analogues regulation of the 
whole physiological process (angiogenesis) can be achieved.  
Soker and co-workers previously reported the inhibition of angiogenesis with gold 
NPs 
[92].  In their work, the inhibition of VEGF-A165 induced in vivo angiogenesis (in mice) 
using uncoated, spherical and around 5 nm diameter gold colloids.  Anti-angiogenic action 
was  attributed  to  the  binding  of  VEGF-A165  to  the  surface  of  gold  NPs.    It  was 
hypothesised that the binding occurred via the side chain thiol group of cysteine residues 
(Note: cysteines are critical to the activity of VEGF-A165, as they are allocated within the 
active site).  Inactivated VEGF-A165 cannot induce angiogenesis.  The authors have utilised 
the affinity of gold NPs towards thiol containing molecules.  Introduced into mice NPs 
themselves did not possess any angiogenic activity.  In such an approach, it is difficult to 
fully control the action of NPs, since in the organism (e.g. mice), there is a number of thiol 
containing  molecules  (e.g.  glutathione),  which  can  also  bind  to  gold  NPs 
[70,71,93,94].  
Consequently, it is hard to predict which molecules and in what ratio (in respect to each 
other) will bind to NPs and what percentage of them will remain unbound.  This rises the  
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following questions: a) will every VEGF-A165 molecule be blocked?; b) will the activity of 
other molecules (which ones?) be affected by binding to NPs? and c) if so, what are the 
consequences  (side  effects)  on  other  (which  ones?)  physiological  processes  in  the 
organism?  One  way  to  overcome  these  issues  would  be  the  use  of  capped  NPs 
[48,50,52,53,58,64,72,74,76,95,96].  Such NPs will not covalently bind (via thiol-gold interactions) to 
any biomolecules in the organism.  The angiogenic activity will come from pro- or anti-
angiogenic molecules incorporated in the organic corona.  Newly developed family of pep-
OEG NPs meet those criteria. 
 
The capability of pep-OEG NPs to regulate the angiogenesis process (conducted by 
HUVECs) was examined by in vitro capillary-like structures formation assay 
[15,50] (see 
chapter 3 for experimental details).  Hence, cells were grown on a basement membrane 
matrix gel (thin layer method, see chapter 3) and stimulated with pep-OEG NPs in serum-
depleted growth media (0.2 % serum proteins).  The selection of such conditions was based 
on the genes profiling assay, as shown in the previous section.  Specifically, the maximum 
inhibition of genes in cells, treated with P3-OEG NPs were observed in serum-depleted 
environment, as well as their sufficient induction with P1-OEG NPs.  On the contrary, in 
serum-depleted and hypoxia mimicked conditions, enhanced induction (with P1-OEG NPs) 
and reduced inhibition (with P3-OEG NPs) was denoted.  In the full-serum growth media 
no  major  effects  on  the  genes  was  observed.    Since,  it  was  anticipated  to  study  both 
regulatory effects (induction and inhibition) on the in vitro angiogenesis simultaneously, 
using the same conditions, the assay was performed in a serum-depleted environment.  The 
reduced  growth  factor  gel  (Geltrex)  was  employed  in  all  experiments,  so  that  the 
stimulation of capillary formation by the matrix components was minimal.  The incubation 
time of cells with NPs was varied between 2 ‚ 20 h.  VEGF-B167 was chosen to serve as a 
positive control and a reference point; at which maximum stimulation was expected (this 
will be further discussed by the end of this section).  
After the cell treatment with gold colloids or VEGF-B167, phase contrast images were 
taken.  The length of capillaries formed by HUVECs was quantified per image area of 
0.216 mm
2, using ImageJ software (see chapter 3 for more details).  Also, the number of 
branching points (BPs)  was counted.  The overall length of capillaries developed after 
stimulation with each type of gold colloid was referred to untreated (but incubated in the 
same conditions – control) and VEGF-B167 treated cells, then presented as a regulation 
index (RI, see chapter 3 for equation).  Branching indexes (BrI) were calculated in an 
analogues way (see chapter 3 for equation).  
 
Chapter 6 – Cell targeting and regulation with pep-OEG NPs 
 
 
163 
 
Only  recently,  Anderson  and  co-workers  reported  that  HUVECs  with  anchored 
‘nanoparticulate patches’ retained their ability to form capillaries on matrix gels 
[50].  In 
their work, the cellular membrane of living HUVECs was first biotinylated then decorated 
with commercially available NeutrAvidin labelled 40 nm fluoSpheres.  Cells modified with 
NPs were forming multi-cellular structures as fast as unmodified HUVECs.  Hence, any 
delay (inhibition) or induction of the capillaries formation by cells with pep-OEG NPs 
should be assigned to the specific activity possessed by NPs. 
As an example, phase contrast images showing HUVECs after 4 h stimulation are 
presented in Fig. 58.  Neo-vascular sprouting by untreated cells (A) was marginal, while 
upon  stimulation  with  VEGF-B167  (B)  or  P1-OEG  NPs  (C),  HUVECs  were  forming 
capillaries.  Hence, the pro-angiogenic activity of P1 based gold colloid was determined.  
P2-OEG and P3-OEG colloids did not induce any notable spouting, either as a result of 
anti-angiogenic activity (as expected for P3-OEG NPs, see the previous section), or a lack 
of any activity.  To verify if P3-OEG NPs possess any anti-angiogenic activity, the assay 
conditions were optimised to achieve neo-vascularisation of the untreated cells.  Instead of 
using a matrix gel with a higher quantity of growth factors (to stimulate tubules formation), 
the assay duration time was extended (up to 20 h).  Such an approach was chosen to avoid 
masking any possible inhibitory effects of P3-OEG NPs with antagonistic action (pro-
angiogenic) of growth factors.  
Phase contrast images of HUVECs were taken after 2, 4, 8 and 20 h of treatment 
(Note: exactly the same areas of culture dishes  were  imaged at each time point).    As 
already  mentioned,  quantitative  analysis  of  the  images  were  performed  for  data 
clarification (see chapter 3 for equations).  The measured overall length of capillaries after 
2, 4 and 8 h of treatment are shown in Fig. 59A, while in B, calculated values of RI’s are 
presented (Note: RI’s are relative to the maximum regulation with VEGF-B167 achieved 
after 4 h – equals to 100 % RI and referred to the background sprouting observed in the 
control sample).  After 20 h of treatment cell apoptosis was observed.  Hence, this set of 
images was discarded from statistical analysis.  Rapid apoptosis of endothelial cells in the 
matrix  gel  assays  is  quite  common,  as  was  previously  reported  by,  e.g.  Riese’s  and 
Brodsky’s research groups 
[97,98].  
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Significant pro-angiogenic activity of P1-OEG NPs can be seen on both graphs, after 2 
and 4 h of treatment.  The maximum activity was observed after 4 h (over 2 mm tubules – 
graph A and over 90 % RI – graph B).  These effects were almost as strong as the neo-
vascularisation induced with the natural cytokine (VEGF-B167, positive control).  After 8 h 
of  treatment  the  overall  tubules  length  and  RI  decreased  in  both,  P1-OEG  NPs  and        
VEGF-B167 stimulated cells; possibly attributed to cell apoptosis, which usually follows 
capillary formation 
[97,98].  Nonetheless, the pro-angiogenic effects of P1-OEG NPs were 
still notable, especially when presented as RI (Fig. 59B).  After 8 h of incubation neo-
Figure 58.   Phase contrast images of capillaries formed by HUVECs after 4 h treatment 
with: VEGF-B167 (B), P1-OEG NPs (C), P2-OEG NPs (D) and P3-OEG NPs 
(E) in serum-depleted growth media.  Untreated cells are shown in (A).  Inserts 
represent magnified fragments of images.  Scale bars are 50 μm. 
A  B 
C  D 
E  
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vascular sprouting was also observed in the control sample (untreated cells,  Fig. 59A).  
This however, did not outweigh the pro-angiogenic effects deriving from P1-OEG NPs and 
VEGF-B167.  The neo-vascularisation of untreated cells was probably induced by the small 
amount of growth factors present in the matrix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The differences in angiogenic activity between P2-OEG and P3-OEG NPs were barely 
distinguishable after 2 and 4 h treatment.  However, it seemed that P3-OEG NPs showed 
minor  anti-angiogenic  activity  (Fig.  59B,  negative  value  of  RI),  whilst  P2-OEG  NPs 
(based  on  a  mutated  sequence)  did  not  show  any  significant  effects  on  neo-vascular 
Figure 59.   Statistical  analysis  of  capillaries  formed  by  HUVECs,  after  2,  4  or  8  h 
treatment.  The total length of tubules per image area (0.216 mm
2) is shown in 
(A).  The regulation index (RI) is shown in (B). 
A 
B  
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sprouting.    These  effects  became much  clearer  after  8  h treatment.    Hence,  HUVECs 
treated with P3-OEG NPs did not form capillaries (Fig. 59A), while cells incubated with 
P2-OEG NPs showed a relatively high (similar to the control) level of neo-vascularisation.  
When RI’s (Fig. 59B) were taken under consideration, it was evident that P3-OEG NPs 
acted as anti-angiogenic factors (over -50 % RI), while P2-OEG NPs did not show any 
activity.  Pro-angiogenic action of P1-OEG NPs was still noticeable (around 25 % RI). 
As  suggested  by  Ribatti  and  co-workers,  when  the  inhibitory  effects  on  the  neo-
vascularisation (or the early stage of this process) are to be assessed, the quantification of 
BPs can be useful 
[99].  Hence, the number of BPs (and BrI’s) formed by sprouting cells 
was determined (Fig. 60).  The maximum number of BPs was found after 4 h of cell 
treatment with the natural cytokine.  After 4 h of stimulation with P1-OEG NPs a relatively 
high (over 75 % BrI) level of branching was achieved, which additionally confirmed the 
pro-angiogenic activity of this colloid.  Strong inhibition of the BPs formation with P3-
OEG NPs was revealed after 8 h treatment (nearly -25 % BrI).  Here, the positive effect on 
BPs formation with P1-OEG NPs decreased, but remained apparent (around 25 % BrI).  At 
all times no major effects of the BPs development was achieved with P2-OEG NPs, which 
gave further evidence to the lack of any major activity of this colloid upon angiogenesis 
regulation. 
Slightly stronger pro-angiogenic activity of VEGF-B167 than P1-OEG NPs can be a 
consequence of the stronger gene up-regulation with VEGF-B167 (see the previous section), 
related  to  the  receptor  binding  affinities  (Note:  as  already  described  in  the  previous 
sections, VEGF-B167 bind to both, VEGFR-1 and NRP-1 receptors, while P1-OEG NPs 
predominantly binds to VEGFR-1).  
On the other hand, the actual concentration of introduced VEGF-B167 was 500 times 
higher than P1-OEG NPs.  This was to keep the number of receptor binding sites constant 
(assuming that each VEGF-B167 can bind to one receptor, while each nanoparticle contains 
around 500 receptor binding sites; see chapter 4 for peptide quantification).  Despite the 
lower concentration of NPs, the local concentration of peptides bound to the NPs surface 
was much higher.  Possibly, peptides were more accessible for receptors when presented 
on the surface of NPs.  Consequently, relatively high pro-angiogenic action (nearly as high 
as with cytokine) was achieved with P1 colloid.   
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Kay  and  co-workers  suggested  that  VEGF-B167  potentiates,  rather  than  induces 
angiogenesis in endothelial cells 
[100].  This is not denied (nor supported) by the results 
presented  in  this  thesis.    However,  it  can  be  hypothesised  that  since  the  matrix  gel 
contained a reduced amount of growth factor, these could have induced the capillaries 
formation.  The sprouting process was definitely enhanced by the presence of VEGF-B167 
(or P1-OEG NPs) as shown in Fig. 59 and 60.  Hence, the pro-angiogenic activity of P1 
colloid (as well as the natural cytokine) was confirmed, which was the aim of performed 
experiments.  On the other hand, Li and co-workers reported that VEGF-B167 up-regulates 
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Figure 60.   Statistical  analysis  of  capillaries  formed  by  HUVECs,  after  2,  4  or  8  h 
treatment.  Overall number of branching points (BPs) per image area (0.216 
mm
2) is shown in (A).  The branching index (BrI) is shown in (B). 
A 
B  
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several angiogenesis related genes in HUVECs, including VEGF A 
[10].  Such activity of 
both, VEGF-B167 and P1 colloids was demonstrated in the previous section.  Consequently, 
even  in  the  absence  of  other  pro-angiogenic  molecules  (other  than  VEGF-B167  or  P1 
colloids), the angiogenesis can still be induced (as long as the gene activation is followed 
by the secretion of VEGF-A isoforms).  Therefore, VEGF-B167 and P1-OEG NPs can be 
considered as self-sufficient angiogenesis inductors, even if only indirect (via VEGF A 
gene activation). 
In general, P3-OEG NPs showed slightly lower angiogenic activity than P1-OEG NPs.  
The highest denoted RI value achieved with P1-OEG NPs reached over 90 %, while P3-
OEG NPs showed -64 %.  One possible explanation can be the presence of growth factors 
in  the  matrix  gel,  which  can  mask  some  of  the  anti-angiogenic  activity  of  P3  based 
colloids, at the same time enhancing the pro-angiogenic action of P1 colloids.  
Generally, colloids acted slightly stronger on the overall length of tubules than the 
branching process.  Specifically, P3-OEG NPs showed over double inhibition of RI than 
BrI,  while  the  BrI  of  P1-OEG  NPs  was  over  20  %  lower  than  the  RI.    It  can  be 
hypothesised  that  this  is  related  to  the  narrow  selectivity  in  receptor  binding  (and 
angiogenic activity) of colloids, when assuming that BPs (and BrI’s) represent the early 
stage of angiogenesis 
[99].  As already discussed, the early angiogenesis can be initiated by 
VEGF-A; since VEGF-B167 binds to NRP-1 and mediates more stable association between 
VEGF-A and VEGFR-2 (required for the signalling) 
[28], possibly enhancing (promoting) 
the early neo-vascularisation stage.  On the contrary, such enhancement did not occur with 
the P1 colloid, since it predominantly binds to VEGFR-1 (rather than NRP-1).  
On the other hand, P3-OEG NPs mediated angiogenesis inhibition was measured with 
respect to the tubules formed by untreated cells.  In control cells, the branching process 
was only ﾼ as effective as in VEGF-B167 stimulated cells, while the tubules were formed 
with ﾽ efficiency of VEGF-B167 treatment (Note: this is based on comparison between 
overall tubules  length and BPs  number in cells stimulated for  4 h with VEGF-B167  or 
untreated cells after 8 h incubation).  Since the BrI of P3 colloid was referred to the control 
sample  (with  a  high  background,  smaller  number  of  BPs),  achieved  value  of  BrI  not 
necessarily  means  less  pronounced  (inhibitory)  effects  on  the  early  angiogenesis,  with 
respect to VEGF-B167 or P1-OEG NPs (pro-angiogenic) activities.   
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7.  Laser-hyperthermia with OEG NPs and P1-OEG NPs. 
Laser light of the appropriate power and frequency causes no damage to mammalian cells 
(e.g. HUVECs) 
[1-3].  NIR frequency is generally considered as safe.  In the spectral region 
between  650  and  900  nm  (Biological  NIR  Window)  tissue  components  show  minimal 
extinction  characteristics,  resulting  in  the  highest  light  transitivity  (see  chapter  2  for 
theoretical basis).  The tissue penetrating properties of NIR light were utilised in photo-
thermal treatment with NPs 
[4-15].  When NIR absorbing NPs (e.g. gold NPs) are associated 
with  the  tissue  components  (cells),  NIR  light  which  passes  the  cell  structure,  will  be 
absorbed by NPs.  Absorbed light will be then converted into heat 
[16].  This generated heat 
will result in an increase of the local temperature, leading to heat induced cellular response 
or cell death 
[4-9,11-13,16-22] (hyperthermia, see Scheme 37).  Laser-hyperthermic treatment of 
HUVECs was performed with NIR absorbing NPs, which were either capped with OEG 
ligands or additionally conjugated to peptides. 
As demonstrated in chapter 5, OEG capped nanocomposites were endocytosed by 
HUVECs following non-specific mechanisms, deriving from the strong charge of these 
NPs.  The overall number of internalised NPs was strongly dependant on their size and 
shape (SP, NR, HG or CS).  On the other hand, it was possible to gain control upon the 
cellular fate of colloids by incorporating bioactive peptides (P1 or P3, see chapter 2 for 
sequences) in the organic corona of NPs (see chapter 6).  The resulting NPs interactions 
with cells were mediated by selective recognition between cell receptors and peptides.  It 
was demonstrated that P1 conjugated colloids (P1-OEG NPs) selectively bind to VEGFR-1 
receptors over-expressed by HUVECs.  Hence, the number of NPs associated with cells 
did not depend on the size and shape of nanocomposites, but was determined by the NPs 
functionality and the number of available cell receptors.  
HUVECs, tagged with P1-OEG NPs or with endocytosed OEG NPs, were illuminated 
with NIR laser light (see Scheme 37 and chapter 3 for experimental details).  Since P1-
OEG NPs bind to the cell surface, whilst OEG NPs are internalised, the differences in 
thermal effects on the cell physiology, deriving from externally or internally associated 
NPs, could be studied. 
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As demonstrated in chapter 4, the optical properties (e.g. extinction frequency) of 
gold colloids can be adjusted by changing the shape and size of NPs.  NIR absorbing NPs: 
NR, HG and CS were synthesised.  Their surfaces were capped with OEG ligands then 
further  functionalised  with  P1  peptides  (see  chapter  3  for  experimental  details  and 
chapter  4  for  physicochemical  properties  of  colloids).    P1-OEG  NPs  were  binding  to 
membrane receptors in HUVECs, whilst OEG NPs were internalised by cells.  Cells loaded 
with NPs were exposed to laser light falling within the narrow band gap between 680 and 
720 nm (Fig. 62, red lines and red shade).  At approximately 700 nm (Fig. 62, black 
lines), the plasmon bands of NR, HG and CS were positioned, so that the laser light was 
absorbed with the highest efficacy.  
 
 
 
 
 
 
 
 
 
 
 
laser  
cellular  
cell death 
response 
light 
laser light         
absorption and 
conversion into heat 
Scheme 37.   Schematic illustration of laser induced P1-OEG NPs mediated thermal effects 
on HUVECs (laser-hyperthermia). 
HUVECs 
P1-OEG NPs  
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It is widely accepted that the efficiency of photo-thermally induced effects on cells 
depends on the applied laser power 
[7,8,10,11,13-15,23].  Hence, the laser power was varied over 
a wide range, from 0.75 to 5 mW (5 ÷ 32 W/cm
2, 200 µm spot size; Note: laser exposure 
time was kept constant at 10 min. in all experiments).  As reported by several research 
groups,  the  overall  percentage  of  damaged  cells,  quantified  immediately  after  laser 
treatment or after additional post-treatment incubation, can vary 
[14,24,25].  Consequently, 
after laser treatment, HUVECs were incubated for 1 or 24 h in fresh growth media (see 
chapter 3 for experimental details), prior to studies upon hyperthermia efficiency.  The 
efficiency  of  photo-induced  thermal  effects  on  HUVECs  was  assessed  by  two 
complimentary  techniques:  cell  viability  and  gene  expression  profiling.    Cell  viability 
studies showing the cell survival rate (see chapter 3 for experimental protocol) will be 
demonstrated in section 7.1.  Gene expression profiling assay, illustrating the heat shock 
response of HUVECs (see chapter 3 for experimental protocol) will be demonstrated in 
section 7.2.  
7.1.  HUVECs survival rate. 
HUVECs were treated with two types of colloids: OEG and P1-OEG coated.  OEG NPs 
were internalised by cells (see chapter 5 for uptake studies), while P1-OEG NPs stayed 
attached to the outer surface of cells (bound to VEGFR-1, see chapter 6).  Consequently, 
0
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Figure 62.   Extinction  spectra  of  OEG  capped  NPs  with  absorbance  maximum  at 
approximately 700 nm; full line –NR, dashed line – CS and dotted-dashed line 
– HG.  OEG NPs were used in hyperthermia with laser light (700 ± 20 nm) 
falling within biological NIR window (650 ÷ 900 nm). 
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two strategies in laser-hyperthermia: intra- and extracellular, were investigated.  As will be 
demonstrated in this section, laser induced intracellular damage in cells lead to a different 
overall cell survival rate than membrane injuries (extracellular approach). 
To investigate further the role of NPs in laser-hyperthermia, three types of NPs (NR, 
HG and CS) were employed.  It was found that in general, the type of NPs have a strong 
effect on the cell survival rate.  Percent of dead HUVECs to the overall number of treated 
cells  was  quantified  by  cell  viability  assays  (trypan  blue  staining,  see  chapter  3  for 
experimental).  Positively stained cells (damaged), as well as the whole cell population 
were manually counted on phase contrast and bright field images.  
 As an example, a set of bright filed and phase contrast images of HUVECs is shown 
in Fig. 63.  Rows represent HUVECs without (control) or with P1-OEG NPs (HG, NR or 
CS).   Phase contrast  images  of  HUVECs  before laser  treatment  are shown in  the left 
column.  After illumination (24 W/cm
2, 200 μm laser spot size designated by red dashed 
circles, 10 min.), cells were incubated in fresh growth media for 1 h (see chapter 3 for 
experimental details) and stained with trypan blue viability stain.  Phase contrast images of 
stained cells are shown in the middle column, while bright field in the right column.  
Clearly,  the  majority  of  cells  within  circles  was  damaged  (blue  spots),  while  non-
illuminated cells (outside circles) or cells without NPs (control) survived treatment.  The 
cell damage rate was estimated at 86.7 % after treatment with P1-OEG HG, 85.4 % for P1-
OEG NR and 49.2 % with P1-OEG CS.  Only background level of damage was observed 
in control sample (1 %).  
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According to the literature, each type of NPs (meaning the size and shape of metallic 
cores)  shows  different  energy  conversion  rate  (absorbed  light  to  heat) 
[6,11-13,16,26].    As 
already mentioned in chapter 2, Richardson and co-workers calculated that a single gold 
nanoparticle, around 60 nm in diameter, can generate 5 μW of heat if SPR illuminated with 
2 mW laser light 
[16].  However, the overall heating intensity can be significantly enhanced 
Before illumination  After illumination  Before illumination  After illumination 
Figure 63.   Phase contrast (left and middle) and bright field (right) images of HUVECs 
before (left) and after (middle and right) exposure to NIR laser (10 min., 24 
W/cm
2) and 1 h incubation at 37  °C followed by viability staining.  Rows 
represent HUVECs without NPs (control), and P1-OEG NPs: hollow gold (P1-
OEG HG), nanorods (P1-OEG NR), and core/shells (P1-OEG CS).  Dashed 
red circles indicate laser spots.  Scale bars are 50 µm. 
control 
P1-OEG HG 
P1-OEG NR 
P1-OEG CS  
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by collective effects of several NPs, e.g. NPs entrapped in cell endosomes or associated 
with the cellular membrane.  Assuming that comparable numbers of each type of P1-OEG 
NPs (NR, HG and CS, approximately 5000 ± 3000 per cell; see chapter 6) were associated 
with HUVECs, the least efficient heating (measured by the number of damaged cells) was 
observed with CS. 
As already mentioned, the efficiency of laser-hyperthermia (referred to the percentage 
of damaged cells in the overall number of treated cells) not only depends on the type of 
NPs, but can be controlled by adjusting the laser power used during treatment 
[7,8,10,11,13-
15,23] (Note: the illumination time was kept constant).  Consequently, laser power density 
(LPD) in presented studies, was varied between 5 ÷ 32 W/cm
2.  To fully investigate the 
effects of variable LPD (along with the type of nanocomposites) on the cell survival rate, 
different types of NPs (NR, HG and CS) with different functionality: P1-OEG NPs or OEG 
NPs,  were  employed.    These studies  were further extended by applying variable post-
treatment incubation time (1 or 24 h), which can be considered as an additional (third) 
parameter on which hyperthermia efficiency depends.  
HUVECs (without and with NR, HG or CS) before and after laser treatment (followed 
by viability staining) were imaged.  On every image, the number of damaged cells and 
overall number of treated cells were counted.  These numbers were plotted against variable 
LPD (Fig. 64).  Separate graphs were prepared for each type of NPs (NR, HG and CS) and 
functionality  (P1-OEG  and  OEG  NPs).    Two  data-sets  are  shown  on  each  graph, 
representing  the  percentage  of  damaged  cells,  quantified  after  1  h  post-treatment 
incubation (triangles) or after 24 h (diamonds).  Controls, showing the damage in laser-
irradiated but NPs-free cells are shown in the Appendix B.  
Comparative studies of the graphs allowed the determination of major aspects of NPs 
mediated treatment, as discussed in the following paragraphs.  Variations in cell survival 
rate, deriving from the type (NR, HG and CS) or functionality (OEG and P1-OEG) of NPs 
were  identified.    The  cell  recovery  rate  after  24  h  post-treatment  incubation  was  also 
assessed.  
 
 
 
 
 
  
 
Chapter 7 – Laser-hyperthermia with OEG NPs and P1-OEG NPs 
 
 
180 
 
0
25
50
75
100
0 10 20 30 40
D
e
a
d
 
c
e
l
l
s
 
[
%
]
LPD [W/cm2]
P1-OEG HG
 
Figure 64.   HUVECs  number  after  the  treatment  with  variable  laser  power  density 
(LPD) and: hollow (A and D), rod-like (B and E) and core/shell (C and D) 
NPs;  P1-OEG  NPs  (A  ÷  C),  OEG  capped  (D  ÷  F).    Symbols  indicate 
percentage  of  dead  cells  determined  after  1  h  (triangles)  and  24  h 
(diamonds) of incubation, which followed the exposure of the laser light.  
Grey areas represent changes in the overall number of cells recovered over 
the post-treatment incubation. 
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The percentage of injured HUVECs increased with LPD.  Clearly, the use of laser 
light induced damage within cells.  Until 24 W/cm
2 LPD was reached, control samples 
(cells without any NPs) showed only a background level of damage (see Appendix B).  
This significantly lower number (or none) of injured cells in the control samples, compared 
to cells with associated NPs, indicated NPs mediated damage in cells.  Further increase of 
LPD to 32 W/cm
2 resulted in 25 % of damage in the control samples.  Evidently this LPD 
value is excessively high for selective (NP mediated) hyperthermia.  On the other hand, no 
major effect on cell viability was observed when 5 W/cm
2 LPD or 8 W/cm
2 LPD was 
applied.  Therefore, to simplify further experiments and data analysis, the lowest LPD was 
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discarded.    Consequently,  only  8  ÷  24  W/cm
2  LPD  range  is  presented  on  graphs  in             
Fig. 64D ÷ F. 
It can be concluded that in general, cell survival rates decrease with LPD.  However, 
the exact percentage of survived cells (thus, the efficacy of treatment) varies with the type 
(NR, HG and CS) and functionality (P1-OEG or OEG) of NPs. 
The efficacy of treatment, depending on the type of anisotropic cores of NPs, was 
assessed  with  P1-OEG  functionalised  NPs  (Fig.  64A  ÷  C);  assuming  that  the  average 
number  of  each  type  of  P1-OEG  NPs  associated  with  the  cellular  membrane  was 
comparable.  As estimated from TEM images (see chapter 6), approximately 5000 ± 3000 
of P1-OEG NPs were attached to each cell (via VEGFR-1 receptors; Note: HUVECs from 
the same umbilical cord and the same passage, thus over-expressing similar number of 
VEGFR-1 were used in each set of experiments).  Consequently, from graphs A ÷ C, it 
can be hypothesised that treatment with NR and HG results in a similar degree of damage 
within  cells  (similar  hyperthermia  efficacy).    This  is  considerably  higher  than  after 
treatment  with CS.   Low hyperthermia  efficacy with  CS was  previously  reported,  e.g. 
Xia’s group demonstrated that 1.5 W/cm
2 LPD (5 min.) is required to effectively inactivate 
SKBR3 breast cancer cells tagged with PEG-antiHER2 capped nanocages 
[8,14,27], while 
according to Drezek and co-workers,  35 W/cm
2 LPD (7 min.) is needed to destroy these 
cells with CS (also PEG-antiHER2 capped) 
[28]. 
Treatment efficacy with OEG functionalised NR, HG and CS was also investigated.  
Here however, direct comparison between each type of NPs was more difficult.  Since, as 
demonstrated in chapter 5, the overall number of internalised OEG NPs depends very 
strongly on their shape and size (Note: 2486 ± 460 OEG NR, 363 ± 82 OEG HG and 901 ± 
99 OEG CS per cell were found, see chapter 5).  Such variations in the quantity of NR, 
HG and CS endocytosed by HUVECs, might affect the intensity of intracellular damage, 
caused by each type of NPs.  However, as can be seen in Fig. 64D ÷ F, it is clear that 
hyperthermia with CS was not as efficient as when NR or HG were used; even though, e.g. 
more CS than HG were internalised by HUVECs.   
Interestingly, OEG NR showed only slightly higher hyperthermia efficiency than OEG 
HG, even though over 6 times more NR than HG were internalised by HUVECs (see 
chapter 5).  One possible explanation can be a slightly higher energy conversion rate 
[13,26] 
(and larger absorption cross-section 
[26,27]) with HG, than with NR, as reported previously.    
Assuming that more heat is generated with HG (than e.g. NR), lower overall number 
of HG (than e.g. NR) is required to generate a similar temperature increase.  However,  
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other  parameters  should  also  be  considered  here,  e.g.  distribution  of  NPs  inside  cells 
(referred to the number of endosomes per cell and number of NPs per each vesicle, see 
chapter 5 for TEM images), could have an effect on the local temperature increase rate 
and  on  the  type  of  cellular  compartment  damaged  the  most.    The  effect  of  heat  level 
(temperature) on cell survival (more heat equals to more damage) was reported in the past 
by  several  research  groups 
[5,6,8,11,16,19,22,24,26],  whilst  the  effect  of  the  type  of  cellular 
compartment damaged during hyperthermia on cell survival was not widely investigated.   
Hence,  the  relationship  between  the  type  of  cell  injuries  (cell  compartment)  and 
treatment efficacy was investigated using OEG and P1-OEG NPs.  Treatment with OEG 
NPs resulted in thermal damages of the inner parts of the cell, while P1-OEG NPs led to 
cellular membrane injuries.  
Initially, the use of P1-OEG NPs (Fig. 64A ÷ C) led to a higher death rate (triangles), 
than the analogous OEG NPs (observed in all types of NPs: NR, HG and CS).  However, 
this  trend  changed  when  elongated  post-treatment  incubation  (24  h)  was  applied 
(diamonds).    Here,  treatment  with  OEG  NPs  seemed  to  be  more  effective  in  cell 
inactivation,  compared  to  P1-OEG  NPs.    Specifically,  irreversible  damage  of  cellular 
organelles leading to 75 % of death was achieved with OEG NR or HG, while irreversible 
damage of cellular membrane resulting in 50 % of death was observed with P1-OEG NR 
or HG.  
One  more  aspect  of  hyperthermia  can  be  identified  by  cell  viability  studies.  
Specifically, the comparison between the number of damaged cells determined after 1 or 
24 h of post-treatment incubation shows the cell recovery rate (designated by gray fields).  
The recovery rate of HUVECs treated with both, OEG NPs (intracellular damage) and    
P1-OEG NPs (extracellular damage) was studied*.  It can be concluded (Fig. 64) that 
HUVECs treated with OEG NPs (NR, HG and CS; intracellular injuries) do not recover 
after elongated post-treatment incubation time, compared to cells treated with analogues 
P1-OEG  NPs  (extracellular  injuries).    These  findings  come  into  agreement  with  the 
literature.  There are reports showing that cells with a damaged cellular membrane are 
prone  to  recovery,  after  e.g.  electroporation  (cell  transfection  technique) 
[29,30]  or 
trypsinisation (cell passaging method) 
[31,32].  
Based on the presented differences in the cell survival rate after treatment with OEG 
NPs and analogues P1-OEG NPs, the importance in selecting the appropriate strategy in 
laser hyperthermia (intra- or extracellular) should be emphasised here.  When intended to 
combine laser-hyperthermia with drug delivery (e.g. into drug resistant cells 
[25]), the use of 
* Note:  Cells are considered damaged, when positively stained with trypan blue. Viability stain can 
penetrate both: dead cells and cells with holes in the outer membrane but still alive, as 
partially destroyed membrane cannot prevent the penetration of the stain.  
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P1-OEG NPs seems to be a rational option.  This is because the majority (nearly 90 %) of 
cells becomes accessible to drugs (holes in the cellular membrane; Note: viability stain 
could penetrate cells), until 1 h after laser illumination.  On the other hand, the use of OEG 
NPs should give better results, when laser hyperthermia is the only method of damaging 
the unhealthy cells (e.g. tumour) 
[7,10,12,14].  This is because here, the death rate (treatment 
efficacy) remains high even after 24 h of post-treatment incubation.  
It is also important to highlight that the presented hyperthermia efficiency values, were 
derived from experiments conducted on healthy mammalian cells, not on malignant cells.  
As  already  explained  in  chapter  2,  malignant  cells  are  more  sensitive  to  temperature 
changes than mammalian cells 
[5,7,9,12,17,19-21,33-36].  This means that if the presented system 
(both, OEG NPs and P1-OEG NPs) is to be used in tumour treatment, higher cell death rate 
can be expected.  
One may consider additional parameter deriving from cell physiology (cell age), when 
discussing possible efficiency of hyperthermic treatment, as the cell survival rate depends 
strongly on the cell division cycle phase 
[18,33,37,38].  Hahn’s group reported the highest 
thermo-sensitivity of HeLa cells in late S (synthesis phase, DNA replication) and early G-2 
phases (growth phase, e.g. synthesis of microtubules), while the lowest thermo-sensitivity 
was observed in early G-1 phase (growth phase, e.g. synthesis of enzymes) 
[37].  Hence, 
higher death rates should be expected among cells in thermo-sensitive phase than cells in 
thermo-resistant phase.  
However, cell physiology deriving from the cell type seems to have a dominating 
effect  not  only  on  the  overall  cell  survival  rate,  but  also  on  the  mechanism  of  cell 
inactivation 
[5,7,9,10,12,17-21,33-35,38-40] (see chapter 2 for more details biochemical basis of 
hyperthermia).    According  to  Bouchier-Hayes  and  co-workers,  heat  shock  stressor  in 
human  endothelial  cells  induces  apoptosis  (programmed  death),  rather  than  necrosis 
(premature death) 
[20].  It was also demonstrated that the apoptosis of endothelial cells can 
be  induced  when  moderate  heat  treatment  is  combined  with  ROS  stimuli.    Such 
combination results in enhanced
 heat shock response (death) by simultaneous oxidative 
stress
  response  (to  ROS).    In  the  presented  NPs  mediated  hyperthermia  no  additional 
stressors (besides NPs and heat) were used.  Despite that sufficient cell damage leading to 
cell  death  was  achieved,  possibly  suggesting  a  high  level  of  heat  generated  with  NPs 
and/or releasing of another type of stressor (e.g. toxic species) from nanocomposites upon 
the laser illumination.  One way to determine whether observed effects on cells indeed 
were  driven  by  the  temperature  increase  is  to  study  the  expression  levels  of  genes  
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selectively regulated by the temperature changes (see chapter 2 for heat shock response in 
HUVECs).  This will be demonstrated in the following section.  
7.2.  Matabolism changes in survived HUVECs. 
As demonstrated in the previous section, laser-hyperthermia with OEG HG and OEG NR 
resulted in up to 75 % of dead HUVECs (24 W/cm
2 LPD).  Over 50 % of cells were found 
dead (after 24 h post-treatment incubation) when P1-OEG HG and P1-OEG NR were used.  
CS based nanocomposites were notably less effective in  hyperthermia than HG or NR 
analogues.  One possible explanation of this might be that not enough heat was generated 
with  CS  to  destroy  the  majority  of  cells.    Since  not  all  cells  were  killed  during  laser 
treatment  (especially  when  CS  and/or  low  LPD  were  used)  it  would  be  interesting  to 
identify if survived HUVECs were affected in any other way.  
 It is well-known that increased temperature induces stress response in mammalian 
cells 
[17-19,21].  Nonlethal heat induces changes in cell metabolism, including up- or down- 
regulation of many important genes and protein expression levels (e.g. heat shock proteins 
– HSPs, see chapter 2 for more details).  Justus and co-workers reported down-regulation 
of  endothelial  adhesion  molecule  1  (ELAM-1)  and  inter-cellular  adhesion  molecule  1 
(ICAM-1)  genes in HUVECs 
[39].  These genes encode adhesion molecules, which are 
critical for angiogenesis (blood vessels growth, primary function of HUVECs, see chapter 
2) and tumour metastasis 
[39,41-46].  Both, ELAM-1 and ICAM-1 affect fundamental cellular 
activities and are regulated by temperature variations.  Thus, their expression levels were 
studied in cells, which survived laser-hyperthermia.  By this way it was possible to assess 
if and how strong the metabolism of cells was affected.  
Genes profiling assays (see chapter 3 for experimental) were performed after cells 
treatment with OEG NPs or P1-OEG NPs and illumination with 12 or 24 W/cm
2 LPD.  
Since, 24 W/cm
2 LPD (10 min.) was the highest power used in selective hyperthermia (see 
the  previous  section;  LPD  over  24  W/cm
2  caused  damage  in  control  samples),  the 
maximum  level  of  gene  regulation  in  survived  HUVECs  was  expected  here.    On  the 
contrary, the exposure to 12 W/cm
2 LPD caused only approximately 25 % damage, thus 
considerably smaller gene regulation was anticipated at this point.  Regulatory effects on 
genes deriving from laser-hyperthermia with three types of NPs (NR, HG and CS) were 
tested, while NPs-free cells served as controls.  All results were normalised to GAPDH 
expression  levels  (standard  used  in  data  normalisation 
[47])  and  referred  to  non-treated  
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HUVECs (no NPs and no laser).  As previously reported by Justus and co-workers, to 
determine inhibitory effect of heat on ELAM-1 and ICAM-1 genes, cells were stimulated 
with tumour necrosis factor α (TNF-α, see chapter 2 for more details and chapter 3 for 
experimental  protocols)  for  5  h  in  fresh  growth  media  (full-serum)  straight  after  laser 
treatment (also non-treated HUVECs) 
[39].  The results are shown in Fig. 65.  Clearly both, 
ELAM-1  and  ICAM-1  genes  in  survived  HUVECs  were  significantly  down-regulated.  
Fold down-regulation was strongly dependent on LPD (increased with LPD) and type of 
NP.  
Laser-hyperthermia with OEG NPs (graphs A and B) resulted in a stronger regulation 
of ELAM-1 than ICAM-1 gene in all tested conditions.  Nearly -160 fold regulation of 
ELAM-1 was achieved after the illumination with 24 W/cm
2 LPD, while 12 W/cm
2 LPD 
resulted in -80 fold.  Clearly, an increase in LPD led to more efficient down-regulation of 
both genes.  ELAM-1 and ICAM-1 were regulated most effectively with OEG NR, while 
with  OEG  CS  the  least.    Similar  trends  were  observed  in  cell  survival  rate,  possibly 
attributed to the overall number of endocytosed NPs (see chapter 5), as explained in the 
previous section.  Low uptake rate of CS along with low energy conversion rate (absorbed 
light  to  heat,  reported  by  several  research  groups 
[11,13,14,27,28,48])  can  be  one  possible 
explanation of the least significant effects on gene expression levels, observed after CS 
mediated hyperthermia.  Graphs C and D represent P1-OEG NPs mediated effects on 
genes induced by illumination with 12 and 24 W/cm
2 LPD, respectively.  Exposure to 12 
W/cm
2 LPD resulted in down to -25 fold regulation of tested genes (NR and HG) with only 
slightly stronger regulation of ICAM-1.  
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Justus and co-workers previously reported down-regulation of ELAM-1 and ICAM-1 
genes after 1 h exposure of HUVECs to 37 ÷ 44 ºC 
[39].  Similar expression levels of both 
genes tested were observed after: a) treatment with 12 W/cm
2 LPD and P1-OEG HG or 
NR, presented here; and b) temperature-hyperthermia, reported by Justus 
[39].  Therefore, it 
can be hypothesised that similar levels of shock response were achieved in HUVECs after 
both, a) and b).  Possibly, illumination with 24 W/cm
2 LPD (HG and NR) generated more 
extreme conditions (more e.g. heat or other factors, like photoelectron emission or shock 
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Figure 65.   Gene expression profiling in HUVECs after the treatment with low, 12 W/cm
2 
(A and C) and high, 24 W/cm
2 (B and D) laser power density and OEG capped 
(A and B) and P1-OEG NPs (C and D); hollow gold (HG), nanorods (NR) and 
core/shell (CS) NPs.    Control samples did not contain any NP s, but were 
exposed to the laser.   
 
Chapter 7 – Laser-hyperthermia with OEG NPs and P1-OEG NPs 
 
 
187 
 
wave 
[26,27,49,50]),  leading  to  stronger  regulation  of  both  genes,  with  notably  higher 
expression level of ELAM-1. 
P1-OEG CS mediated hyperthermia with 12 W/cm
2 LPD had only minor effects on 
cell  metabolism,  which  was  indicated  by  a  negligible  inhibition  of  genes  (referred  to 
control samples).  This is in agreement with cell viability studies (see the previous section), 
which showed much stronger effects on HUVECs achieved with NR and HG mediated 
hyperthermia,  than  CS.    This  can  be  attributed  to  the  smaller  shock  (e.g.  heat  shock) 
generated with CS than NR or HG, since as previously mentioned comparable numbers of 
CS, NR and HG were attached to each cell (see chapter 6 for more details).  
Importantly, even though over 50 % cells survived treatment with P1-OEG HG or         
P1-OEG  NR  and  12  W/cm
2  LPD  (see  the  previous  section),  their  metabolism  was 
significantly  affected.   Sufficient inhibition  of  the expression of  adhesion  proteins  can 
possibly prevent  tumour metastasis, if  the presented system  is  to  be applied in  cancer 
treatment.  
  As demonstrated by Ito and co-workers, hyperthermia (42 ºC, 4 h) suppresses the 
expression of VEGF-A (all isoforms, see chapter 2 for theoretical background on growth 
factors) in human fibrosarcoma HT-1080 cells, resulting in the inhibition of proliferation 
of  endothelial  cells  (ECs)  in  vitro 
[47].    ECs  inhibition  was  attributed  to  the  lack  of 
sufficient quantity of growth factors in growth media.  It is also known that hyperthermia 
can affect basic functions carried out by ECs in vivo, e.g. Kwan and co-workers reported 
inhibition  of  angiogenesis  in  mice 
[51].    However,  hyperthermia  mediated  inhibition  of 
expression of VEGF A gene in ECs themselves has not been reported so far. 
Given that P1-OEG NPs can activate the expression of VEGF A gene in HUVECs, as 
shown in chapter 6, it was critical to assess, whether any effects on the expression of         
VEGF A gene in HUVECs deriving from P1-OEG NPs binding to receptors along with 
laser induced hyperthermia, can be observed.  As shown in Fig. 66, only background levels 
(below 0.1 fold; Note: the activation of VEGF-A with P1-OEG NPs at 37 ºC was 0.8 ÷ 25 
fold; see chapter 6) of VEGF A regulation were denoted.  Insignificant effects on the 
VEGF A gene can be attributed to, e.g. thermal inactivation of receptors by localised heat 
(assuming residual levels of VEGF A in serum; see the previous chapter).  On the other 
hand, the same background level of VEGF A expression after the illumination with 24 
W/cm
2 LPD (as 12 W/cm
2 LPD; data not shown) suggests rather marginal role of the 
temperature itself (assuming that the temperature increases with LPD 
[25]) on the regulation 
of VEGF A gene (in agreement with the literature 
[17,21]).  
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In  general,  stronger  gene  regulation  was  observed  with  OEG  NPs  than  with                             
P1-OEG  NPs.    One  possible  explanation  can  be  the  post-treatment  cell  recovery.    As 
demonstrated in the previous section, laser and P1-OEG NPs treated cells can recover to an 
extent, while OEG NPs treated cannot.  Consequently, it was hypothesised that HUVECs 
(after hyperthermia with P1-OEG NPs) can start the recovery process during 5 h of post-
treatment incubation 
[35,40,52], which can result in less significant effects on gene expression 
levels.  
To investigate whether post-treatment  incubation has an effect  on gene expression 
levels, HUVECs after laser-hyperthermia were either immediately treated with TNF-α (to 
induce the expression of ELAM-1 
[36,39]) or incubated for 1 h (to allow recovery) before the 
stimulation.  P1-OEG NR and P1-OEG HG were utilised in this experiment, since CS 
based nanocomposites showed only minor effects on genes (see Fig. 65).  Thus, it would 
be hard to  observe  any changes  in  gene  expression levels deriving  from  CS mediated 
treatment.  
Clear differences in fold regulation of ELAM-1 (Fig. 67) were detected (-120 before 
and -70 after the recovery), while no major changes in the expression levels of ICAM-1 
were denoted; possibly because ELAM-1 is not constituently expressed, but induced upon 
stimulation with TNF-α 
[36,39], while ICAM-1 is over-expressed by non-stimulated cells 
Figure 66.   VEGF A gene expression profiling of HUVECs tagged with P1-OEG NPs, 
after illumination with 12 W/cm
2 LPD.    
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[43,44].  Consequently, 1 h delay in the cell stimulation after laser treatment resulted in much 
lower expression levels of ELAM-1 (cell recovery).   
 
 
 
 
 As  already  mentioned  at  the  beginning  of  this  section  and  demonstrated  in  the 
previous  section,  selective  (NP  mediated)  damage  in  cells  can  be  achieved  with  a 
maximum  24 W/cm
2  LPD  (Note:  above  24  W/cm
2,  up  to  30  %  of  cells  without  NPs 
‘control samples’ was damaged).  To investigate if LPD higher than 24 W/cm
2 LPD affects 
the metabolism of survived cells in the control samples, the expression levels of ELAM-1 
and ICAM-1 genes were studied. 
As  seen  in  Fig.  68,  strong  down-regulation  of  both  genes  (down  to  -100  fold  of 
ELAM-1) was observed with 32 W/cm
2 LPD.  Illumination with 24 W/cm
2 LPD or less 
resulted in reasonably lower alteration of gene expression levels (compared to cells treated 
with NPs).  Thus, confirming the maximum value of LPD, at which hyperthermia can be 
considered as selective to cells containing NPs. 
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Figure 67.   Gene expression profiling of P1-OEG NR and P1-OEG HG tagged HUVECs 
after illumination with 24 W/cm
2 LPD and after additional 1 h post-treatment 
incubation: rec. P1-OEG NR and rec. P1-OEG HG.  
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  Relatively  high  down-regulation  of  genes  in  control  samples  illuminated  with           
32  W/cm
2  should  be  attributed  to  heat,  since  no  other  stressor  (NPs)  was  present.  
Therefore, it can be hypothesised that the cellular response to treatment with NPs and laser 
can  be  also  derived  from  heat,  rather  than  additional  stressors  coming  from  NPs  (e.g. 
photoelectron emission or other toxic species released by illuminated NPs 
[49,50]).  
To  summarise,  laser-hyperthermia  with  gold  colloids  led  to  a  down-regulation  of            
ELAM-1 and ICAM-1 genes in survived HUVECs.  An increase in LPD resulted in more 
pronounced down-regulation of both genes, with the highest efficiency achieved using NR 
and HG, while the lowest  with  CS.  Laser-hyperthermia with  OEG  NPs  (internalised) 
resulted in more down-regulation than with P1-OEG NPs (associated with cell membrane).  
In both cases however, cell metabolism was significantly affected.  Physical association of 
P1-OEG  NPs  with  VEGFR-1  did  not  induce  any  notable  changes  in  VEGF  A  gene 
expression levels, possibly due to the thermal inactivation of receptors by localised heat.  
Post-treatment cell recovery studies reviled significant differences in the expression level 
of ELAM-1 gene, while no major effects on ICAM-1 were denoted.  Gene expression 
studies in laser treated control samples (without NPs), confirmed the maximum threshold 
for selective (NPs mediated) hyperthermic damage in HUVECs, at 24 W/cm
2 LPD or less.  
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Figure 68.   Gene  expression  profiling  of  NPs-free  HUVECs,  after  illumination  with 
various LPD (8 ÷ 32 W/cm
2).  
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8.  Summary and outlook. 
For centuries, NPs have held a prime position in the world of alchemy 
[1,2].  In medieval 
times, glass staining techniques involving colloidal gold solutions were commonly used.  It 
was not until 1851 however, when gold NPs were properly introduced into the world of 
science  through  Faraday’s  work 
[3].    In  modern  chemistry,  physics,  engineering  and 
biomedicine, inorganic NPs have found a number of applications; all based on the unique 
properties of nanomaterials, very different to those observed at the macroscopic scale 
[4-19].  
Unlike bulk gold, nanoscale gold colloids exist in a range of colours covering the entire 
visible spectrum (e.g. red,  green and blue).   Such properties derive from  the  resonant 
interactions  of  the  nanogold  with  an  applied  electromagnetic  wave  (longer  than  NPs 
diameter).  The size and shape of nanocomposites can be adjusted chemically 
[1,3,4,11,20-34].  
Several methods have been utilised in this project, the summary of which will be given in 
the following sub-sections.  Synthesised ‘bare’ gold NPs were coated with water soluble 
organic molecules 
[35-44].   To the organic corona, bioactive peptides  were attached 
[45].  
Appropriate  surface  functionality  enabled  biomedical  applications  of  the  resulting 
nanocomposites.  
Bioactive  nanocomposites  were  utilised  in  selective  targeting  of  human  cells 
(HUVECs).  These cells cover the internal layer of blood vessels (endothelium) in the 
circulatory  system  and  conduct  important  physiological  processes,  e.g.  angiogenesis 
(formation of new blood vessels) 
[46-51].  New vessels are excessively formed during severe 
pathological developments, including cancer 
[52,53].  Tumours growth and progression can 
be  suppressed  by  inhibiting  angiogenesis 
[54-59].    Key  selectivity  was  achieved  with 
HUVECs targeting colloids.  Bioactive NPs targeted two receptors over-expressed on the 
cell membrane.    The binding event triggered  a cellular  response, resulting in selective 
regulation of the angiogenesis process.    
On the other hand, HUVECs targeting NPs were employed in photo-thermal therapy 
(hyperthermia)  using  laser  light  illumination 
[60-67].    The  light  was  absorbed  by  NPs 
(associated with cell components) and converted to heat 
[68].  Heating served as a stressor 
[69-72], which induced stress response within the cells, or at the extreme led to cell death.  
Cells with no associated NPs were not affected.  This technique can be considered as an 
alternative way of selective regulation of angiogenesis along with cancer treatment. 
Obtained results will be summarised in section 8.1.  The outlook to future experiments 
and further developments will be proposed in section 8.2.                 
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8.1.  Summary of results. 
Several methods were utilised in the preparation of gold colloids, capped with previously 
reported  (e.g.  CALNN  peptide,  OEG  ligand) 
[36-38,40,41,73]  or  novel  (e.g.  DA-PEG) 
[35] 
ligands.  CALNN derivative (CALNN-Ahex-FQGII) functionalised NPs were employed in 
the formation of NPs assemblies 
[39], while OEG NPs were further modified with octa-
peptides 
[45].  These results will be summarised in section 8.1.1.  The cellular fate of both, 
OEG capped and octa-peptide modified (pep-OEG) NPs were studied in HUVECs.  OEG 
NPs  were  internalised  following  a  non-selective  mechanism  (see  section  8.1.2.  for 
summary), while the type of interactions between pep-OEG NPs and cells was determined 
by peptide sequence (P1, P2 or P3).  P1 and P3 based colloids were binding selectively to 
membrane receptors over-expressed by HUVECs.  Receptor binding initiated signalling 
cascades  within  cells,  resulting  in  a  regulation  of  certain  physiological  processes  (see 
section  8.1.3  for  summary).    HUVECs  tagged  with  P1-OEG  NPs  or  with  associated 
(internalised)  OEG  NPs  were  illuminated  with  a  laser  light.    This  effectively  led  to 
hyperthermia and heat shock, which depending on the laser power applied, led to a cellular 
response or cell death (see section 8.1.4. for summary).  
8.1.1.  Synthesis, surface capping and assembly of NPs. 
Gold  colloids  (spherical  and  anisotropic)  were  prepared  according  to  established  wet 
chemistry  methods  with  slight  modifications  to literature  protocols 
[1,3,11,20,21,23,24,26-30,32-
34,74-84] (see chapter 3 for protocols; related publication is listed in Author’s Declaration).  
Citrate reduction was utilised in the synthesis of spherical NPs, while rod-like structures 
were prepared by seed mediated approaches.  A method developed by Hals was employed 
in the production of spherical gold shells with silica cores, while spherical shells (or cages) 
with hollow interiors were obtained by a galvanic replacement reaction.  
Spherical colloids were capped with a mixed layer of CALNN and CALNN-Ahex-
FQGII (c-FQGII) ligands, then utilised in the formation of assembled structures 
[39].  NPs 
assembling was achieved with oligodeoxynucleotide based (ODN) templates via selective 
recognition  between  AT-rich  regions  in  ODNs  and  FQGII  sequence 
[85,86].    As 
demonstrated  in  chapter  4,  the  architecture  of  NPs  assemblies  can  be  controlled  by 
varying the amount of c-FGQII incorporated in the organic corona and/or the type ODNs 
(short or pseudo-infinite duplexes) used.   This led to the formation of dimers, trimers, 
shorter and longer chains of NPs, or even more complex three dimensional arrays, making  
 
Chapter 8 – Summary and outlook 
 
 
196 
the method highly attractive in the engineering of NPs assemblies (related publication is 
listed in Author’s Declaration).  
DA-PEG capping ligand was employed in the preparation of new family of spherical 
gold colloids, showing enhanced stability in aqueous media 
[35].  Colloidal stability against 
aggregations was tested in a varied pH range (1.2 ‚ 9), during heat/cool (100 ºC/25 ºC) and 
freeze/thaw (-20 ºC/25 ºC) cycles.  DA-PEG capped NPs also showed resistance to ligand 
exchange reactions in the presence of high concentration of thiolated molecules.  Enhanced 
stability  of  DA-PEG  colloids  derived  from  photo-polymerised  DA-PEG  shell,  tightly 
encapsulating inorganic cores (see chapter 4 for more details; related publication is listed 
in Author’s Declaration).   
OEG capped and pep-OEG NPs with spherical and inorganic cores (see chapter 4 for 
physicochemical properties) were utilised in experiments with HUVECs. 
8.1.2.  Cellular fate of OEG NPs. 
Mechanisms of fundamental interactions between HUVECs and NPs were studied with 
OEG capped colloids.  Strong charge of OEG NPs (see chapter 4 for physicochemical 
properties)  was  identified  as  a  driving  force  of  NPs  uptake,  based  on  non-selective 
endocytosis.  The uptake rate was determined by the NPs size and shape, rather than the 
NPs functionality.  
Spherical (SP), rod-like (NR), core/shell (CS) and hollow (HG) NPs employed in OEG 
system were all negatively charged, but significantly varied in size and shape.  These two 
parameters (rather than the charge strength) were dominant in the regulation of the uptake 
rate.  The smallest OEG SP (hydrodynamic diameter around 25 nm) were most efficiently 
taken-up by HUVECs, whilst the largest OEG HG (96 nm) the least.   OEG NR were 
endocytosed in greater numbers than OEG CS, with a diameter comparable to the NR 
length (around 50 nm).  OEG NR and OEG SP, with the same diameter as the NR width 
were similar in uptake rate.  These results were presented in chapter 5 and are to be 
published in academic press (the manuscript is in preparation). 
More efficient control upon cellular fate of gold colloids was gained with bioactive 
pep-OEG NPs. 
 
  
 
Chapter 8 – Summary and outlook 
 
 
197 
8.1.3.  Cell targeting and regulation with pep-OEG NPs. 
 
Pep-OEG NPs were prepared by conjugating octa-peptides (either P1 – wild type, P2 – 
scrambled mutant or P3 – inhibitor) to the outer part of the OEG capping layer 
[45,87,88] (see 
chapter 3 for experimental protocol).  Resulting colloids showed similar physicochemical 
properties (size and charge, see chapter 4), but different bioactivity, as determined by the 
primary structure of the peptide (amino acids arrangements, see chapter 2).  
HUVECs  were  targeted  with  P1-OEG  and  P3-OEG  NPs  via  selective  recognition 
between  over-expressed  membrane  receptors  and  peptides 
[89,90].    As  demonstrated  in 
chapter 6, P1-OEG NPs bind to VEGFR-1, while P3-OEG NPs to NRP-1.  The formation 
of  receptor-NPs  complexes  with  NRP-1  was  followed  by  trafficking  on  the  cellular 
membrane, then complex internalisation.  On the contrary, NPs associated with VEGFR-1 
remained  outside  the  cellular  milieu.    The  receptor  binding  event  triggered  a  cellular 
response, which was monitored by gene expression profiling.  Up to 60 fold regulation of 
three angiogenesis related genes (VEGF A, HIF-1α, C-MYC) was denoted.  P1-OEG NPs 
activated the tested genes; whilst P3-OEG NPs had inhibitory effects (related publication is 
listed in Author’s Declaration).  
Except of changes in cell metabolism, controlled regulation of physiological processes 
conducted by HUVECs was also achieved, which was studied with in vitro angiogenesis 
model.  Capillaries were formed by cells upon stimulation with P1-OEG NPs; while P3-
OEG  NPs  suppressed  neo-vascular  sprouting  (related manuscript is  in  preparation,  see 
Author’s Declaration).  
The scrambled version of the wild type peptide (P2 mutant) was also incorporated in 
the organic corona of NPs.  The resulting P2-OEG colloid lost its affinity towards growth 
factor receptors, was therefore incapable of triggering any angiogenesis related response in 
HUVECs.  
8.1.4.  Laser-hyperthermia with OEG NPs and P1-OEG NPs. 
HUVECs associated with anisotropic (NR, HG or CS) OEG capped or P1-OEG NPs were 
exposed to the NIR laser light.  At NIR frequency, anisotropic NPs exhibit maximum 
extinction (see chapter 4 for physicochemical characterisation), whilst tissue components 
have the highest transitivity 
[91-93].  Consequently NIR light can penetrate cells, while being 
absorbed by associated NPs 
[60,62,66,67,94].  NPs will then convert the light into heat 
[68].  This  
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will induce a heat shock response in the cell, or at the extreme lead to cell death, depending 
on the applied laser power (LPD, see chapter 7 for results).  
Generally, cell mortality was increasing with LPD.  However, the exact percentage of 
damaged cells was dependent on the type (NR, HG and CS) and functionality (P1-OEG or 
OEG) of NPs.  P1-OEG NPs led to a higher rate of cell damage (up to 90 %), compared to 
the analogous OEG NPs (quantified after 1 h post-treatment incubation).  When the post-
treatment incubation time was extended (24 h), OEG NPs resulted in up to 75 % of death, 
while P1-OEG NPs in only 50 %.  Hence, it was concluded that cells with membrane 
injuries  (P1-OEG  NPs)  can  recover,  whilst  the  intracellular  damage  is  potentially 
irreversible. 
Physiological changes in survived cells deriving from heat stimuli were monitored by 
the expression profiling of two genes (ELAM-1 and ICAM-1), which are responsive to 
heat stressor and important for angiogenesis (and tumour metastasis).  Up to -160 fold 
inhibition was denoted.  Gene regulation was increasing with LPD and was higher with NR 
or HG than CS, as well as OEG NPs than P1-OEG analogues (related publication is listed 
in Author’s Declaration). 
8.2.  Outlook to future work. 
Novel pep-OEG NPs, developed during this project, show promising bioactivity.  Selective 
regulation of several angiogenesis related genes in primary HUVECs along with in vitro 
angiogenesis regulation was demonstrated.  However, further experiments aiming to fully 
appreciate the bioactivity of these novel nanocomposites could be proposed. 
One could further extend the presented development by applying pep-OEG NPs in 
vivo.  The capability of spherical core based nanocomposites to regulate in vivo (e.g. mice) 
angiogenesis, is to be explored in the presence of naturally existing growth factors, at 
physiological concentrations.  In mice, baring tumours, endothelium around the tumour site 
can  be  targeted  with  anisotropic  pep-OEG  NPs,  then  illuminated  with  the  NIR  laser, 
followed  by  assessing  the  efficiency  of  resulting  tumour  regression  (if  any)  and/or 
metastasis suppression.  
On the other hand, given that another physiological role of HUVECs is to participate 
in  the  inflammatory  response  (to  a  pathogen) 
[47,48],  it  would  be  interesting  to  study 
possible  cyto-toxicity  related  effects,  deriving  from  the  prolonged  exposure  to               
pep-OEG NPs (and OEG NPs).  Assessing the safety of pep-OEG NPs can be considered  
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as an important step in future real-life applications using these novel nanocomposites, as 
well as the development of new ‘smart’ treatments. 
The  author  of  the  thesis  was  awarded  a  one  year  fellowship,  entitled  ‘PhD  plus 
programme’, funded by the EPSRC.  Over the course of this PhD-follow-up research, it is 
intended  to  investigate  the  effects  of  novel  pep-OEG  NPs  on  in  vivo  angiogenesis, 
extended to laser-hyperthermic treatment using  NIR absorbing nanocomposites.   Cyto-
toxicity of applied nanomaterials will be also monitored.   
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Appendix A – list of reagents suppliers 
All  reagents  were  purchased  from  the  following  suppliers  and  used  without  further 
purification:  
A1.   Sigma-Aldrich: 
sodium  tetrachloroaurete  (III)  dihydrate,  trisodium  citrate,  sodium  borohydride,  silver 
nitrate,  L-ascorbic  acid,  ammonia  solution  (30%),  absolute  ethanol, methanol,  acetone, 
acetonitrile,  chloroform,  isopropanol,  tetraethyl  orthosilicate  (TEOS),  (3-
aminopropyl)trimethoxysilane  (APTMS),  tetrakis(hydroxymethyl)phosphonium  chloride 
(THPC),  sodium  hydroxide,  potassium  carbonate,  formaldehyde, 
tris(hydroxymethyl)aminomethane (Tris), boric acid, piperazine-N,N’-bis(2-ethanesulfonic 
acid)  (PIPES),  sodium  phosphate  monobasic,  sodium  phosphate  dibasic,   
ethylenediaminetetraacetic  acid  (EDTA),  sodium  hydroxide,  sodium  azide,  agarose, 
mercaptoethanol,  dithiothreitol,  cysteamine,  cysteine,  α-lipoic  acid,  11-amino-1-
undecanethiol,  Ellman’s  reagent  –  5,5’-dithiobis(2-nitrobenzoic  acid),  FluoroProfile 
Protein Quantification Kit, porcine gelatin, Hank's Buffered Salt Solution (HBSS), fetal 
bovine serum (FBS), trypsin, trypan blue, TRIzol reagent, cobalt II chloride (CoCl2); 
A2.   ProChimia Surfaces Sp. z o.o:.  
α-thio-ω-carboxy  polyethylene  glycol  (OEG)  and  46-mercapto-22,43-dioxo-
3,6,9,12,15,18-hexaoxa-21,44-diazahexatetraconta-31,33-diyn-1-oic acid (DA-PEG); 
A3.   Strem-Chemicals, Inc.: 
bis(p-sulfonatophenyl)phenyl phosphine dehydrate dipotassium salt (BSPP); 
A4.   Alfa Aesar: 
hexadecyltrimethylammonium bromide (CTAB); 
A5.   Pierce Biotechnology: 
N-hydroxysulfosuccinimide  (s-NHS)  and  1-(3-(dimethylamino)propyl)-3-ethyl-
carbodiimidemethiodide (EDC); 
A6.   Agar Scientific Ltd.: 
osmium tetroxide, uranyl acetate, lead nitrate, Spurr resin and glutaraldehyde; 
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A7.   3M: 
perfluorohexane (FC-72); 
A8.   Anna Spec Inc.: 
HiLyte Fluor 680 amine (HiLyte); 
A9.   Activotec SPP Ltd.: 
P1  (KPQPRPLS),  P2  (KATWLPPR)  and  P3  (KPRQPSLP)  octa-peptides,  as  well  as 
CALNN and CALNN-Ahex-FQGII; 
A10. Link Technologies Ltd. and SAFC Supply Solutions: 
Phosphoramidite monomers and reagents for OL synthesis; 
A11. Worthington: 
Type 1 collagenase solution; 
A12. Invitrogen: 
M199 growth media, Penicillin / Streptomycin, glycogen and TNF-α; 
A13. Autogen Bioclear: 
human serum; 
A14. Gibco: 
DNEM media growth and reduced growth factor membrane matrix (Geltrex); 
A15. PeproTech, Inc.: 
VEGF-B167; 
A16.  Applied Biosystems: 
VEGF A, HIF1-α, V-MYC, GAPDH, ELAM-1 and ICAM-1 TaqMan primers, 10 x RT 
buffer, random primers, RNAsin, dNTPs, nuclease-free water and reverse transcriptase and 
2 x PCR mix; 
A17. Innova Biosciences, Ltd.: 
LL-RPE fluorescent label.  
    
 
 
 
iii 
 
Appendix B – supplementary information  
B1.   OEG and DA-PEG ligands quantification: 
Average  number  of  DA-PEG  and  OEG  ligands,  attached  to  each  nanoparticle,  was 
quantified with Ellman’s method (see chapter 3 for experimental details). In tables below, 
5 ￷ 10 independent measurements from each set of quantification-experiments are shown. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
   
Estimated number of DA-PEGs  
15.5 ± 1.5 nm 
spherical NPs 
Average  3.25 ± 1.5 nm 
spherical NPs 
Average 
2027 
2073 ± 250 
82 
67 ± 22 
2118  37 
1944  64 
1945  72 
2330  80 
Table B1.1.   DA-PEG ligand quantification.  
 
 
 
 
 
Estimated number of OEGs 
SP  Average  NR  Average  HG  Average  CS  Average 
2187 
1876 ± 156 
6976 
6820 ± 877 
55898 
55871 ± 570 
21893 
21368 ± 830 
1738  6265  54996  21772 
1879  5662  55849  21533 
1787  5902  56273  20747 
2056  7798  54925  22382 
1782  7173  55626  20177 
1687  7554  55982  21156 
1798  7816  56716  21825 
1865  7432  56032  22217 
1987  5624  56413  19976 
Table B1.2.   OEG  ligand quantification – different types of NPs. 
iv
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B2.   Octa-peptides quantification: 
Average  number  of  octa-peptides,  attached  to  each  nanoparticle,  was  estimated  with 
FluoroProfile Protein Quantification Kit (see chapter 3 for experimental details). In tables 
below, 5 ÷ 10 independent measurements from each set of quantification-experiments are 
shown. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Estimated number of octa-peptides  
P1  Average  P3  Average 
384 
436 ± 44 
420 
417 ± 10 
398  441 
466  419 
452  402 
469  412 
442  414 
485  417 
358  421 
424  418 
486  412 
Table B2.1.   Octa-peptide quantification; spherical gold NPs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Estimated number of P1 peptide 
NR  Average  HG  Average  CS  Average 
1469 
1457 ± 149 
17193 
17514 ± 1904 
6941 
6931 ± 300 
1677  18909  7291 
1501  19845  7125 
1346  15028  6518 
1295  16596  6781 
Table B2.2.   P1 peptide quantification; anisotropic NPs. 
vi
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B3.   Calculations of the number of gold atoms per nanoparticle. 
Each  type  of  NPs  (column  1,  Table  B3.1.)  was  imaged  with  transmission  electron 
microscope.  On images, the size of NPs was measured.  Statistical analyses of the size 
distribution were drowned into histograms.  From histograms, the average size of NPs in 
each sample was estimated (column 2, Table B3.1.).  
Assuming that NPs possess fcc crystal structure 
[1,2], in each unit cell there are 8 atoms 
at the edges and 6 atoms at the faces, thus the single unit cell contains 4 atoms.   Since, 1 
mole of gold weights 197 g and contains 6.02 · 10
23 atoms, while the density of gold is 
19.32 g/cm
3, there is 5.9 · 10
22 atoms/cm
3.  Consequently, 4 atoms (the unit cell) will 
occupy the volume of 6.7 · 10
-2 nm
3.  Taking the dimensions of NPs, their volumes can be 
easily calculated (column 3, Table B3.1.; Note: for hollow and core/shell NPs the volume 
of gold part of the NP equals to the volume of the whole NP minus the volume of hollow 
or silica interior).   By dividing the volume of NP by the volume of the unit  cell  and 
multiplying by the number of gold atoms in the unit (4), the number of gold atoms per NP 
was calculated (column 4, Table B3.1.).   
These numbers multiplied by the weight of a gold atom (197 / 6.02 · 10
23) gave the 
weight of a single NP (column 5, Table B3.1.). 
 
 
 
  
   
 
 
 
 
Type of NP  Average size 
[nm] 
Volume of NP 
[nm
3] 
No. of gold atoms 
per NP 
Weight of NP 
[g] 
spherical  15   1766  105448  3.45 · 10
-17 
nanorod  16   x   47   12032  718328  2.35 · 10
-16 
hollow  92   x   9   108278  6464370  2.12 · 10
-15 
core/shell  44   x   6   15863  947061  3.10 · 10
-16 
Table B3.1.   Gold atoms per nanoparticle.  
 
 
 
viii 
 
References: 
[1]   Xia, Y.; Xiong, Y.; Lim, B.; Skrabalak, S. Angew Chem, Int Ed 2009, 48, 60-103. 
[2]   Day, H. A.; Bartczak, D.; Fairbairn, N.; McGuire, E.; Ardakani, M.; Porter, A. E.; 
Kanaras, A. G. CrystEngComm 2010, 12, 4312-4316. 
 
   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
ix 
 
0
25
50
75
100
0 10 20 30 40
D
e
a
d
 
c
e
l
l
s
 
[
%
]
LPD [W/cm2]
B4.   Laser-hyperthermia with OEG NPs and P1-OEG NPs. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
   
   
Figure B4.   HUVECs number after the treatment with variable laser power density (LPD). 
Crosses represent laser-treated cells after 1 h post-treatment incubation, while 
dots after 24 h. 